

Curriculum Vitae

The Johns Hopkins University School of Medicine

(Signature) 
 Name: Robert A. Wise, M.D.

April 23, 2022

DEMOGRAPHIC AND PERSONAL INFORMATION

Current Appointment

University: Professor of Medicine with Joint Appointment in
 Environmental Health and Engineering, Johns Hopkins Medical Institutions,
 Baltimore, Maryland

Hospital: Director, Pulmonary Function Laboratory
 Johns Hopkins Bayview Medical Center, Baltimore, MD

Office Address: The Division of Pulmonary and Critical Care Medicine
 The Johns Hopkins Asthma and Allergy Center
 5501 Hopkins Bayview Circle
 Baltimore, Maryland 21224
 Telephone: (410) 550-0545 FAX (410) 550-2612
 Email: rwise@jhmi.edu

Education and Training:

1963-67	A.B.	Cum Laude, Dartmouth College, Hanover, NH
1967-69	B.M.S.	Cum Laude, Dartmouth Medical School, Hanover, NH
1969-71	M.D.	Harvard Medical School, Boston, MA
1971-72	Intern	University of Michigan Medical Center, Ann Arbor, Michigan
1972-73	Resident	University of Michigan Medical Center, Ann Arbor, Michigan
1975-77	Resident	University of Michigan Medical Center, Ann Arbor, Michigan
1975-77	Sr. Resident	University of Michigan Medical Center, Ann Arbor, Michigan
1977-80	Fellow	Respiratory Division, Johns Hopkins University School of Medicine
1978-80	Fellow	Environmental Physiology Division, Johns Hopkins Univ. School of Hygiene & Public Health

Professional Experience:

1973 -75	USPHS	National Health Service Corps, Colebrook, New Hampshire
1980-81	Instructor	Medicine and Environ. Physiology, Johns Hopkins School of Medicine, Hygiene & Public Health
1981-87	Assistant Professor	Medicine with Joint Appointments in Environmental Health Sciences, Johns Hopkins Medical Institutions
	Instructor	Radiology (Nuclear Medicine) The Johns Hopkins Medical Institutions, Baltimore, Maryland
1987-98	Associate Professor	Medicine with Joint Appointments in Environmental Health Sciences
1987-2010	Instructor	Radiology (Nuclear Medicine) The Johns Hopkins University School of Medicine

1988-1997	Associate Director	Division of Pulmonary and Critical Care Medicine, Johns Hopkins Medical Institutions
1997-1998	Interim Director	Division of Pulmonary and Critical Care Medicine, The Johns Hopkins Medical Institutions
1998-	Professor	Medicine with Joint Appointment in Environmental Health Sciences, Johns Hopkins University School of Medicine
1993-2005	Director	Pulmonary & Critical Care Fellowship Program Division of Pulmonary & Critical Care Medicine Johns Hopkins Medical Institutions
1998-2006	Director	Pulmonary Function Laboratory Johns Hopkins Hospital, Baltimore, MD
2014-2018	Associate Director	Division of Pulmonary and Critical Care Medicine, Johns Hopkins Medical Institutions

RESEARCH ACTIVITIES

Publications:

Scientific articles

1. Schroeder HA, Baker JT, Hansen NM, Jr, Size JG and **Wise R**. Vascular reactivity of rats altered by cadmium and a zinc chelate. *Arch Environ Health* 1970; 21:609-614
2. Wang KP, **Wise R**, Terry PB and Summer WR. A new controllable suction catheter for blind cannulation of the main stem bronchi. *Crit Care Med* 1978; 6:347-348
3. Wang KP, **Wise R**, Terry PB, Kaplan J, Britt EJ, Haponik EF, Summer WR and Marsh B. Comparison of standard and large forceps for transbronchial lung biopsy in the diagnosis of lung infiltrates. *Endoscopy* 1980; 12:151-154
4. **Wise R**, Robotham JL and Summer WR. Effects of spontaneous ventilation on the circulation. *Lung* 1981; 159:175-186
5. **Wise R**, Wigley F, Newball HH and Stevens MB. The effect of cold exposure on diffusing capacity in patients with Raynaud's phenomenon. *Chest* 1982; 81:695-698
6. **Wise R** and Summer WR. Pulsus Paradoxus: Why it happens, how to treat it. *J Respir Dis* 1982; 3:89-99
7. Schneider PD, **Wise R**, Hochberg MC and Wigley FM. Serial pulmonary function in systemic sclerosis. *Am J Med* 1982; 73:385-394
8. Ettinger WH, **Wise R**, Stevens MB and Wigley FM. Absence of positional change in pulmonary diffusing capacity in systemic sclerosis. *Am J Med* 1983; 75:305-312
9. Pinsky MR, Summer WR, **Wise R**, Permutt S and Bromberger-Barnea B. Augmentation of cardiac function by elevation of intrathoracic pressure. *J Appl Physiol* 1983; 54:950-955
10. **Wise R** and Summer WR. Pulmonary mechanics and artificial support of the arrested circulation. *Clin Chest Med* 1983; 4:189-198
11. Peters-Golden M, **Wise R**, Hochberg MC, Stevens MB and Wigley FM. Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. *Am J Med* 1984; 77:1027-1034
12. Peters-Golden M, **Wise R**, Schneider P, Hochberg M, Stevens MB and Wigley F. Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis. *Medicine (Baltimore)* 1984; 63:221-231

13. Ettinger WH, **Wise R**, Schaffhauser D and Wigley FM. Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. *Am J Med* 1984; 77:451-456
14. Karam M, **Wise R**, Natarajan TK, Permutt S and Wagner HN. Mechanism of decreased left ventricular stroke volume during inspiration in man. *Circulation* 1984; 69:866-873
15. Haponik EF, Munster AM, **Wise R**, Smith PL, Meyers DA, Britt EJ and Bleecker ER. Upper airway function in burn patients. Correlation of flow-volume curves and nasopharyngoscopy. *Am Rev Respir Dis* 1984; 129:251-257
16. **Wise R**, Wigley FM and Malamet R. Digital pressure-flow relationships in subjects with Raynaud's phenomenon. *Angiology* 1985; 36:596-602
17. **Wise R**. Effect of alterations of pleural pressure on cardiac output. *South Med J* 1985; 78:423-428
18. Brower R, **Wise R**, Hassapoyannes C, Bromberger-Barnea B and Permutt S. Effect of lung inflation on lung blood volume and pulmonary venous flow. *J Appl Physiol* 1985; 58:954-963
19. Robotham JL, **Wise R** and Bromberger-Barnea B. Effects of changes in abdominal pressure on left ventricular performance and regional blood flow. *Crit Care Med* 1985; 13:803-809
20. Peters-Golden M, **Wise R**, Hochberg M, Stevens MB and Wigley FM. Incidence of lung cancer in systemic sclerosis. *J Rheumatol* 1985; 12:1136-1139
21. Malamet R, **Wise R**, Ettinger WH and Wigley FM. Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation. *Am J Med* 1985; 78:602-608
22. **Wise R**. Effect of circulatory mechanics on hydrostatic forces producing pulmonary edema. *J Crit Care* 1986; 1:247-256
23. Hausknecht MJ, **Wise R**, Brower RG, Hassapoyannes C, Weisfeldt ML, Suzuki J and Permutt S. Effects of lung inflation on blood flow during cardiopulmonary resuscitation in the canine isolated heart-lung preparation. *Circ Res* 1986; 59:676-683
24. Brower RG, **Wise R**, Hassapoyannes C, Hausknecht M and Permutt S. Longitudinal distribution of vascular compliance in the canine lung. *J Appl Physiol* 1986; 61:240-247
25. **Wise R**, Malamet R and Wigley FM. Acute effects of nifedipine on digital blood flow in human subjects with Raynaud's phenomenon: a double blind placebo controlled trial. *J Rheumatol* 1987; 14:278-283
26. Haponik EF, Meyers DA, Munster AM, Smith PL, Britt EJ, **Wise R** and Bleecker ER. Acute upper airway injury in burn patients. Serial changes of flow-volume curves and nasopharyngoscopy. *Am Rev Respir Dis* 1987; 135:360-366
27. Scott TE, **Wise R**, Hochberg MC and Wigley FM. HLA-DR4 and pulmonary dysfunction in rheumatoid arthritis. *Am J Med* 1987; 82:765-771
28. Natarajan TK, **Wise R**, Karam M, Permutt S and Wagner HN, Jr. Immediate effect of expiratory loading on left ventricular stroke volume. *Circulation* 1987; 75:139-145
29. Brower RG, Gottlieb J, **Wise R**, Permutt S and Sylvester JT. Locus of hypoxic vasoconstriction in isolated ferret lungs. *J Appl Physiol* 1987; 63:58-65
30. Wigley FM, **Wise R**, Malamet R and Scott TE. Nicardipine in the treatment of Raynaud's phenomenon. Dissociation of platelet activation from vasospasm. *Arthritis Rheum* 1987; 30:281-286

31. Wigley FM, Malamet R and **Wise R**. Reproducibility of cold provocation in patients with Raynaud's phenomenon. *J Rheumatol* 1987; 14:751-755
32. **Wise R**, Wigley FM, Scott TE and Hochberg MC. HLA-DQw alloantigens and pulmonary dysfunction in rheumatoid arthritis. *Chest* 1988; 94:609-614
33. Schwartz AR, Smith PL, **Wise R**, Gold AR and Permutt S. Induction of upper airway occlusion in sleeping individuals with subatmospheric nasal pressure. *J Appl Physiol* 1988; 64:535-542
34. Einagle V, Bertrand F, **Wise R**, Roussos C and Magder S. Interposed abdominal compressions and carotid blood flow during cardiopulmonary resuscitation. Support for a thoracoabdominal unit. *Chest* 1988; 93:1206-1212
35. Passerini L, **Wise R**, Roussos C and Magder S. Maintenance of circulation without chest compression during CPR. *J Crit Care* 1988; 3:96-102
36. Fessler HE, Brower RG, **Wise R** and Permutt S. Mechanism of reduced LV afterload by systolic and diastolic positive pleural pressure. *J Appl Physiol* 1988; 65:1244-1250
37. Stokes DC, Pyeritz RE, **Wise R**, Fairclough D and Murphy EA. Spirometry and chest wall dimensions in achondroplasia. *Chest* 1988; 93:364-369
38. Smith PL, **Wise R**, Gold AR, Schwartz AR and Permutt S. Upper airway pressure-flow relationships in obstructive sleep apnea. *J Appl Physiol* 1988; 64:789-795
39. Schwartz AR, Smith PL, **Wise R**, Bankman I and Permutt S. Effect of positive nasal pressure on upper airway pressure-flow relationships. *J Appl Physiol* 1989; 66:1626-1634
40. Prince DS, Wingard JR, Saral R, Santos GW and **Wise R**. Longitudinal changes in pulmonary function following bone marrow transplantation. *Chest* 1989; 96:301-306
41. Gleadhill IC, **Wise R**, Schonfeld SA, Scott PP, Guarnieri T, Levine JH, Griffith LS and Veltri EP. Serial lung function testing in patients treated with amiodarone: a prospective study. *Am J Med* 1989; 86:4-10
42. Takata M, **Wise R** and Robotham JL. Effects of abdominal pressure on venous return: abdominal vascular zone conditions. *J Appl Physiol* 1990; 69:1961-1972
43. Stokes DC, Wohl ME, **Wise R**, Pyeritz RE and Fairclough DL. The lungs and airways in achondroplasia. Do little people have little lungs? *Chest* 1990; 98:145-152
44. Smith PL, Schwartz AR, Gauda E, **Wise R**, Brower R and Permutt S. The modulation of upper airway critical pressures during sleep. *Prog Clin Biol Res* 1990; 345:253-8; discussion 258-60
45. Fessler HE, Brower RG, **Wise R** and Permutt S. Positive pleural pressure decreases coronary perfusion. *Am J Physiol* 1990; 258:H814-20
46. Wigley FM, **Wise R**, Mikdashi J, Schaefer S and Spence RJ. The post-occlusive hyperemic response in patients with systemic sclerosis. *Arthritis Rheum* 1990; 33:1620-1625
47. Schwartz AR, Gold AR, Schubert N, Stryzak A, **Wise R**, Permutt S and Smith PL. Effect of weight loss on upper airway collapsibility in obstructive sleep apnea. *Am Rev Respir Dis* 1991; 144:494-498
48. Fessler HE, Brower RG, **Wise R** and Permutt S. Effects of positive end-expiratory pressure on the gradient for venous return. *Am Rev Respir Dis* 1991; 143:19-24

49. Thurm CA, Wigley FM, Dole WP and **Wise R**. Failure of vasodilator infusion to alter pulmonary diffusing capacity in systemic sclerosis. *Am J Med* 1991; 90:547-552
50. Tashkin DP, Rand C, Nides M, Simmons M, **Wise R**, Coulson AH, Li V and Gong H,Jr. A nebulizer chronolog to monitor compliance with inhaler use. *Am J Med* 1991; 91:33S-36S
51. Gleadhill IC, Schwartz AR, Schubert N, **Wise R**, Permutt S and Smith PL. Upper airway collapsibility in snorers and in patients with obstructive hypopnea and apnea. *Am Rev Respir Dis* 1991; 143:1300-1303
52. Wigley FM, **Wise R**, Miller R, Needleman BW and Spence RJ. Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis. *Arthritis Rheum* 1992; 35:688-693
53. Fessler HE, Brower RG, **Wise R** and Permutt S. Effects of positive end-expiratory pressure on the canine venous return curve. *Am Rev Respir Dis* 1992; 146:4-10
54. Fessler HE, Brower RG, **Wise R** and Permutt S. Effects of systolic and diastolic positive pleural pressure pulses with altered cardiac contractility. *J Appl Physiol* 1992; 73:498-505
55. Bankman IN, Sigillito VG, **Wise R** and Smith PL. Feature-based detection of the K-complex wave in the human electroencephalogram using neural networks. *IEEE Trans Biomed Eng* 1992; 39:1305-1310
56. Blosser S, Wigley FM and **Wise R**. Increase in translaryngeal resistance during phonation in rheumatoid arthritis. *Chest* 1992; 102:387-390
57. Wigley FM, Seibold JR, **Wise R**, McCloskey DA and Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. *J Rheumatol* 1992; 19:1407-1414
58. Tashkin DP, Altose MD, Bleecker ER, Connett JE, Kanner RE, Lee WW and **Wise R**. The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. *Am Rev Respir Dis* 1992; 145:301-310
59. Rand CS, **Wise R**, Nides M, Simmons MS, Bleecker ER, Kusek JW, Li VC and Tashkin DP. Metered-dose inhaler adherence in a clinical trial. *Am Rev Respir Dis* 1992; 146:1559-1564
60. Jabs EW, Tuck-Muller CM, Anhalt GJ, Earnshaw W, **Wise R** and Wigley F. Cytogenetic survey in systemic sclerosis: correlation of aneuploidy with the presence of anticentromere antibodies. *Cytogenet Cell Genet* 1993; 63:169-175
61. Schwartz AR, Thut DC, Russ B, Seelagy M, Yuan X, Brower RG, Permutt S, **Wise R** and Smith PL. Effect of electrical stimulation of the hypoglossal nerve on airflow mechanics in the isolated upper airway. *Am Rev Respir Dis* 1993; 147:1144-1150
62. Nides MA, Tashkin DP, Simmons MS, **Wise R**, Li VC and Rand CS. Improving inhaler adherence in a clinical trial through the use of the nebulizer chronolog. *Chest* 1993; 104:501-507
63. Gold AR, Schwartz AR, **Wise R** and Smith PL. Pulmonary function and respiratory chemosensitivity in moderately obese patients with sleep apnea. *Chest* 1993; 103:1325-1329
64. Thut DC, Schwartz AR, Roach D, **Wise R**, Permutt S and Smith PL. Tracheal and neck position influence upper airway airflow dynamics by altering airway length. *J Appl Physiol* 1993; 75:2084-2090
65. **Wise R** and Wigley F. Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon. *J Rheumatol* 1994; 21:80-83

66. Yurovsky VV, Sutton PA, Schulze DH, Wigley FM, **Wise R**, Howard RF and White B. Expansion of selected V delta 1 gamma delta T cells in systemic sclerosis patients. *J Immunol* 1994; 153:881-891
67. Kanner RE, Connett JE, Altose MD, Buist AS, Lee WW, Tashkin DP and **Wise R**. Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. *Am J Respir Crit Care Med* 1994; 150:956-961
68. Wigley FM, **Wise R**, Seibold JR, McCloskey DA, Kujala G, Medsger TA, Jr, Steen VD, Varga J, Jimenez S, Mayes M, Clements PJ, Weiner SR, Porter J, Ellman M, Wise C, Kaufman LD, Williams J and Dole W. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. *Ann Intern Med* 1994; 120:199-206
69. Rand CS and **Wise R**. Measuring adherence to asthma medication regimens. *Am J Respir Crit Care Med* 1994; 149:S69-76; discussion S77-8
70. **Wise R**. Physiologic Measures in Asthma. *Am J Respir Crit Care Med* 1994; 149:S19
71. Seelagy MM, Schwartz AR, Russ DB, King ED, **Wise R** and Smith PL. Reflex modulation of airflow dynamics through the upper airway. *J Appl Physiol* 1994; 76:2692-2700
72. Whitmore SE, Wigley FM and **Wise R**. Acute effect of topical minoxidil on digital blood flow in patients with Raynaud's phenomenon. *J Rheumatol* 1995; 22:50-54
73. Rand CS, Nides M, Cowles MK, **Wise R** and Connett J. Long-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research Group. *Am J Respir Crit Care Med* 1995; 152:580-588
74. **Wise R**, Connett J, Kurnow K, Grill J, Johnson L, Kanner R and Enright P. Selection of spirometric measurements in a clinical trial, the Lung Health Study. *Am J Respir Crit Care Med* 1995; 151:675-681
75. Tashkin DP, Altose MD, Connett JE, Kanner RE, Lee WW and **Wise R**. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. *Am J Respir Crit Care Med* 1996; 153:1802-1811
76. Putman MT and **Wise R**. Myasthenia gravis and upper airway obstruction. *Chest* 1996; 109:400-404
77. Todd NW and **Wise R**. Respiratory complications in the collagen vascular diseases. *Clin Pulm Med* 1996; 3:101-112
78. Yurovsky VV, Wigley FM, **Wise R** and White B. Skewing of the CD8 T-cell repertoire in the lungs of patients with systemic sclerosis. *Hum Immunol* 1996; 48:84-97
79. Simmons MS, Nides MA, Rand CS, **Wise R** and Tashkin DP. Trends in compliance with bronchodilator inhaler use between follow-up visits in a clinical trial. *Chest* 1996; 109:963-968
80. **Wise R**. Changing smoking patterns and mortality from chronic obstructive pulmonary disease. *Prev Med* 1997; 26:418-421
81. **Wise R**, Szklo M, Matanoski G and Neugut AI. Workshop discussion panel. III: Implications of the changing tobacco-related mortality from COPD in the CPS-1 and CPS-2 surveys. *Prev Med* 1997; 26:457-459
82. Greidinger EL, Flaherty KT, White B, Rosen A, Wigley FM and **Wise R**. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. *Chest* 1998; 114:801-807
83. Punjabi NM, Shade D and **Wise R**. Correction of single-breath helium lung volumes in patients with airflow obstruction. *Chest* 1998; 114:907-918

84. Harik-Khan RI, **Wise R** and Fozard JL. Determinants of maximal inspiratory pressure. The Baltimore Longitudinal Study of Aging. *Am J Respir Crit Care Med* 1998; 158:1459-1464
85. O'Hara P, Connett JE, Lee WW, Nides M, Murray R and **Wise R**. Early and late weight gain following smoking cessation in the Lung Health Study. *Am J Epidemiol* 1998; 148:821-830
86. **Wise R**, Enright PL, Connett JE, Anthonisen NR, Kanner RE, Lindgren P, O'Hara P, Owens GR, Rand CS and Tashkin DP. Effect of weight gain on pulmonary function after smoking cessation in the Lung Health Study. *Am J Respir Crit Care Med* 1998; 157:866-872
87. Murray RP, Anthonisen NR, Connett JE, **Wise R**, Lindgren PG, Greene PG and Nides MA. Effects of multiple attempts to quit smoking and relapses to smoking on pulmonary function. Lung Health Study Research Group. *J Clin Epidemiol* 1998; 51:1317-1326
88. Diette GB, White P, Jr, Terry P, Jenckes M, **Wise R** and Rubin HR. Quality assessment through patient self-report of symptoms prefiberoptic and postfiberoptic bronchoscopy. *Chest* 1998; 114:1446-1453
89. Harik-Khan R, **Wise R**, Lou C, Morrell CH, Brant LJ and Fozard JL. The effect of gestational parity on FEV1 in a group of healthy volunteer women. *Respir Med* 1999; 93:382-388
90. Fessler HE and **Wise R**. Lung volume reduction surgery: is less really more? *Am J Respir Crit Care Med* 1999; 159:1031-1035
91. Atamas SP, Yurovsky VV, **Wise R**, Wigley FM, Goter Robinson CJ, Henry P, Alms WJ and White B. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. *Arthritis Rheum* 1999; 42:1168-1178
92. Jennings JR, Maricq HR, Canner J, Thompson B, Freedman RR, **Wise R** and Kaufmann PG. A thermal vascular test for distinguishing between patients with Raynaud's phenomenon and healthy controls. Raynaud's Treatment Study Investigators. *Health Psychol* 1999; 18:421-426
93. White B, Moore WC, Wigley FM, Xiao HQ and **Wise R**. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. *Ann Intern Med* 2000; 132:947-954
94. **Wise R**, Connett JE, Weinmann GG, Scanlon PD, Skeans MA and the Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. *N Engl J Med* 2000; 343:1902-1909
95. Taylor ML, Noble PW, White B, **Wise R**, Liu MC and Bochner BS. Extensive surface phenotyping of alveolar macrophages in interstitial lung disease. *Clin Immunol* 2000; 94:33-41
96. Szeffler SS, Weiss ST, Tonascia J, Adkinson NF, Bender B, Cherniack RM, Donithan M, Kelly HW, Reisman J, Shapiro GG, Sternberg AL, Strunk RC, Taggart VC, VanNatta M, **Wise R**, Wu M, Zeiger RS and for the Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. *N Engl J Med* 2000; 343:1054-1063
97. Patel A, Kesler B and **Wise R**. Persistent pneumomediastinum in interstitial fibrosis associated with rheumatoid arthritis: treatment with high-concentration oxygen. *Chest* 2000; 117:1809-1813
98. Simmons MS, Nides MA, Rand CS, **Wise R** and Tashkin DP. Unpredictability of deception in compliance with physician-prescribed bronchodilator inhaler use in a clinical trial. *Chest* 2000; 118:290-295
99. Harik-Khan RI, Fleg JL, Muller DC and **Wise R**. The effect of anthropometric and socioeconomic factors on the racial difference in lung function. *Am J Respir Crit Care Med* 2001; 164:1647-1654

100. Harik-Khan RI, **Wise R** and Fleg JL. The effect of gender on the relationship between body fat distribution and lung function. *J Clin Epidemiol* 2001; 54:399-406
101. Greidinger EL, Gaine SP, **Wise R**, Boling C, Houston-Harris T and Wigley FM. Primary pulmonary hypertension is not associated with scleroderma-like changes in nailfold capillaries. *Chest* 2001; 120:796-800
102. Castro M, Dozor AJ, Fish JE, Irvin CG, Scharf SM, Scheipeter ME, Holbrook JT, Tonascia J, **Wise R** and for the American Lung Association Asthma Clinical Research Centers. The safety of inactivated influenza vaccine in adults and children with asthma. *N Engl J Med* 2001; 345:1529-1536
103. Weil MH, Becker L, Budinger T, Kern K, Nichol G, Shechter I, Traystman R, Wiedemann H, **Wise R**, Weisfeldt M and Sopko G. Workshop Executive Summary Report: Post-resuscitative and initial Utility in Life Saving Efforts (PULSE): June 29-30, 2000; Lansdowne Resort and Conference Center; Leesburg, VA. *Circulation* 2001; 103:1182-1184
104. Harik-Khan RI, Fleg JL and **Wise R**. Body mass index and the risk of COPD. *Chest* 2002; 121:370-376
105. Holbrook JT, **Wise R**, Gerald LB and American Lung Association Asthma Clinical Research Centers. Drug distribution for a large crossover trial of the safety of inactivated influenza vaccine in asthmatics. *Control Clin Trials* 2002; 23:87-92
106. Luzina IG, Atamas SP, **Wise R**, Wigley FM, Xiao HQ and White B. Gene expression in bronchoalveolar lavage cells from scleroderma patients. *Am J Respir Cell Mol Biol* 2002; 26:549-557
107. Bilchick KC and **Wise R**. Paradoxical physical findings described by Kussmaul: pulsus paradoxus and Kussmaul's sign. *Lancet* 2002; 359:1940-1942
108. Becker LB, Weisfeldt ML, Weil MH, Budinger T, Carrico J, Kern K, Nichol G, Shechter I, Traystman R, Webb C, Wiedemann H, **Wise R** and Sopko G. The PULSE initiative: scientific priorities and strategic planning for resuscitation research and life saving therapies. *Circulation* 2002; 105:2562-2570
109. Schachna L, Wigley FM, Chang B, White B, **Wise R** and Gelber AC. Age and risk of pulmonary arterial hypertension in scleroderma. *Chest* 2003; 124:2098-2104
110. Schatz M, Dombrowski MP, **Wise R**, Thom EA, Landon M, Mabie W, Newman RB, Hauth JC, Lindheimer M, Caritis SN, Leveno KJ, Meis P, Miodovnik M, Wapner RJ, Paul RH, Varner MW, O'sullivan MJ, Thurnau GR, Conway D and McNellis D. Asthma morbidity during pregnancy can be predicted by severity classification. *J Allergy Clin Immunol* 2003; 112:283-288
111. Connett JE, Murray RP, Buist AS, **Wise R**, Bailey WC, Lindgren PG, Owens GR and Lung Health Study Research Group. Changes in smoking status affect women more than men: results of the Lung Health Study. *Am J Epidemiol* 2003; 157:973-979
112. Croxton TL, Weinmann GG, Senior RM, **Wise R**, Crapo JD and Buist AS. Clinical research in chronic obstructive pulmonary disease: needs and opportunities. *Am J Respir Crit Care Med* 2003; 167:1142-1149
113. **Wise R**, Kanner RE, Lindgren P, Connett JE, Altose MD, Enright PL, Tashkin DP and Lung Health Study Research Group. The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: the Lung Health Study. *Chest* 2003; 124:449-458
114. Eichenhorn MS, **Wise R**, Madhok TC, Gerald LB, Bailey WC, Tashkin DP, Scanlon PD and Lung Health Study Research Group. Lack of long-term adverse adrenal effects from inhaled triamcinolone: Lung Health Study II. *Chest* 2003; 124:57-62

115. Punjabi NM, Shade D, Patel AM and **Wise R**. Measurement variability in single-breath diffusing capacity of the lung. *Chest* 2003; 123:1082-1089
116. Luzina IG, Atamas SP, **Wise R**, Wigley FM, Choi J, Xiao HQ and White B. Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. *Arthritis Rheum* 2003; 48:2262-2274
117. Fishman A, Martinez F, Naunheim K, Piantadosi S, **Wise R**, Ries A, Weinmann G, Wood DE and National Emphysema Treatment Trial Research Group (incl **Wise R**). A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. *N Engl J Med* 2003; 348:2059-2073
118. Chang B, Wigley FM, White B and **Wise R**. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. *J Rheumatol* 2003; 30:2398-2405
119. Mohsenifar Z, Lee SM, Diaz P, Criner G, Scirba F, Ginsburg M and **Wise R**. Single-breath diffusing capacity of the lung for carbon monoxide: a predictor of PaO₂, maximum work rate, and walking distance in patients with emphysema. *Chest* 2003; 123:1394-1400
120. Scirba F, Criner GJ, Lee SM, Mohsenifar Z, Shade D, Slivka W, **Wise R** and National Emphysema Treatment Trial Research Group (incl **Wise R**). Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. *Am J Respir Crit Care Med* 2003; 167:1522-1527
121. Ash-Bernal R, **Wise R** and Wright SM. Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals. *Medicine (Baltimore)* 2004; 83:265-273
122. Zaas D, **Wise R**, Wiener C and Longcope Spirometry Investigation Team. Airway obstruction is common but unsuspected in patients admitted to a general medicine service. *Chest* 2004; 125:106-111
123. Dombrowski MP, Schatz M, **Wise R**, Momirova V, Landon M, Mabie W, Newman RB, McNellis D, Hauth JC, Lindheimer M, Caritis SN, Leveno KJ, Meis P, Miodovnik M, Wapner RJ, Paul RH, Varner MW, O'Sullivan MJ, Thurnau GR, Conway DL and National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network and the National Heart, Lung, and Blood Institute. Asthma during pregnancy. *Obstet Gynecol* 2004; 103:5-12
124. Smith LJ, Holbrook JT, **Wise R**, Blumenthal M, Dozor AJ, Mastrorarde J, Williams L and American Lung Association Asthma Clinical Research Centers. Dietary intake of soy genistein is associated with lung function in patients with asthma. *J Asthma* 2004; 41:833-843
125. **Wise R**, Wigley FM, White B, Leatherman G, Zhong J, Krasa H, Kambayashi J, Orlandi C and Czerwiec FS. Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. *Arthritis Rheum* 2004; 50:3994-4001
126. Hanania NA, Sockrider M, Castro M, Holbrook JT, Tonascia J, **Wise R**, Atmar RL and American Lung Association Asthma Clinical Research Centers. Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. *J Allergy Clin Immunol* 2004; 113:717-724
127. Scanlon PD, Connett JE, **Wise R**, Tashkin DP, Madhok T, Skeans M, Carpenter PC, Bailey WC, Buist AS, Eichenhorn M, Kanner RE, Weinmann G and Lung Health Study Research Group. Loss of bone density with inhaled triamcinolone in Lung Health Study II. *Am J Respir Crit Care Med* 2004; 170:1302-1309
128. Lee SM, **Wise R**, Sternberg AL, Tonascia J, Piantadosi S and National Emphysema Treatment Trial Research Group (incl **Wise R**). Methodologic issues in terminating enrollment of a subgroup of patients in a multicenter randomized trial. *Clin Trials* 2004; 1:326-338

129. Harik-Khan RI, Muller DC and **Wise R**. Racial difference in lung function in African-American and White children: effect of anthropometric, socioeconomic, nutritional, and environmental factors. *Am J Epidemiol* 2004; 160:893-900
130. Dombrowski MP, Schatz M, **Wise R**, Thom EA, Landon M, Mabie W, Newman RB, McNellis D, Hauth JC, Lindheimer M, Caritis SN, Leveno KJ, Meis P, Miodovnik M, Wapner RJ, Varner MW, O'Sullivan MJ, Conway DL, National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network and National Heart, Lung, and Blood Institute. Randomized trial of inhaled beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy. *Am J Obstet Gynecol* 2004; 190:737-744
131. Schatz M, Dombrowski MP, **Wise R**, Momirova V, Landon M, Mabie W, Newman RB, Hauth JC, Lindheimer M, Caritis SN, Leveno KJ, Meis P, Miodovnik M, Wapner RJ, Paul RH, Varner MW, O'Sullivan MJ, Thurnau GR, Conway DL, Maternal-Fetal Medicine Units Network, The National Institute of Child Health and Development and National Heart, Lung and Blood Institute. The relationship of asthma medication use to perinatal outcomes. *J Allergy Clin Immunol* 2004; 113:1040-1045
132. Harik-Khan RI, Muller DC and **Wise R**. Serum vitamin levels and the risk of asthma in children. *Am J Epidemiol* 2004; 159:351-357
133. Limb SL, Brown KC, Wood RA, **Wise R**, Eggleston PA, Tonascia J, Hamilton RG and Adkinson NF, Jr. Adult asthma severity in individuals with a history of childhood asthma. *J Allergy Clin Immunol* 2005; 115:61-66
134. Anthonisen NR, Skeans MA, **Wise R**, Manfreda J, Kanner RE, Connett JE and Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. *Ann Intern Med* 2005; 142:233-239
135. Limb SL, Brown KC, Wood RA, **Wise R**, Eggleston PA, Tonascia J and Adkinson NF, Jr. Irreversible lung function deficits in young adults with a history of childhood asthma. *J Allergy Clin Immunol* 2005; 116:1213-1219
136. **Wise R** and Brown CD. Minimal clinically important differences in the six-minute walk test and the incremental shuttle walking test. *COPD* 2005; 2:125-129
137. Barr RG, Celli BR, Martinez FJ, Ries AL, Rennard SI, Reilly JJ, Jr, Sciurba FC, Thomashow BM and **Wise R**. Physician and patient perceptions in COPD: the COPD Resource Network Needs Assessment Survey. *Am J Med* 2005; 118:1415
138. Dixon AE, Kaminsky DA, Holbrook JT, **Wise R**, Shade DM and Irvin CG. Allergic rhinitis and sinusitis in asthma: differential effects on symptoms and pulmonary function. *Chest* 2006; 130:429-435
139. Hendler I, Schatz M, Momirova V, **Wise R**, Landon M, Mabie W, Newman RB, Kiley J, Hauth JC, Moawad A, Caritis SN, Spong CY, Leveno KJ, Miodovnik M, Meis P, Wapner RJ, Paul RH, Varner MW, O'Sullivan MJ, Thurnau GR, Conway DL and National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Association of obesity with pulmonary and nonpulmonary complications of pregnancy in asthmatic women. *Obstet Gynecol* 2006; 108:77-82
140. Lima JJ, Holbrook JT, Wang J, Sylvester JE, Blake KV, Blumenthal MN, Castro M, Hanania N and **Wise R**. The C523A beta2 adrenergic receptor polymorphism associates with markers of asthma severity in African Americans. *J Asthma* 2006; 43:185-191
141. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, **Wise R**, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M and Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. *N Engl J Med* 2006; 354:2655-2666

142. Dixon AE, Shade DM, Cohen RI, Skloot GS, Holbrook JT, Smith LJ, Lima JJ, Allayee H, Irvin CG, **Wise R** and American Lung Association-Asthma Clinical Research Centers. Effect of obesity on clinical presentation and response to treatment in asthma. *J Asthma* 2006; 43:553-558
143. Roth MD, Connett JE, D'Armiento JM, Foronjy RF, Friedman PJ, Goldin JG, Louis TA, Mao JT, Muindi JR, O'Connor GT, Ramsdell JW, Ries AL, Scharf SM, Schluger NW, Sciruba FC, Skeans MA, Walter RE, Wendt CH, **Wise R** and FORTE Study Investigators. Feasibility of retinoids for the treatment of emphysema study. *Chest* 2006; 130:1334-1345
144. Fuhlbrigge AL, Weiss ST, Kuntz KM, Paltiel AD and CAMP Research Group (incl **Wise R**). Forced expiratory volume in 1 second percentage improves the classification of severity among children with asthma. *Pediatrics* 2006; 118:e347-55
145. Lima JJ, Zhang S, Grant A, Shao L, Tantisira KG, Allayee H, Wang J, Sylvester J, Holbrook J, **Wise R**, Weiss ST and Barnes K. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. *Am J Respir Crit Care Med* 2006; 173:379-385
146. Chang B, Schachna L, White B, Wigley FM and **Wise R**. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. *J Rheumatol* 2006; 33:269-274
147. Martinez FJ, Foster G, Curtis JL, Criner G, Weinmann G, Fishman A, DeCamp MM, Benditt J, Sciruba F, Make B, Mohsenifar Z, Diaz P, Hoffman E, **Wise R** and NETT Research Group (incl **Wise R**). Predictors of mortality in patients with emphysema and severe airflow obstruction. *Am J Respir Crit Care Med* 2006; 173:1326-1334
148. **Wise R**, Polito AJ and Krishnan V. Respiratory physiologic changes in pregnancy. *Immunol Allergy Clin North Am* 2006; 26:1-12
149. Schatz M, Dombrowski MP, **Wise R**, Momirova V, Landon M, Mabie W, Newman RB, Rouse DJ, Lindheimer M, Miodovnik M, Caritis SN, Leveno KJ, Meis P, Wapner RJ, Paul RH, O'Sullivan MJ, Varner MW, Thurnau GR, Conway DL, National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network and National Heart, Lung, and Blood Institute. Spirometry is related to perinatal outcomes in pregnant women with asthma. *Am J Obstet Gynecol* 2006; 194:120-126
150. **Wise R**. The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression. *Am J Med* 2006; 119:4-11
151. Herpel LB, Kanner RE, Lee SM, Fessler HE, Sciruba FC, Connett JE and **Wise R**. Variability of spirometry in chronic obstructive pulmonary disease: results from two clinical trials. *Am J Respir Crit Care Med* 2006; 173:1106-1113
152. McGarvey LP, John M, Anderson JA, Zvarich M, **Wise R** and TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. *Thorax* 2007; 62:411-415
153. Irvin CG, Kaminsky DA, Anthonisen NR, Castro M, Hanania NA, Holbrook JT, Lima JJ, **Wise R** and for the American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. *Am J Respir Crit Care Med* 2007; 175:235-242
154. Criner GJ, Scharf SM, Falk JA, Gaughan JP, Sternberg AL, Patel NB, Fessler HE, Minai OA, Fishman AP and National Emphysema Treatment Trial Research Group (incl **Wise R**). Effect of lung volume reduction surgery on resting pulmonary hemodynamics in severe emphysema. *Am J Respir Crit Care Med* 2007; 176:253-260
155. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, **Wise R**, Wigley F, White B, Steen

- V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Khanna D, Li N, Li G and Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. *Am J Respir Crit Care Med* 2007; 176:1026-1034
156. **Wise R**. Ethical issues confronted in pulmonary clinical trials. *Proc Am Thorac Soc* 2007; 4:200-5; discussion 205
157. Brown CD and **Wise R**. Field tests of exercise in COPD: the six-minute walk test and the shuttle walk test. *COPD* 2007; 4:217-223
158. Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, **Wise R**, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ and Scleroderma Lung Study Group. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. *Arthritis Rheum* 2007; 56:1676-1684
159. **Wise R** and Tashkin DP. Optimizing treatment of chronic obstructive pulmonary disease: an assessment of current therapies. *Am J Med* 2007; 120:S4-13
160. Drummond MB and **Wise R**. Oxygen therapy in COPD: what do we know? *Am J Respir Crit Care Med* 2007; 176:321-322
161. Mittoo S, Wigley FM, **Wise R**, Xiao H and Hummers L. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease. *Arthritis Rheum* 2007; 56:4195-4202
162. Eden E, Holbrook JT, Brantly ML, Turino GM and **Wise R**. Prevalence of alpha-1 antitrypsin deficiency in poorly controlled asthma--results from the ALA-ACRC low-dose theophylline trial. *J Asthma* 2007; 44:605-608
163. **Wise R** and Tashkin DP. Preventing chronic obstructive pulmonary disease: what is known and what needs to be done to make a difference to the patient? *Am J Med* 2007; 120:S14-22
164. Peters SP, Anthonisen N, Castro M, Holbrook JT, Irvin CG, Smith LJ, **Wise R** and for the American Lung Association Asthma Clinical Research Centers. Randomized comparison of strategies for reducing treatment in mild persistent asthma. *N Engl J Med* 2007; 356:2027-2039
165. Clements PJ, Roth MD, Elashoff R, Tashkin DP, Goldin J, Silver RM, Sterz M, Seibold JR, Schraufnagel D, Simms RW, Bolster M, **Wise R**, Steen V, Mayes MD, Connelly K, Metersky M, Furst DE and Scleroderma Lung Study Group. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. *Ann Rheum Dis* 2007; 66:1641-1647
166. Martinez FJ, Curtis JL, Sciruba F, Mumford J, Giardino ND, Weinmann G, Kazerooni E, Murray S, Criner GJ, Sin DD, Hogg J, Ries AL, Han M, Fishman AP, Make B, Hoffman EA, Mohsenifar Z, **Wise R** and National Emphysema Treatment Trial Research Group (incl **Wise R**). Sex differences in severe pulmonary emphysema. *Am J Respir Crit Care Med* 2007; 176:243-252
167. Fan VS, Ramsey SD, Giardino ND, Make BJ, Emery CF, Diaz PT, Benditt JO, Mosenifar Z, McKenna R, Jr, Curtis JL, Fishman AP, Martinez FJ and National Emphysema Treatment Trial (NETT) Research Group (incl **Wise R**). Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease. *Arch Intern Med* 2007; 167:2345-2353
168. McCormack MC, Shade D and **Wise R**. Spirometer calibration checks: is 3.5% good enough? *Chest* 2007; 131:1486-1493

169. **Wise R**, Teeter JG, Jensen RL, England RD, Schwartz PF, Giles DR, Ahrens RC, MacIntyre NR, Riese RJ and Crapo RO. Standardization of the single-breath diffusing capacity in a multicenter clinical trial. *Chest* 2007; 132:1191-1197
170. Salzman SH, Marciniuk DD, **Wise R**, Ries AL and Pulmonary Physiology, Function, and Rehabilitation NetWork of the ACCP. Survey on quality of training in pulmonary physiology during fellowship. *Chest* 2007; 131:1270-1271
171. Gelb AF, Karpel J, **Wise R**, Cassino C, Johnson P and Conoscenti CS. Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma. *Pulm Pharmacol Ther* 2008; 21:630-636
172. Snyder ML, Goss CH, Neradilek B, Polissar NL, Mosenifar Z, **Wise R**, Fishman AP, Benditt JO and National Emphysema Treatment Trial Research Group (incl **Wise R**). Changes in arterial oxygenation and self-reported oxygen use after lung volume reduction surgery. *Am J Respir Crit Care Med* 2008; 178:339-345
173. Man SF, Xing L, Connett JE, Anthonisen NR, **Wise R**, Tashkin DP, Zhang X, Vessey R, Walker TG, Celli BR and Sin DD. Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? *Eur Respir J* 2008; 32:1451-1457
174. Drummond MB, Blackford AL, Benditt JO, Make BJ, Sciruba FC, McCormack MC, Martinez FJ, Fessler HE, Fishman AP, **Wise R** and NETT Investigators (incl **Wise R**). Continuous oxygen use in nonhypoxemic emphysema patients identifies a high-risk subset of patients: retrospective analysis of the National Emphysema Treatment Trial. *Chest* 2008; 134:497-506
175. Washko GR, Fan VS, Ramsey SD, Mohsenifar Z, Martinez F, Make BJ, Sciruba FC, Criner GJ, Minai O, Decamp MM, Reilly JJ and National Emphysema Treatment Trial Research Group (incl **Wise R**). The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. *Am J Respir Crit Care Med* 2008; 177:164-169
176. Patel AC, Van Natta ML, Tonascia J, **Wise R** and Strunk RC. Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma. *J Allergy Clin Immunol* 2008; 122:781-787.e8
177. Lomas DA, Silverman EK, Edwards LD, Miller BE, Coxson HO, Tal-Singer R and Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators (Incl. **Wise R**). Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. *Thorax* 2008; 63:1058-1063
178. Brown CD, Benditt JO, Sciruba FC, Lee SM, Criner GJ, Mosenifar Z, Shade DM, Slivka WA, **Wise R** and National Emphysema Treatment Trial Research Group (incl **Wise R**). Exercise testing in severe emphysema: association with quality of life and lung function. *COPD* 2008; 5:117-124
179. McGrath-Morrow S, Rangasamy T, Cho C, Sussan T, Neptune E, **Wise R**, Tudor RM and Biswal S. Impaired lung homeostasis in neonatal mice exposed to cigarette smoke. *Am J Respir Cell Mol Biol* 2008; 38:393-400
180. Drummond MB, Schwartz PF, Duggan WT, Teeter JG, Riese RJ, Ahrens RC, Crapo RO, England RD, Macintyre NR, Jensen RL and **Wise R**. Intersession variability in single-breath diffusing capacity in diabetics without overt lung disease. *Am J Respir Crit Care Med* 2008; 178:225-232
181. Martinez FJ, Han MK, Andrei AC, **Wise R**, Murray S, Curtis JL, Sternberg A, Criner G, Gay SE, Reilly J, Make B, Ries AL, Sciruba F, Weinmann G, Mosenifar Z, DeCamp M, Fishman AP, Celli BR and National Emphysema Treatment Trial Research Group (incl **Wise R**). Longitudinal change in the BODE index predicts mortality in severe emphysema. *Am J Respir Crit Care Med* 2008; 178:491-499
182. Kim V, Benditt JO, **Wise R** and Sharafkhaneh A. Oxygen therapy in chronic obstructive pulmonary disease. *Proc Am Thorac Soc* 2008; 5:513-518

183. Muindi JR, Roth MD, **Wise R**, Connett JE, O'Connor GT, Ramsdell JW, Schluger NW, Romkes M, Branch RA, Sciruba FC and FORTE Study Investigators. Pharmacokinetics and metabolism of all-trans- and 13-cis-retinoic acid in pulmonary emphysema patients. *J Clin Pharmacol* 2008; 48:96-107
184. Springmeyer SC, Casaburi R, Make B, Jones P and **Wise R**. Pulmonary rehabilitation and clinical trial design in patients with severe COPD. *COPD* 2008; 5:305-309
185. **Wise R** and Drummond MB. The role of NETT in emphysema research. *Proc Am Thorac Soc* 2008; 5:385-392
186. Mastronarde JG, **Wise R**, Shade DM, Olopade CO, Scharf SM and American Lung Association Asthma Clinical Research Centers. Sleep quality in asthma: results of a large prospective clinical trial. *J Asthma* 2008; 45:183-189
187. He JQ, Foreman MG, Shumansky K, Zhang X, Akhbar L, Sin DD, Man SF, DeMeo DL, Litonjua AA, Silverman EK, Connett JE, Anthonisen NR, **Wise R**, Pare PD and Sandford AJ. Associations of IL6 polymorphisms with lung function decline and COPD. *Thorax* 2009; 64:698-704
188. Han MK, Bartholmai B, Liu LX, Murray S, Curtis JL, Sciruba FC, Kazerooni EA, Thompson B, Frederick M, Li D, Schwarz M, Limper A, Freeman C, Landreneau RJ, **Wise R** and Martinez FJ. Clinical significance of radiologic characterizations in COPD. *COPD* 2009; 6:459-467
189. Dixon AE, Sugar EA, Zinreich SJ, Slavin RG, Corren J, Naclerio RM, Ishii M, Cohen RI, Brown ED, **Wise R**, Irvin CG and American Lung Association-Asthma Clinical Research Centers. Criteria to screen for chronic sinonasal disease. *Chest* 2009; 136:1324-1332
190. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP and UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. *Lancet* 2009; 374:1171-1178
191. DiMango E, Holbrook JT, Simpson E, Reibman J, Richter J, Narula S, Prusakowski N, Mastronarde JG, **Wise R** and American Lung Association Asthma Clinical Research Centers. Effects of asymptomatic proximal and distal gastroesophageal reflux on asthma severity. *Am J Respir Crit Care Med* 2009; 180:809-816
192. Mastronarde JG, Anthonisen NR, Castro M, Holbrook JT, Leone FT, Teague WG, **Wise R** and for the American Lung Association Asthma Clinical Research Centers. Efficacy of esomeprazole for treatment of poorly controlled asthma. *N Engl J Med* 2009; 360:1487-1499
193. D'Armiento JM, Scharf SM, Roth MD, Connett JE, Ghio A, Sternberg D, Goldin JG, Louis TA, Mao JT, O'Connor GT, Ramsdell JW, Ries AL, Schluger NW, Sciruba FC, Skeans MA, Voelker H, Walter RE, Wendt CH, Weinmann GG, **Wise R** and Foronjy RF. Eosinophil and T cell markers predict functional decline in COPD patients. *Respir Res* 2009; 10:113
194. Malhotra D, Thimmulappa R, Vij N, Navas-Acien A, Sussan T, Merali S, Zhang L, Kelsen SG, Myers A, **Wise R**, Tudor R and Biswal S. Heightened endoplasmic reticulum stress in the lungs of patients with chronic obstructive pulmonary disease: the role of Nrf2-regulated proteasomal activity. *Am J Respir Crit Care Med* 2009; 180:1196-1207
195. Benzo R, Farrell MH, Chang CC, Martinez FJ, Kaplan R, Reilly J, Criner G, **Wise R**, Make B, Luketich J, Fishman AP, Sciruba FC and NETT Research Group (incl **Wise R**). Integrating health status and survival data: the palliative effect of lung volume reduction surgery. *Am J Respir Crit Care Med* 2009; 180:239-246
196. Berry CE and **Wise R**. Interpretation of pulmonary function test: issues and controversies. *Clin Rev Allergy Immunol* 2009; 37:173-180
197. Hansel NN, Gao L, Rafaels NM, Mathias RA, Neptune ER, Tankersley C, Grant AV, Connett J, Beaty TH, **Wise R** and Barnes KC. Leptin receptor polymorphisms and lung function decline in COPD. *Eur Respir J* 2009; 34:103-110

198. **Wise R**, Bartlett SJ, Brown ED, Castro M, Cohen R, Holbrook JT, Irvin CG, Rand CS, Sockrider MM, Sugar EA and American Lung Association Asthma Clinical Research Centers. Randomized trial of the effect of drug presentation on asthma outcomes: the American Lung Association Asthma Clinical Research Centers. *J Allergy Clin Immunol* 2009; 124:436-44, 444e1-8
199. Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller BE, Horstman DH, Tal-Singer R and Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints study investigators. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. *Eur Respir J* 2009; 34:95-102
200. Hersh CP, Hansel NN, Barnes KC, Lomas DA, Pillai SG, Coxson HO, Mathias RA, Rafaels NM, **Wise R**, Connett JE, Klanderman BJ, Jacobson FL, Gill R, Litonjua AA, Sparrow D, Reilly JJ, Silverman EK and ICGN Investigators. Transforming growth factor-beta receptor-3 is associated with pulmonary emphysema. *Am J Respir Cell Mol Biol* 2009; 41:324-331
201. Drummond MB, **Wise R**, John M, Zvarich MT and McGarvey LP. Accuracy of death certificates in COPD: analysis from the TORCH trial. *COPD* 2010; 7:179-185
202. Giardino ND, Curtis JL, Andrei AC, Fan VS, Benditt JO, Lyubkin M, Naunheim K, Criner G, Make B, **Wise R**, Murray SK, Fishman AP, Sciruba FC, Liberzon I, Martinez FJ and NETT Research Group (incl **Wise R**). Anxiety is associated with diminished exercise performance and quality of life in severe emphysema: a cross-sectional study. *Respir Res* 2010; 11:29
203. Hansel NN, Sidhaye V, Rafaels NM, Gao L, Gao P, Williams R, Connett JE, Beaty TH, Mathias RA, **Wise R**, King LS and Barnes KC. Aquaporin 5 polymorphisms and rate of lung function decline in chronic obstructive pulmonary disease. *PLoS One* 2010; 5:e14226
204. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Wouters E, Yates JC, Vestbo J and (ECLIPSE investigators, incl. **Wise R**). Characterisation of COPD heterogeneity in the ECLIPSE cohort. *Respir Res* 2010; 11:122-9921-11-122
205. Reinke C, Bevans-Fonti S, Grigoryev DN, Drager LF, Myers AC, **Wise R**, Schwartz AR, Mitzner W and Polotsky VY. Chronic Intermittent Hypoxia Induces Lung Growth in Adult Mice. *Am J Physiol Lung Cell Mol Physiol* 2010;
206. Baldwin MR, Checkley W, **Wise R**, Khattry SK, LeClerq SC and West KP, Jr. A cleaning and calibration method for the SpiroPro portable spirometer's pneumotachometer tube in a remote field study. *Respir Care* 2010; 55:443-452
207. Drummond MB, Kirk GD, Ricketts EP, McCormack MC, Hague JC, McDyer JF, Mehta SH, Engels EA, **Wise R** and Merlo CA. Cross sectional analysis of respiratory symptoms in an injection drug user cohort: the impact of obstructive lung disease and HIV. *BMC Pulm Med* 2010; 10:27
208. Newman RB, Momirova V, Dombrowski MP, Schatz M, **Wise R**, Landon M, Rouse DJ, Lindheimer M, Caritis SN, Sheffield J, Miodovnik M, Wapner RJ, Varner MW, O'Sullivan MJ, Conway DL and Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (MFMU) Network. The effect of active and passive household cigarette smoke exposure on pregnant women with asthma. *Chest* 2010; 137:601-608
209. Celli B, Vestbo J, Jenkins CR, Jones PW, Ferguson GT, Calverley PM, Yates JC, Anderson JA, Willits LR, **Wise R** and on behalf of the investigators of the TORCH study. Gender Differences in Mortality and Clinical Expressions of Patients with COPD: The TORCH Experience. *Am J Respir Crit Care Med* 2010;
210. Moldenhauer JS, Lai Y, Schatz M, **Wise R**, Landon MB, Newman RB, Rouse DJ, Simhan HN, Leveno KJ, Miodovnik M, Lindheimer MD, Wapner RJ, Varner MW, O'Sullivan MJ, Conway DL and Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Influence of maternal asthma and asthma severity on newborn morphometry. *J Asthma* 2010; 47:145-149

211. Pillai SG, Kong X, Edwards LD, Cho MH, Anderson WH, Coxson HO, Lomas DA, Silverman EK and ECLIPSE and ICGN Investigators (incl **Wise R**). Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2010; 182:1498-1505
212. Checkley W, West KP, Jr, **Wise R**, Baldwin MR, Wu L, LeClerq SC, Christian P, Katz J, Tielsch JM, Khattry S and Sommer A. Maternal vitamin A supplementation and lung function in offspring. *N Engl J Med* 2010; 362:1784-1794
213. Puhan MA, Chandra D, Mosenifar Z, Ries A, Make B, Hansel NN, **Wise R**, Sciruba F and for the NETT Research Group. The minimal important difference of exercise tests in severe COPD. *Eur Respir J* 2010;
214. Berry CE and **Wise R**. Mortality in COPD: Causes, Risk Factors, and Prevention. *COPD* 2010; 7:375-382
215. Washko GR, Martinez FJ, Hoffman EA, Loring SH, Estepar RS, Diaz AA, Sciruba FC, Silverman EK, Han MK, Decamp M, Reilly JJ and National Emphysema Treatment Trial Research Group (incl. Wise, RA). Physiological and computed tomographic predictors of outcome from lung volume reduction surgery. *Am J Respir Crit Care Med* 2010; 181:494-500
216. Han MK, **Wise R**, Mumford J, Sciruba F, Criner GJ, Curtis JL, Murray S, Sternberg A, Weinman G, Kazerooni E, Fishman AP, Make B, Hoffman EA, Mosenifar Z, Martinez FJ and NETT Research Group (incl **Wise R**). Prevalence and clinical correlates of bronchoreversibility in severe emphysema. *Eur Respir J* 2010; 35:1048-1056
217. Sciruba FC, Ernst A, Herth FJ, Strange C, Criner GJ, Marquette CH, Kovitz KL, Chiacchierini RP, Goldin J, McLennan G and VENT Study Research Group. A randomized study of endobronchial valves for advanced emphysema. *N Engl J Med* 2010; 363:1233-1244
218. Schatz M, Dombrowski MP, **Wise R**, Lai Y, Landon M, Newman RB, Rouse DJ, Miodovnik M, O'Sullivan MJ, Caritis SN, Leveno KJ, Wapner RJ, Conway DL and Eunice Kennedy Shriver National Institute Of Child Health And Human Development Maternal-Fetal Medicine Units Network And The National Heart Lung And Blood Institute. The relationship of asthma-specific quality of life during pregnancy to subsequent asthma and perinatal morbidity. *J Asthma* 2010; 47:46-50
219. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA and Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators (Incl. **Wise R**). Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med* 2010; 363:1128-1138
220. Krishnan JA, Bender BG, Wamboldt FS, Szeffler SJ, Adkinson NF, Jr, Zeiger RS, **Wise R**, Bilderback AL, Rand CS and Adherence Ancillary Study Group. Adherence to inhaled corticosteroids: An ancillary study of the Childhood Asthma Management Program clinical trial. *J Allergy Clin Immunol* 2011;
221. Drummond MB, Kirk GD, Astemborski J, Marshall MM, Mehta SH, McDyer JF, Brown RH, **Wise R** and Merlo CA. Association between obstructive lung disease and markers of HIV infection in a high-risk cohort. *Thorax* 2011;
222. Hanania NA, King MJ, Braman SS, Saltoun C, **Wise R**, Enright P, Falsey AR, Mathur SK, Ramsdell JW, Rogers L, Stempel DA, Lima JJ, Fish JE, Wilson SR, Boyd C, Patel KV, Irvin CG, Yawn BP, Halm EA, Wasserman SI, Sands MF, Ershler WB, Ledford DK and Asthma in Elderly workshop participants. Asthma in the elderly: Current understanding and future research needs--a report of a National Institute on Aging (NIA) workshop. *J Allergy Clin Immunol* 2011; 128:S4-24
223. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, MacNee W, Miller BE, Silverman EK, Tal-Singer R, Wouters E, Rennard SI, ECLIPSE Investigators (incl **Wise R**) and (incl. **Wise R**). Changes in forced expiratory volume in 1 second over time in COPD. *N Engl J Med* 2011; 365:1184-1192

224. Reinke C, Bevans-Fonti S, Grigoryev DN, Drager LF, Myers AC, **Wise R**, Schwartz AR, Mitzner W and Polotsky VY. Chronic intermittent hypoxia induces lung growth in adult mice. *Am J Physiol Lung Cell Mol Physiol* 2011; 300:L266-73
225. Han MK, Kazerooni EA, Lynch DA, Liu LX, Murray S, Curtis JL, Criner GJ, Kim V, Bowler RP, Hanania NA, Anzueto AR, Make BJ, Hokanson JE, Crapo JD, Silverman EK, Martinez FJ, Washko GR and COPDGene Investigators (incl Wise, RA). Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. *Radiology* 2011; 261:274-282
226. Hill J, Heslop C, Man SF, Frohlich J, Connett JE, Anthonisen NR, **Wise R**, Tashkin DP and Sin DD. Circulating surfactant protein-D and the risk of cardiovascular morbidity and mortality. *Eur Heart J* 2011; 32:1918-1925
227. Yoon H, Li Y, Man SF, Tashkin D, **Wise R**, Connett JE, Anthonisen NA, Churg A, Wright JL and Sin DD. The complex relationship of serum adiponectin to COPD outcomes. *Chest* 2011;
228. Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Tal-Singer R and Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. *Respir Res* 2011; 12:146
229. Malhotra D, Thimmulappa RK, Mercado N, Ito K, Kombairaju P, Kumar S, Ma J, Feller-Kopman D, **Wise R**, Barnes P and Biswal S. Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. *J Clin Invest* 2011; 121:4289-4302
230. Lang JE, Hossain J, Dixon AE, Shade D, **Wise R**, Peters SP, Lima JJ and for the American Lung Association-Asthma Clinical Research Centers. Does Age Impact the Obese Asthma Phenotype?: Longitudinal Asthma Control, Airway Function, and Airflow Perception Among Mild Persistent Asthmatics. *Chest* 2011; 140:1524-1533
231. Robinson CL, Baumann LM, Romero K, Combe JM, Gomez A, Gilman RH, Cabrera L, Gonzalez G, Hansel NN, **Wise R**, Barnes KC, Breyse PN and Checkley W. Effect of urbanisation on asthma, allergy and airways inflammation in a developing country setting. *Thorax* 2011; 66:1051-1057
232. Baumann LM, Robinson CL, Combe JM, Gomez A, Romero K, Gilman RH, Cabrera L, Hansel NN, **Wise R**, Breyse PN, Barnes K, Hernandez JE and Checkley W. Effects of distance from a heavily transited avenue on asthma and atopy in a periurban shantytown in Lima, Peru. *J Allergy Clin Immunol* 2011; 127:875-882
233. McGrath-Morrow S, Malhotra D, Lauer T, Michael Collaco J, Mitzner W, Neptune E, **Wise R** and Biswal S. Exposure to neonatal cigarette smoke causes durable lung changes but does not potentiate cigarette smoke-induced chronic obstructive pulmonary disease in adult mice. *Exp Lung Res* 2011; 37:354-363
234. Qiu W, Cho MH, Riley JH, Anderson WH, Singh D, Bakke P, Gulsvik A, Litonjua AA, Lomas DA, Crapo JD, Beaty TH, Celli BR, Rennard S, Tal-Singer R, Fox SM, Silverman EK, Hersh CP and ECLIPSE Investigators (incl **Wise R**). Genetics of sputum gene expression in chronic obstructive pulmonary disease. *PLoS One* 2011; 6:e24395
235. Siedlinski M, Cho MH, Bakke P, Gulsvik A, Lomas DA, Anderson W, Kong X, Rennard SI, Beaty TH, Hokanson JE, Crapo JD, Silverman EK, COPDGene Investigators (incl Wise, RA) and ECLIPSE Investigators (incl **Wise R**). Genome-wide association study of smoking behaviours in patients with COPD. *Thorax* 2011; 66:894-902
236. Mittoo S, Wigley FM, **Wise R**, Woods A, Xiao H and Hummers LK. Long term effects of cyclophosphamide treatment on lung function and survival in scleroderma patients with interstitial lung disease. *Open Rheumatol J* 2011; 5:1-6
237. Hegewald MJ, Jensen RL, Teeter JG, **Wise R**, Riese RJ, England RD, Ahrens RC, Crapo RO and Macintyre NR. Long-Term Intersession Variability for Single-Breath Diffusing Capacity. *Respiration* 2011;

238. Clerisme-Beaty EM, Bartlett SJ, Teague WG, Lima J, Irvin CG, Cohen R, Castro M, **Wise R** and Rand CS. The Madison Avenue effect: How drug presentation style influences adherence and outcome in patients with asthma. *J Allergy Clin Immunol* 2011; 127:406-411
239. Puhan MA, Chandra D, Mosenifar Z, Ries A, Make B, Hansel NN, **Wise R**, Scirba F and for the National Emphysema Treatment Trial (NETT) Research Group. The minimal important difference of exercise tests in severe COPD. *Eur Respir J* 2011; 37:784-790
240. Drummond MB, Kirk GD, Astemborski J, McCormack MC, Marshall MM, Mehta SH, **Wise R** and Merlo CA. Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users. *Int J Chron Obstruct Pulmon Dis* 2011; 6:89-95
241. Crim C, Celli B, Edwards LD, Wouters E, Coxson HO, Tal-Singer R, Calverley PM and ECLIPSE Investigators (incl **Wise R**). Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. *Respir Med* 2011; 105:1069-1078
242. Drummond MB, Peters SP, Castro M, Holbrook JT, Irvin CG, Smith LJ, **Wise R**, Sugar EA and for the American Lung Association Asthma Clinical Research Center Research Group. Risk Factors for Montelukast Treatment Failure in Step-Down Therapy for Controlled Asthma. *J Asthma* 2011; 48:1051-1057
243. Sin DD, Miller BE, Duvoix A, Man SF, Zhang X, Silverman EK, Connett JE, Anthonisen NA, **Wise R**, Tashkin D, Celli BR, Edwards LD, Locantore N, Macnee W, Tal-Singer R, Lomas DA and ECLIPSE Investigators (incl **Wise R**). Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2011; 183:1187-1192
244. Celli B, Vestbo J, Jenkins CR, Jones PW, Ferguson GT, Calverley PM, Yates JC, Anderson JA, Willits LR, **Wise R** and on behalf of the investigators of the TORCH study. Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease: The TORCH Experience. *Am J Respir Crit Care Med* 2011; 183:317-322
245. Checkley W, West KP, Jr, **Wise R**, Wu L, Leclercq SC, Khatry S, Katz J, Christian P, Tielsch JM and Sommer A. Supplementation with vitamin A early in life and subsequent risk of asthma. *Eur Respir J* 2011; 38:1310-1319
246. Harvey CJ, Thimmulappa RK, Sethi S, Kong X, Yarmus L, Brown RH, Feller-Kopman D, **Wise R** and Biswal S. Targeting Nrf2 Signaling Improves Bacterial Clearance by Alveolar Macrophages in Patients with COPD and in a Mouse Model. *Sci Transl Med* 2011; 3:78ra32
247. Krishnan JA, Bender BG, Wamboldt FS, Szeffler SJ, Adkinson NF, Jr, Zeiger RS, **Wise R**, Bilderback AL, Rand CS and Adherence Ancillary Study Group. Adherence to inhaled corticosteroids: an ancillary study of the Childhood Asthma Management Program clinical trial. *J Allergy Clin Immunol* 2012; 129:112-118
248. Podowski M, Calvi C, Metzger S, Misono K, Poonyagariyagorn H, Lopez-Mercado A, Ku T, Lauer T, McGrath-Morrow S, Berger A, Cheadle C, Tuder R, Dietz HC, Mitzner W, **Wise R** and Neptune E. Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. *J Clin Invest* 2012; 122:229-240
249. Drummond MB, Kirk GD, Astemborski J, Marshall MM, Mehta SH, McDyer JF, Brown RH, **Wise R** and Merlo CA. Association between obstructive lung disease and markers of HIV infection in a high-risk cohort. *Thorax* 2012; 67:309-314
250. Tepper RS, **Wise R**, Covar R, Irvin CG, Kercksmar CM, Kraft M, Liu MC, O'Connor GT, Peters SP, Sorkness R and Togias A. Asthma outcomes: pulmonary physiology. *J Allergy Clin Immunol* 2012; 129:S65-87

251. Bime C, Wei CY, Holbrook JT, Sockrider MM, Revicki DA and **Wise R**. Asthma symptom utility index: reliability, validity, responsiveness, and the minimal important difference in adult asthmatic patients. *J Allergy Clin Immunol* 2012; 130:1078-1084
252. Shah AA, Chung SE, Wigley FM, **Wise R** and Hummers LK. Changes in estimated right ventricular systolic pressure predict mortality and pulmonary hypertension in a cohort of scleroderma patients. *Ann Rheum Dis* 2012;
253. Yoon HI, Li Y, Man SF, Tashkin D, **Wise R**, Connett JE, Anthonisen NA, Churg A, Wright JL and Sin DD. The complex relationship of serum adiponectin to COPD outcomes COPD and adiponectin. *Chest* 2012; 142:893-899
254. Tse SM, Kelly HW, Litonjua AA, Van Natta ML, Weiss ST, Tantisira KG and Childhood Asthma Management Program Research Group (incl **Wise R**). Corticosteroid use and bone mineral accretion in children with asthma: effect modification by vitamin D. *J Allergy Clin Immunol* 2012; 130:53-60.e4
255. Lockett AD, Van Demark M, Gu Y, Schweitzer KS, Sigua N, Kamocki K, Fijalkowska I, Garrison J, Fisher AJ, Serban K, **Wise R**, Flotte TR, Mueller C, Presson RG, Jr, Petrache HI, Tudor RM and Petrache I. Effect of cigarette smoke exposure and structural modifications on the alpha-1 Antitrypsin interaction with caspases. *Mol Med* 2012; 18:445-454
256. Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, Zeiger RS, Raissy HH, Van Natta ML, Tonascia J, Strunk RC and CAMP Research Group (incl **Wise R**). Effect of inhaled glucocorticoids in childhood on adult height. *N Engl J Med* 2012; 367:904-912
257. Checkley W, Robinson CL, Baumann LM, Romero K, Combe JM, Gilman RH, **Wise R**, Hamilton RG, Gonzalez G, Cama V, Hansel NN and PURA study investigators. Effect of urbanization on the relation of total serum immunoglobulin E to asthma. *Eur Respir J* 2012;
258. Wu AC, Tantisira K, Li L, Fuhlbrigge AL, Weiss ST, Litonjua A and Childhood Asthma Management Program Research Group (incl **Wise R**). Effect of vitamin D and inhaled corticosteroid treatment on lung function in children. *Am J Respir Crit Care Med* 2012; 186:508-513
259. Kim DK, Cho MH, Hersh CP, Lomas DA, Miller BE, Kong X, Bakke P, Gulsvik A, Agusti A, Wouters E, Celli B, Coxson H, Vestbo J, MacNee W, Yates JC, Rennard S, Litonjua A, Qiu W, Beaty TH, Crapo JD, Riley JH, Tal-Singer R, Silverman EK and ECLIPSE, ICGN, and COPDGene Investigators (incl **Wise R**). Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2012; 186:1238-1247
260. Cho MH, Castaldi PJ, Wan ES, Siedlinski M, Hersh CP, Demeo DL, Himes BE, Sylvia JS, Klanderman BJ, Ziniti JP, Lange C, Litonjua AA, Sparrow D, Regan EA, Make BJ, Hokanson JE, Murray T, Hetmanski JB, Pillai SG, Kong X, Anderson WH, Tal-Singer R, Lomas DA, Coxson HO, Edwards LD, MacNee W, Vestbo J, Yates JC, Agusti A, Calverley PM, Celli B, Crim C, Rennard S, Wouters E, Bakke P, Gulsvik A, Crapo JD, Beaty TH, Silverman EK, ICGN Investigators, ECLIPSE Investigators (incl **Wise R**) and COPDGene Investigators (Incl. **Wise R**). A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. *Hum Mol Genet* 2012; 21:947-957
261. Writing Committee for the American Lung Association Asthma Clinical Research Centers, Holbrook JT, **Wise R**, Gold BD, Blake K, Brown ED, Castro M, Dozor AJ, Lima JJ, Mastronarde JG, Sockrider MM and Teague WG. Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. *JAMA* 2012; 307:373-381
262. Sumino K, Sugar EA, Irvin CG, Kaminsky DA, Shade D, Wei CY, Holbrook JT, **Wise R**, Castro M and American Lung Association Asthma Clinical Research Centers. Methacholine challenge test: diagnostic characteristics in asthmatic patients receiving controller medications. *J Allergy Clin Immunol* 2012; 130:69-75.e6

263. Mathai SC, Puhan MA, Lam D and **Wise R**. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2012; 186:428-433
264. Hummers LK, Dugowson CE, Dechow FJ, **Wise R**, Gregory J, Michalek J, Yenokyan G, McGready J and Wigley FM. A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon. *Ann Rheum Dis* 2012;
265. Lang JE, Holbrook JT, **Wise R**, Dixon AE, Teague WG, Wei CY, Irvin CG, Shade D, Lima JJ and for the American Lung Association-Asthma Clinical Research Centers. Obesity in children with poorly controlled asthma: Sex differences. *Pediatr Pulmonol* 2012;
266. Chandra D, **Wise R**, Kulkarni HS, Benzo RP, Criner G, Make B, Slivka WA, Ries AL, Reilly JJ, Martinez FJ, Sciruba FC and NETT Research Group (incl **Wise R**). Optimizing the 6-min walk test as a measure of exercise capacity in COPD. *Chest* 2012; 142:1545-1552
267. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, Vestbo J, Lomas DA, Calverley PM, Wouters E, Crim C, Yates JC, Silverman EK, Coxson HO, Bakke P, Mayer RJ, Celli B and Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators (incl R Wise). Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. *PLoS One* 2012; 7:e37483
268. Mougey EB, Chen C, Tantisira KG, Blake KV, Peters SP, **Wise R**, Weiss ST and Lima JJ. Pharmacogenetics of asthma controller treatment. *Pharmacogenomics J* 2012;
269. Spruit MA, Polkey MI, Celli B, Edwards LD, Watkins ML, Pinto-Plata V, Vestbo J, Calverley PM, Tal-Singer R, Agusti A, Coxson HO, Lomas DA, MacNee W, Rennard S, Silverman EK, Crim CC, Yates J, Wouters EF and Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Study Investigators (incl Wise, RA). Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. *J Am Med Dir Assoc* 2012; 13:291-297
270. Wells JM, Washko GR, Han MK, Abbas N, Nath H, Marmay AJ, Regan E, Bailey WC, Martinez FJ, Westfall E, Beaty TH, Curran-Everett D, Curtis JL, Hokanson JE, Lynch DA, Make BJ, Crapo JD, Silverman EK, Bowler RP, Dransfield MT, COPD Gene Investigators and ECLIPSE Study Investigators (incl. **Wise R**). Pulmonary arterial enlargement and acute exacerbations of COPD. *N Engl J Med* 2012; 367:913-921
271. Berry CE, Drummond MB, Han MK, Li D, Fuller C, Limper AH, Martinez FJ, Schwarz MI, Sciruba FC and **Wise R**. Relationship between lung function impairment and health-related quality of life in COPD and interstitial lung disease. *Chest* 2012; 142:704-711
272. Drummond MB, Hansel NN, Connett JE, Scanlon PD, Tashkin DP and **Wise R**. Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2012; 185:1301-1306
273. Kim V, Kretschman DM, Sternberg AL, DeCamp MM, Jr, Criner GJ and National Emphysema Treatment Trial Research Group (incl **Wise R**). Weight gain after lung reduction surgery is related to improved lung function and ventilatory efficiency. *Am J Respir Crit Care Med* 2012; 186:1109-1116
274. Mougey E, Lang JE, Allayee H, Teague WG, Dozor AJ, **Wise R** and Lima JJ. ALOX5 Polymorphism associates with increased leukotriene production and reduced lung function and asthma control in children with poorly controlled asthma. *Clin Exp Allergy* 2013; 43:512-520
275. Lang JE, Dozor AJ, Holbrook JT, Mougey E, Krishnan S, Sweeten S, **Wise R**, Teague WG, Wei CY, Shade D, Lima JJ and American Lung Association-Asthma Clinical Research Centers. Biologic mechanisms of environmental

- tobacco smoke in children with poorly controlled asthma: results from a multicenter clinical trial. *J Allergy Clin Immunol Pract* 2013; 1:172-180
276. Agusti A, Edwards LD, Celli B, Macnee W, Calverley PM, Mullerova H, Lomas DA, Wouters E, Bakke P, Rennard S, Crim C, Miller BE, Coxson HO, Yates JC, Tal-Singer R, Vestbo J and ECLIPSE Investigators (incl **Wise R**). Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. *Eur Respir J* 2013; 42:636-646
277. Miller J, Edwards LD, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Vestbo J, Wouters E, Yates JC, Macnee W and Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators (Incl. **Wise R**). Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. *Respir Med* 2013; 107:1376-1384
278. Romme EA, Murchison JT, Edwards LD, van Beek E, Jr, Murchison DM, Rutten EP, Smeenk FW, Williams MC, Wouters EF, MacNee W and Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Study Investigators (incl Wise, RA). CT-measured bone attenuation in patients with chronic obstructive pulmonary disease: relation to clinical features and outcomes. *J Bone Miner Res* 2013; 28:1369-1377
279. Cottrell TR, **Wise R**, Wigley FM and Boin F. The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis. *Ann Rheum Dis* 2013;
280. Siedlinski M, Tingley D, Lipman PJ, Cho MH, Litonjua AA, Sparrow D, Bakke P, Gulsvik A, Lomas DA, Anderson W, Kong X, Rennard SI, Beaty TH, Hokanson JE, Crapo JD, Lange C, Silverman EK and COPDGene and ECLIPSE Investigators. Dissecting direct and indirect genetic effects on chronic obstructive pulmonary disease (COPD) susceptibility. *Hum Genet* 2013; 132:431-441
281. Drummond MB, Merlo CA, Astemborski J, Kalmin MM, Kisalu A, Mcdyer JF, Mehta SH, Brown RH, **Wise R** and Kirk GD. The effect of HIV infection on longitudinal lung function decline among IDUs: a prospective cohort. *AIDS* 2013; 27:1303-1311
282. Benzo R, Siemion W, Novotny P, Sternberg A, Kaplan RM, Ries A, **Wise R**, Martinez F, Utz J, Sciruba F and National Emphysema Treatment Trial (NETT) Research Group (incl **Wise R**). Factors to Inform Clinicians About the End of Life in Severe Chronic Obstructive Pulmonary Disease. *J Pain Symptom Manage* 2013;
283. Brown RH, Brooker A, **Wise R**, Reynolds C, Loccioni C, Russo A and Risby TH. Forced expiratory capnography and chronic obstructive pulmonary disease (COPD). *J Breath Res* 2013; 7:017108-7155/7/1/017108. Epub 2013 Feb 27
284. Fischer Ii WA, Drummond MB, Merlo CA, Thomas DL, Brown R, Mehta SH, **Wise R** and Kirk GD. Hepatitis C Virus Infection Is Not An Independent Risk Factor For Obstructive Lung Disease. *COPD* 2013;
285. Gietema HA, Edwards LD, Coxson HO, Bakke PS and ECLIPSE Investigators (incl. **Wise R**). Impact of emphysema and airway wall thickness on quality of life in smoking-related COPD. *Respir Med* 2013; 107:1201-1209
286. D'Armiento JM, Goldklang MP, Hardigan AA, Geraghty P, Roth MD, Connett JE, **Wise R**, Sciruba FC, Scharf SM, Thankachen J, Islam M, Ghio AJ and Foronjy RF. Increased matrix metalloproteinase (MMPs) levels do not predict disease severity or progression in emphysema. *PLoS One* 2013; 8:e56352
287. Hummers LK, Dugowson CE, Dechow FJ, **Wise R**, Gregory J, Michalek J, Yenokyan G, McGready J and Wigley FM. A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon. *Ann Rheum Dis* 2013; 72:1962-1967
288. Shah AA, Schiopu E, Hummers LK, Wade M, Phillips K, Anderson C, **Wise R**, Boin F, Seibold JR, Wigley F and Rollins KD. Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic

- sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion. *Arthritis Res Ther* 2013; 15:R54
289. Hansel NN, Washko GR, Foreman MG, Han MK, Hoffman EA, Demeo DL, Barr RG, Van Beek EJ, Kazerooni EA, **Wise R**, Brown RH, Black-Shinn J, Hokanson JE, Hanania NA, Make B, Silverman EK, Crapo JD and Dransfield For The Copdgene Investigators, M.T. Racial Differences in CT Phenotypes in COPD. *COPD* 2013; 10:20-27
290. Park HY, Man SF, Tashkin D, **Wise R**, Connett JE, Anthonisen NA and Sin DD. The Relation of Serum Myeloperoxidase to Disease Progression and Mortality in Patients with Chronic Obstructive Pulmonary Disease (COPD). *PLoS One* 2013; 8:e61315
291. Drummond MB and **Wise R**. Reply: Prognostic value of functional decline in middle-aged smokers. *Am J Respir Crit Care Med* 2013; 187:1029
292. Cheng DT, Kim DK, Cockayne DA, Belousov A, Bitter H, Cho MH, Duvoix A, Edwards LD, Lomas DA, Miller BE, Reynaert N, Tal-Singer R, Wouters EF, Agusti A, Fabbri LM, Rames A, Visvanathan S, Rennard SI, Jones P, Parmar H, MacNee W, Wolff G, Silverman EK, Mayer RJ, Pillai SG and TESRA and ECLIPSE Investigators (incl Wise, R.A.). Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2013; 188:948-957
293. **Wise R**, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P and TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD. *N Engl J Med* 2013; 369:1491-1501
294. **Wise R**, Anzueto A, Calverley P, Dahl R, Dusser D, Pledger G, Koenen-Bergmann M, Joseph E, Cotton D and Disse B. The Tiotropium Safety and Performance in Respimat(R) Trial (TIOSPIR(R)), a large scale, randomized, controlled, parallel-group trial-design and rationale. *Respir Res* 2013; 14:40-9921-14-40
295. Cooper CB, Celli BR, Jardim JR, **Wise R**, Legg D, Guo J and Kesten S. Treadmill Endurance During 2-Year Treatment With Tiotropium in Patients With COPD: A Randomized Trial. *Chest* 2013; 144:490-497
296. Nguyen JM, Holbrook JT, Wei CY, Gerald LB, Teague WG, **Wise R** and on behalf of the American Lung Association Asthma Clinical Research Centers. Validation and psychometric properties of the Asthma Control Questionnaire among children. *J Allergy Clin Immunol* 2013;
297. Checkley W, Robinson CL, Baumann LM, Hansel NN, Romero K, Pollard SL, **Wise R**, Gilman RH, Mougey E, Lima JJ and PURA study investigators. 25-hydroxy vitamin D levels are associated with childhood asthma in a population-based study in Peru. *Clin Exp Allergy* 2014;
298. Popescu I, Drummond MB, Gama L, Coon T, Merlo CA, **Wise R**, Clements JE, Kirk GD and McDyer JF. Activation-induced cell death drives profound lung CD4(+) T-cell depletion in HIV-associated chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2014; 190:744-755
299. Kim V, Desai P, Newell JD, Make BJ, Washko GR, Silverman EK, Crapo JD, Bhatt SP, Criner GJ and COPDGene Investigators (incl Wise, RA). Airway wall thickness is increased in COPD patients with bronchodilator responsiveness. *Respir Res* 2014; 15:84-014-0084-3
300. Drummond MB, Buist AS, Crapo JD, **Wise R** and Rennard SI. Chronic obstructive pulmonary disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. *Ann Am Thorac Soc* 2014; 11 Suppl 3:S154-60
301. Putcha N, Drummond MB, Connett JE, Scanlon PD, Tashkin DP, Hansel NN and **Wise R**. Chronic productive cough is associated with death in smokers with early COPD. *COPD* 2014; 11:451-458

302. Howrylak JA, Fuhlbrigge AL, Strunk RC, Zeiger RS, Weiss ST, Raby BA and Childhood Asthma Management Program Research Group (incl Wise, RA). Classification of childhood asthma phenotypes and long-term clinical responses to inhaled anti-inflammatory medications. *J Allergy Clin Immunol* 2014; 133:1289-300, 1300.e1-12
303. Lambert AA, Kirk GD, Astemborski J, Neptune ER, Mehta SH, **Wise R** and Drummond MB. A Cross Sectional Analysis of the Role of the Antimicrobial Peptide Cathelicidin in Lung Function Impairment within the ALIVE Cohort. *PLoS One* 2014; 9:e95099
304. Caffrey D, Miranda JJ, Gilman RH, Davila-Roman VG, Cabrera L, Dowling R, Stewart T, Bernabe-Ortiz A, **Wise R**, Leon-Velarde F, Checkley W and CRONICAS Cohort Study Group. A cross-sectional study of differences in 6-min walk distance in healthy adults residing at high altitude versus sea level. *Extrem Physiol Med* 2014; 3:3-7648-3-3
305. American Lung Association-Asthma Clinical Research Centers' Writing Committee; Dixon AE, Castro M, Cohen RI, Gerald LB, Holbrook JT, Irvin CG, Mohapatra S, Peters SP, Rayapudi S, Sugar EA and **Wise R**. Efficacy of nasal mometasone for the treatment of chronic sinonasal disease in patients with inadequately controlled asthma. *J Allergy Clin Immunol* 2014;
306. Fitzpatrick AM, Holbrook JT, Wei CY, Brown MS, **Wise R**, Teague WG and American Lung Association's Asthma Clinical Research Centers Network. Exhaled breath condensate pH does not discriminate asymptomatic gastroesophageal reflux or the response to lansoprazole treatment in children with poorly controlled asthma. *J Allergy Clin Immunol Pract* 2014; 2:579-86.e7
307. Mathai SC, Hassoun PM, Puhan MA, Zhou Y and **Wise R**. Gender Differences in Response to Tadalafil in Pulmonary Arterial Hypertension. *Chest* 2014;
308. Hansel NN, Pare PD, Rafaels N, Sin D, Sandford A, Daley D, Vergara C, Huang L, Elliott WM, Pascoe CD, Arsenault BA, Postma DS, Boezen HM, Bosse Y, van den Berge M, Hiemstra PS, Cho MH, Litonjua AA, Sparrow D, Ober C, **Wise R**, Connett J, Neptune ER, Beaty TH, Ruczinski I, Mathias R, Barnes KC and on behalf of the Lung Health Study. Genome Wide Association Study Identifies Novel Loci Associated with Airway Responsiveness in COPD. *Am J Respir Cell Mol Biol* 2014;
309. Wood DE, Nader DA, Springmeyer SC, Elstad MR, Coxson HO, Chan A, Rai NS, Mularski RA, Cooper CB, **Wise R**, Jones PW, Mehta AC, Gonzalez X, Sterman DH and IBV Valve Trial Research Team. The IBV Valve trial: a multicenter, randomized, double-blind trial of endobronchial therapy for severe emphysema. *J Bronchology Interv Pulmonol* 2014; 21:288-297
310. Kapadia SG, Wei C, Bartlett SJ, Lang J, **Wise R**, Dixon AE and American Lung Association Asthma Clinical Research Centers. Obesity and symptoms of depression contribute independently to the poor asthma control of obesity. *Respir Med* 2014; 108:1100-1107
311. Berry CE, Han MK, Thompson B, Limper AH, Martinez FJ, Schwarz MI, Sciruba FC, Criner GJ and **Wise R**. Older Adults with Chronic Lung Disease Report Less Limitation Compared to Younger Adults with Similar Lung Function Impairment. *Ann Am Thorac Soc* 2014;
312. Baumann LM, Romero KM, Robinson CL, Hansel NN, Gilman RH, Hamilton RG, Lima JJ, **Wise R**, Checkley W and PURA Study Investigators. Prevalence and risk factors for allergic rhinitis in two resource-limited settings in Peru with disparate degrees of urbanization. *Clin Exp Allergy* 2014;
313. Drummond MB, Astemborski J, Lambert AA, Goldberg S, Stitzer ML, Merlo CA, Rand CS, **Wise R** and Kirk GD. A randomized study of contingency management and spirometric lung age for motivating smoking cessation among injection drug users. *BMC Public Health* 2014; 14:761-2458-14-761
314. Cho MH, McDonald ML, Zhou X, Mattheisen M, Castaldi PJ, Hersh CP, Demeo DL, Sylvia JS, Ziniti J, Laird NM, Lange C, Litonjua AA, Sparrow D, Casaburi R, Barr RG, Regan EA, Make BJ, Hokanson JE, Lutz S, Dudenkov TM,

- Farzadegan H, Hetmanski JB, Tal-Singer R, Lomas DA, Bakke P, Gulsvik A, Crapo JD, Silverman EK, Beaty TH and NETT Genetics, ICGN, ECLIPSE and COPDGene Investigators (incl **Wise R**). Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis. *Lancet Respir Med* 2014; 2:214-225
315. Putcha N, Puhan MA, Drummond MB, Han MK, Regan EA, Hanania NA, Martinez CH, Foreman M, Bhatt SP, Make B, Ramsdell J, DeMeo DL, Barr RG, Rennard SI, Martinez F, Silverman EK, Crapo J, **Wise R** and Hansel NN. A Simplified Score to Quantify Comorbidity in COPD. *PLoS One* 2014; 9:e114438
316. **Wise R**. Tiotropium and the risk of death in COPD. *N Engl J Med* 2014; 370:482
317. Sumino K, Sugar EA, Irvin CG, Kaminsky DA, Shade D, Wei CY, Holbrook JT, **Wise R**, Castro M and Writing Committee for the American Lung Association Asthma Clinical Research Centers. Variability of methacholine bronchoprovocation and the effect of inhaled corticosteroids in mild asthma. *Ann Allergy Asthma Immunol* 2014; 112:354-360.e1
318. Strunk RC, Colvin R, Bacharier LB, Fuhlbrigge A, Forno E, Arbelaez AM, Tantisira KG and Childhood Asthma Management Program Research Group (incl Wise, RA). Airway Obstruction Worsens in Young Adults with Asthma Who Become Obese. *J Allergy Clin Immunol Pract* 2015; 3:765-71.e2
319. Benson VS, Mullerova H, Vestbo J, Wedzicha JA, Patel A, Hurst JR and Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators (Incl. **Wise R**). Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. *Respir Med* 2015; 109:1147-1154
320. Stewart T, Caffrey DG, Gilman RH, Mathai SC, Lerner A, Hernandez A, Pinto ME, Huaylinos Y, Cabrera L, **Wise R**, Miranda JJ and Checkley W. Can a simple test of functional capacity add to the clinical assessment of diabetes? *Diabet Med* 2015;
321. Stoller JK, Aboussouan LS, Kanner RE, Wilson LA, Diaz P, **Wise R** and LOTT Research Group. Characteristics of Alpha-1 Antitrypsin-Deficient Individuals in the Long-term Oxygen Treatment Trial and Comparison with Other Subjects with Chronic Obstructive Pulmonary Disease. *Ann Am Thorac Soc* 2015; 12:1796-1804
322. Hayden LP, Hobbs BD, Cohen RT, **Wise R**, Checkley W, Crapo JD, Hersh CP and COPDGene Investigators. Childhood pneumonia increases risk for chronic obstructive pulmonary disease: the COPDGene study. *Respir Res* 2015; 16:115-015-0273-8
323. Caravedo MA, Herrera PM, Mongilardi N, de Ferrari A, Davila-Roman VG, Gilman RH, **Wise R**, Miele CH, Miranda JJ and Checkley W. Chronic exposure to biomass fuel smoke and markers of endothelial inflammation. *Indoor Air* 2015;
324. Regan EA, Lynch DA, Curran-Everett D, Curtis JL, Austin JH, Grenier PA, Kauczor HU, Bailey WC, DeMeo DL, Casaburi RH, Friedman P, Van Beek EJ, Hokanson JE, Bowler RP, Beaty TH, Washko GR, Han MK, Kim V, Kim SS, Yagihashi K, Washington L, McEvoy CE, Tanner C, Mannino DM, Make BJ, Silverman EK, Crapo JD and COPDGene Investigators (Incl. **Wise R**). Clinical and Radiologic Disease in Smokers With Normal Spirometry. *JAMA Intern Med* 2015; 175:1539-1549
325. Putcha N, Drummond MB, **Wise R** and Hansel NN. Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management. *Semin Respir Crit Care Med* 2015; 36:575-591
326. Lambert A, Drummond MB, Wei C, Irvin C, Kaminsky D, McCormack M and **Wise R**. Diagnostic accuracy of FEV/forced vital capacity ratio z scores in asthmatic patients. *J Allergy Clin Immunol* 2015;

327. Smith LJ, Kalhan R, **Wise R**, Sugar EA, Lima JJ, Irvin CG, Dozor AJ, Holbrook JT and American Lung Association Asthma Clinical Research Centers. Effect of a soy isoflavone supplement on lung function and clinical outcomes in patients with poorly controlled asthma: a randomized clinical trial. *JAMA* 2015; 313:2033-2043
328. Hardin M, Cho MH, McDonald ML, Wan E, Lomas DA, Coxson HO, MacNee W, Vestbo J, Yates JC, Agusti A, Calverley PM, Celli B, Crim C, Rennard S, Wouters E, Bakke P, Bhatt SP, Kim V, Ramsdell J, Regan EA, Make BJ, Hokanson JE, Crapo JD, Beaty TH, Hersh CP and ECLIPSE and COPDGene Investigators (incl. Wise, RA). A genome-wide analysis of the response to inhaled beta-agonists in chronic obstructive pulmonary disease. *Pharmacogenomics J* 2015;
329. Lutz SM, Cho MH, Young K, Hersh CP, Castaldi PJ, McDonald ML, Regan E, Mattheisen M, DeMeo DL, Parker M, Foreman M, Make BJ, Jensen RL, Casaburi R, Lomas DA, Bhatt SP, Bakke P, Gulsvik A, Crapo JD, Beaty TH, Laird NM, Lange C, Hokanson JE, Silverman EK, ECLIPSE Investigators (incl. **Wise R**) and COPDGene Investigators (Incl. **Wise R**). A genome-wide association study identifies risk loci for spirometric measures among smokers of European and African ancestry. *BMC Genet* 2015; 16:138-015-0299-4
330. Lambert AA, Kirk GD, Astemborski J, Mehta SH, **Wise R** and Drummond MB. HIV Infection Is Associated With Increased Risk for Acute Exacerbation of COPD. *J Acquir Immune Defic Syndr* 2015; 69:68-74
331. Lang JE, Holbrook JT, Mougey EB, Wei CY, **Wise R**, Teague WG, Lima JJ and American Lung Association-Airways Clinical Research Centers. Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype. *Ann Am Thorac Soc* 2015; 12:878-885
332. Brown RH, **Wise R**, Kirk G, Drummond MB and Mitzner W. Lung density changes with growth and inflation. *Chest* 2015;
333. Park SJ, Foreman MG, Demeo DL, Bhatt SP, Hansel NN, **Wise R**, Soler X and Bowler RP. Menthol cigarette smoking in the COPDGene cohort: Relationship with COPD, comorbidities and CT metrics. *Respirology* 2015; 20:108-114
334. Vyas KJ, Danz D, Gilman RH, **Wise R**, Leon-Velarde F, Miranda JJ and Checkley W. Noninvasive Assessment of Excessive Erythrocytosis as a Screening Method for Chronic Mountain Sickness at High Altitude. *High Alt Med Biol* 2015; 16:162-168
335. Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agusti AA, Criner GJ, MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH, Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M, Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravittles M, Meek PM, Papi A, Rabe KF, Roche N, Sciruba FC, Sethi S, Siafakas N, Sin DD, Soriano JB, Stoller JK, Tashkin DP, Troosters T, Verleden GM, Verschakelen J, Vestbo J, Walsh JW, Washko GR, **Wise R**, Wouters EF, ZuWallack RL and ATS/ERS Task Force for COPD Research. An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. *Eur Respir Rev* 2015; 24:159-172
336. Jaganath D, Miranda JJ, Gilman RH, **Wise R**, Diette GB, Miele CH, Bernabe-Ortiz A, Checkley W and CRONICAS Cohort Study Group. Prevalence of chronic obstructive pulmonary disease and variation in risk factors across four geographically diverse resource-limited settings in Peru. *Respir Res* 2015; 16:40-015-0198-2
337. Jaramillo JD, Wilson C, Stinson DJ, Lynch DA, Bowler RP, Lutz S, Bon JM, Arnold B, McDonald ML, Washko GR, Wan ES, DeMeo DL, Foreman MG, Soler X, Lindsay SE, Lane NE, Genant HK, Silverman EK, Hokanson JE, Make BJ, Crapo JD, Regan EA and COPDGene Investigators (Incl. **Wise R**). Reduced Bone Density and Vertebral Fractures in Smokers. Men and COPD Patients at Increased Risk. *Ann Am Thorac Soc* 2015; 12:648-656
338. Sze MA, Chen YW, Tam S, Tashkin D, **Wise R**, Connett JE, Man SP and Sin DD. The relationship between *Helicobacter pylori* seropositivity and COPD. *Thorax* 2015;

339. Dahl R, Calverley PM, Anzueto A, Metzdorf N, Fowler A, Mueller A, **Wise R** and Dusser D. Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial. *BMJ Open* 2015; 5:e009015-2015-009015
340. **Wise R**, Calverley PM, Dahl R, Dusser D, Metzdorf N, Muller A, Fowler A and Anzueto A. Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial. *NPJ Prim Care Respir Med* 2015; 25:15067
341. Anzueto A, **Wise R**, Calverley P, Dusser D, Tang W, Metzdorf N and Dahl R. The Tiotropium Safety and Performance in Respimat(R) (TIOSPIR(R)) Trial: Spirometry Outcomes. *Respir Res* 2015; 16:107-015-0269-4
342. Miele CH, Jaganath D, Miranda JJ, Bernabe-Ortiz A, Gilman RH, Johnson CM, Diette GB, **Wise R**, Checkley W and CRONICAS Cohort Study Group. Urbanization and Daily Exposure to Biomass Fuel Smoke Both Contribute to Chronic Bronchitis Risk in a Population with Low Prevalence of Daily Tobacco Smoking. *COPD* 2015; 1-10
343. Blake K, Holbrook JT, Antal H, Shade D, Bunnell HT, McCahan SM, **Wise R**, Pennington C, Garfinkel P and Wysocki T. Use of mobile devices and the internet for multimedia informed consent delivery and data entry in a pediatric asthma trial: Study design and rationale. *Contemp Clin Trials* 2015; 42:105-118
344. Tkacova R, Dai DL, Vonk JM, Leung JM, Hiemstra PS, van den Berge M, Kunz L, Hollander Z, Tashkin D, **Wise R**, Connett J, Ng R, McManus B, Paul Man SF, Postma DS and Sin DD. Airway hyperresponsiveness in chronic obstructive pulmonary disease: A marker of asthma-chronic obstructive pulmonary disease overlap syndrome? *J Allergy Clin Immunol* 2016; 138:1571-1579.e10
345. Bhatt SP, Terry NL, Nath H, Zach JA, Tschirren J, Bolding MS, Stinson DS, Wilson CG, Curran-Everett D, Lynch DA, Putcha N, Soler X, **Wise R**, Washko GR, Hoffman EA, Foreman MG, Dransfield MT and Genetic Epidemiology of COPD (COPDGene) Investigators. Association Between Expiratory Central Airway Collapse and Respiratory Outcomes Among Smokers. *JAMA* 2016; 315:498-505
346. Bhatt SP, Soler X, Wang X, Murray S, Anzueto AR, Beaty TH, Boriak AM, Casaburi R, Criner GJ, Diaz AA, Dransfield MT, Curran-Everett D, Galban CJ, Hoffman EA, Hogg JC, Kazerooni EA, Kim V, Kinney GL, Lagstein A, Lynch DA, Make BJ, Martinez FJ, Ramsdell JW, Reddy R, Ross BD, Rossiter HB, Steiner RM, Strand MJ, van Beek EJ, Wan ES, Washko GR, Wells JM, Wendt CH, **Wise R**, Silverman EK, Crapo JD, Bowler RP, Han MK and COPDGene Investigators. Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2016; 194:178-184
347. Putcha N and **Wise R**. Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome: Nothing New Under the Sun. *Immunol Allergy Clin North Am* 2016; 36:515-528
348. Zaeh S, Miele CH, Putcha N, Gilman RH, Miranda JJ, Bernabe-Ortiz A, **Wise R** and Checkley W. Chronic respiratory disease and high altitude are associated with depressive symptoms in four diverse settings. *Int J Tuberc Lung Dis* 2016; 20:1263-1269
349. Woodruff PG, Barr RG, Bleecker E, Christenson SA, Couper D, Curtis JL, Gouskova NA, Hansel NN, Hoffman EA, Kanner RE, Kleeerup E, Lazarus SC, Martinez FJ, Paine R,3rd, Rennard S, Tashkin DP, Han MK and SPIROMICS Research Group (incl **Wise R**). Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. *N Engl J Med* 2016; 374:1811-1821
350. Tashkin DP, Bateman ED, Jones P, Zubek VB, Metzdorf N, Liu D, Leonard T, Clerisme-Beaty E and **Wise R**. Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses. *Respir Med* 2016; 120:91-100

351. Checkley W, Foreman MG, Bhatt SP, Dransfield MT, Han M, Hanania NA, Hansel NN, Regan EA, **Wise R** and COPD Gene Study Investigators. Differences between absolute and predicted values of forced expiratory volumes to classify ventilatory impairment in chronic obstructive pulmonary disease. *Respir Med* 2016; 111:30-38
352. Dusser D, **Wise R**, Dahl R, Anzueto A, Carter K, Fowler A and Calverley PM. Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR((R)) trial. *Int J Chron Obstruct Pulmon Dis* 2016; 11:133-145
353. Holbrook JT, Sugar EA, Brown RH, Drye LT, Irvin CG, Schwartz AR, Tepper RS, **Wise R**, Yasin RZ, Busk MF and American Lung Association Airways Clinical Research Centers. Effect of Continuous Positive Airway Pressure on Airway Reactivity in Asthma. A Randomized, Sham-controlled Clinical Trial. *Ann Am Thorac Soc* 2016; 13:1940-1950
354. Donohue JF, **Wise R**, Busse WW, Garfinkel S, Zubek VB, Ghafouri M, Manuel RC, Schlenker-Herceg R and Bleecker ER. Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. *BMC Pulm Med* 2016; 16:65-016-0223-3
355. Kaminsky DA, Wang LL, Bates JH, Thamrin C, Shade DM, Dixon AE, **Wise R**, Peters S and Irvin CG. Fluctuation Analysis of Peak Expiratory Flow and its Association with Treatment Failure in Asthma. *Am J Respir Crit Care Med* 2016;
356. Lang JE, Hossain J, Holbrook JT, Teague WG, Gold BD, **Wise R** and Lima JJ. Gastro-oesophageal reflux and worse asthma control in obese children: a case of symptom misattribution? *Thorax* 2016; 71:238-246
357. McGeachie MJ, Yates KP, Zhou X, Guo F, Sternberg AL, Van Natta ML, **Wise R**, Szeffler SJ, Sharma S, Kho AT, Cho MH, Croteau-Chonka DC, Castaldi PJ, Jain G, Sanyal A, Zhan Y, Lajoie BR, Dekker J, Stamatoyannopoulos J, Covar RA, Zeiger RS, Adkinson NF, Williams PV, Kelly HW, Grasemann H, Vonk JM, Koppelman GH, Postma DS, Raby BA, Houston I, Lu Q, Fuhlbrigge AL, Tantisira KG, Silverman EK, Tonascia J, Strunk RC, Weiss ST and CAMP Research Group. Genetics and Genomics of Longitudinal Lung Function Patterns in Individuals with Asthma. *Am J Respir Crit Care Med* 2016; 194:1465-1474
358. **Wise R**, Acevedo RA, Anzueto AR, Hanania NA, Martinez FJ, Ohar JA and Tashkin DP. Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus. *Chronic Obstr Pulm Dis* 2016; 4:7-20
359. Bonilla Arcos D, Krishnan JA, Vandivier RW, Sevransky JE, Checkley W, Kiser TH, Sullivan JL, Walsh JW, **Wise R** and Wilson KC. High-Dose Versus Low-Dose Systemic Steroids in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Systematic Review. *Chronic Obstr Pulm Dis* 2016; 3:580-588
360. Popescu I, Drummond MB, Gama L, Lambert A, Hoji A, Coon T, Merlo CA, **Wise R**, Keruly J, Clements JE, Kirk GD and McDyer JF. HIV Suppression Restores the Lung Mucosal CD4+ T-Cell Viral Immune Response and Resolves CD8+ T-Cell Alveolitis in Patients at Risk for HIV-Associated Chronic Obstructive Pulmonary Disease. *J Infect Dis* 2016; 214:1520-1530
361. Checkley W, Deza MP, Klawitter J, Romero KM, Klawitter J, Pollard SL, **Wise R**, Christians U and Hansel NN. Identifying biomarkers for asthma diagnosis using targeted metabolomics approaches. *Respir Med* 2016; 121:59-66
362. Lambert AA, Drummond MB, Kisalu A, Moxley J, Keruly J, Moore RD, **Wise R** and Kirk GD. Implementation of a COPD Screening Questionnaire in an Outpatient HIV Clinic. *COPD* 2016; 1-6
363. Miele CH, Schwartz AR, Gilman RH, Pham L, **Wise R**, Davila-Roman VG, Jun JC, Polotsky VY, Miranda JJ, Leon-Velarde F and Checkley W. Increased Cardiometabolic Risk and Worsening Hypoxemia at High Altitude. *High Alt Med Biol* 2016; 17:93-100

364. Zafari Z, Sin DD, Postma DS, Lofdahl CG, Vonk J, Bryan S, Lam S, Tammemagi CM, Khakban R, Man SF, Tashkin D, **Wise R**, Connett JE, McManus B, Ng R, Hollander Z and Sadatsafavi M. Individualized prediction of lung-function decline in chronic obstructive pulmonary disease. *CMAJ* 2016; 188:1004-1011
365. **Wise R**, Holbrook JT, Criner G, Sethi S, Rayapudi S, Sudini KR, Sugar EA, Burke A, Thimmulappa R, Singh A, Talalay P, Fahey JW, Berenson CS, Jacobs MR, Biswal S and Broccoli Sprout Extract Trial Research Group. Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial. *PLoS One* 2016; 11:e0163716
366. Bime C, Gerald JK, Wei CY, Holbrook JT, Teague WG, **Wise R** and Gerald LB. Measurement characteristics of the childhood Asthma-Control Test and a shortened, child-only version. *NPJ Prim Care Respir Med* 2016; 26:16075
367. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, **Wise R**, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzier MJ, Kim GH, Tseng CH, Elashoff RM and Scleroderma Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. *Lancet Respir Med* 2016; 4:708-719
368. McGeachie MJ, Yates KP, Zhou X, Guo F, Sternberg AL, Van Natta ML, **Wise R**, Szeffler SJ, Sharma S, Kho AT, Cho MH, Croteau-Chonka DC, Castaldi PJ, Jain G, Sanyal A, Zhan Y, Lajoie BR, Dekker J, Stamatoyannopoulos J, Covar RA, Zeiger RS, Adkinson NF, Williams PV, Kelly HW, Grasemann H, Vonk JM, Koppelman GH, Postma DS, Raby BA, Houston I, Lu Q, Fuhlbrigge AL, Tantisira KG, Silverman EK, Tonascia J, Weiss ST, Strunk RC and CAMP Research Group. Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. *N Engl J Med* 2016; 374:1842-1852
369. Kim V, Zhao H, Boriek AM, Anzueto A, Soler X, Bhatt SP, Rennard SI, **Wise R**, Comellas A, Ramsdell JW, Kinney GL, Han MK, Martinez CH, Yen A, Black-Shinn J, Porszasz J, Criner GJ, Hanania NA, Sharafkhaneh A, Crapo JD, Make BJ, Silverman EK, Curtis JL and COPDGene Investigators. Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. *Ann Am Thorac Soc* 2016;
370. **Wise R** Corresponding Author for Long-Term Oxygen Treatment Trial Research Group, Albert RK, Au DH, Blackford AL, Casaburi R, Cooper JA, Jr, Criner GJ, Diaz P, Fuhlbrigge AL, Gay SE, Kanner RE, MacIntyre N, Martinez FJ, Panos RJ, Piantadosi S, Sciruba F, Shade D, Stibolt T, Stoller JK, **Wise R**, Yusef RD, Tonascia J, Sternberg AL and Bailey W. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. *N Engl J Med* 2016; 375:1617-1627
371. **Wise R**, Anzueto A, Dahl R, Duser D and Calverley P. Tiotropium safety in 'real-world' populations: Response to Schmedl, et al. in the *British Journal of Clinical Pharmacology*. *Br J Clin Pharmacol* 2016;
372. Putcha N, Barr RG, Han MK, Woodruff PG, Bleeker ER, Kanner RE, Martinez FJ, Smith BM, Tashkin DP, Bowler RP, Eisner MD, Rennard SI, **Wise R**, Hansel NN and SPIROMICS Investigators. Understanding the impact of second-hand smoke exposure on clinical outcomes in participants with COPD in the SPIROMICS cohort. *Thorax* 2016;
373. Gaviola C, Miele CH, **Wise R**, Gilman RH, Jaganath D, Miranda JJ, Bernabe-Ortiz A, Hansel NN, Checkley W and CRONICAS Cohort Study Group. Urbanisation but not biomass fuel smoke exposure is associated with asthma prevalence in four resource-limited settings. *Thorax* 2016; 71:154-160
374. Miele CH, Jaganath D, Miranda JJ, Bernabe-Ortiz A, Gilman RH, Johnson CM, Diette GB, **Wise R**, Checkley W and CRONICAS Cohort Study Group. Urbanization and Daily Exposure to Biomass Fuel Smoke Both Contribute to Chronic Bronchitis Risk in a Population with Low Prevalence of Daily Tobacco Smoking. *COPD* 2016; 13:186-195

375. Yawn BB, Thomashaw B, Mannino DM, Han MK, Kalhan R, Rennard S, Cerrata S, Crapo JD and **Wise R**. The 2017 Update to the COPD Foundation COPD Pocket Consultant Guide. *Chronic Obstr Pulm Dis* 2017; 4:177-185
376. Woodruff PG, van den Berge M, Boucher RC, Brightling C, Burchard EG, Christenson SA, Han MK, Holtzman MJ, Kraft M, Lynch DA, Martinez FD, Reddel HK, Sin DD, Washko GR, Wenzel SE, Punturieri A, Freemer MM and **Wise R**. American Thoracic Society/National Heart, Lung, and Blood Institute Asthma-Chronic Obstructive Pulmonary Disease Overlap Workshop Report. *Am J Respir Crit Care Med* 2017; 196:375-381
377. Aboumatar H, Naqibuddin M, Chung S, Adebowale H, Bone L, Brown T, Cooper LA, Gurses AP, Knowlton A, Kurtz D, Piet L, Putcha N, Rand C, Roter D, Shattuck E, Sylvester C, Urteaga-Fuentes A, **Wise R**, Wolff JL, Yang T, Hibbard J, Howell E, Myers M, Shea K, Sullivan J, Syron L, Wang NY, Pronovost P and BREATHE Study Patient Family Partners Group. Better Respiratory Education and Treatment Help Empower (BREATHE) study: Methodology and baseline characteristics of a randomized controlled trial testing a transitional care program to improve patient-centered care delivery among chronic obstructive pulmonary disease patients. *Contemp Clin Trials* 2017; 62:159-167
378. Calverley PM, Tetzlaff K, Dusser D, **Wise R**, Mueller A, Metzdorf N and Anzueto A. Determinants of exacerbation risk in patients with COPD in the TIOSPIR study. *Int J Chron Obstruct Pulmon Dis* 2017; 12:3391-3405
379. Wu H, **Wise R** and Medinger AE. Do Patients Hospitalized With COPD Have Airflow Obstruction? *Chest* 2017; 151:1263-1271
380. Calverley PMA, Mueller A, Fowler A, Metzdorf N and **Wise R**. The Effect of Defining COPD by the Lower Limit of Normal of FEV1/FVC Ratio in TIOSPIR(R) Participants. *Ann Am Thorac Soc* 2017;
381. Dixon AE, Castro M, Gerald LB, Holbrook JT, Henderson RJ, Casale TB, Irvin CG, Black K, **Wise R**, Sugar EA and American Lung Association Airways Clinical Research Centers' Writing Committee. Effect of intranasal corticosteroids on allergic airway disease in asthma. *J Allergy Clin Immunol Pract* 2017; 5:1125-1128.e3
382. Kanagalingam S, Shehab SS, Kaminsky DA, **Wise R**, Lang JE and Dixon AE. Effect of obesity on sinonasal disease in asthma. *J Asthma* 2017; 1-7
383. Sussan TE, Shahzad FG, Tabassum E, Cohen JE, **Wise R**, Blaha MJ, Holbrook JT and Biswal S. Electronic cigarette use behaviors and motivations among smokers and non-smokers. *BMC Public Health* 2017; 17:686-017-4671-3
384. Bowler RP, Hansel NN, Jacobson S, Graham Barr R, Make BJ, Han MK, O'Neal WK, Oelsner EC, Casaburi R, Barjaktarevic I, Cooper C, Foreman M, **Wise R**, DeMeo DL, Silverman EK, Bailey W, Harrington KF, Woodruff PG, Drummond MB and for COPD Gene and SPIROMICS Investigators. Electronic Cigarette Use in US Adults at Risk for or with COPD: Analysis from Two Observational Cohorts. *J Gen Intern Med* 2017;
385. Parulekar AD, Martinez C, Tsai CL, Locantore N, Atik M, Yohannes AM, Kao CC, Al-Azzawi H, Mohsin A, **Wise R**, Foreman MG, Demeo DL, Regan EA, Make BJ, Boriak AM, Wiener LE and Hanania NA. Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts. *J Am Med Dir Assoc* 2017; 18:1063-1068
386. Calverley PMA, Anderson JA, Brook RD, Crim C, Gallot N, Kilbride S, Martinez F, Yates J, Newby DE, Vestbo J, **Wise R**, Celli BR and SUMMIT Investigators. Fluticasone Furoate, Vilanterol and Lung Function Decline in Patients with Moderate COPD and Heightened Cardiovascular Risk. *Am J Respir Crit Care Med* 2017;
387. Abston E, Comellas A, Reed RM, Kim V, **Wise R**, Brower R, Fortis S, Beichel R, Bhatt S, Zabner J, Newell J, Hoffman EA and Eberlein M. Higher BMI is associated with higher expiratory airflow normalised for lung volume (FEF25-75/FVC) in COPD. *BMJ Open Respir Res* 2017; 4:e000231-2017-000231. eCollection 2017

388. Drummond MB, Lambert AA, Hussien AF, Lin CT, Merlo CA, **Wise R**, Kirk GD and Brown RH. HIV Infection Is Independently Associated with Increased CT Scan Lung Density. *Acad Radiol* 2017; 24:137-145
389. Boueiz A, Chang Y, Cho MH, Washko GR, San Jose Estepar R, Bowler RP, Crapo JD, DeMeo DL, Dy JG, Silverman EK, Castaldi PJ and COPDGene Investigators. Lobar Emphysema Distribution Is Associated With 5-Year Radiological Disease Progression. *Chest* 2017;
390. **Wise R**. Long-Term Oxygen for COPD. *N Engl J Med* 2017; 376:287
391. Wilson SR, Mulligan MJ, Ayala E, Chausow A, Huang Q, Knowles SB, Gummidipundi S, Castro M and **Wise R**. A new measure to assess asthma's effect on quality of life from the patient's perspective. *J Allergy Clin Immunol* 2017;
392. Lambert AA, Putcha N, Drummond MB, Boriek AM, Hanania NA, Kim V, Kinney GL, McDonald MN, Brigham EP, **Wise R**, McCormack MC, Hansel NN and COPDGene Investigators. Obesity Is Associated With Increased Morbidity in Moderate to Severe COPD. *Chest* 2017; 151:68-77
393. Siddharthan T, Grigsby M, Miele CH, Bernabe-Ortiz A, Miranda JJ, Gilman RH, **Wise R**, Porter JC, Hurst JR and Checkley W. Prevalence and risk factors of restrictive spirometry in a cohort of Peruvian adults. *Int J Tuberc Lung Dis* 2017; 21:1062-1068
394. Ferguson GT, Beck B, Clerisme-Beaty E, Liu D, Thomashow BM, **Wise R**, ZuWallack R and Make BJ. Recruiting Patients After Hospital Discharge for Acute Exacerbation of COPD: Challenges and Lessons Learned. *Chronic Obstr Pulm Dis* 2017; 4:265-278
395. Rogers L, Sugar EA, Blake K, Castro M, Dimango E, Hanania NA, Happel KI, Peters SP, Reibman J, Saams J, Teague WG, **Wise R**, Holbrook JT and American Lung Association Airways Clinical Research Centers. Step-Down Therapy for Asthma Well Controlled on Inhaled Corticosteroid and Long-Acting Beta-Agonist: A Randomized Clinical Trial. *J Allergy Clin Immunol Pract* 2017;
396. Kiser TH, Sevransky JE, Krishnan JA, Tonascia J, **Wise R**, Checkley W, Walsh J, Sullivan JB, Wilson KC, Barker A, Moss M and Vandivier RW. A Survey of Corticosteroid Dosing for Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Assisted Ventilation. *Chronic Obstr Pulm Dis* 2017; 4:186-193
397. Siddharthan T, Grigsby MR, Goodman D, Chowdhury M, Rubinstein A, Irazola V, Gutierrez L, Miranda JJ, Bernabe-Ortiz A, Alam D, Kirenga B, Jones R, van Gemert F, **Wise R** and Checkley W. Association between Household Air Pollution Exposure and Chronic Obstructive Pulmonary Disease Outcomes in 13 Low- and Middle-Income Country Settings. *Am J Respir Crit Care Med* 2018; 197:611-620
398. Fawzy A, Putcha N, Paulin LM, Aaron CP, Labaki WW, Han MK, **Wise R**, Kanner RE, Bowler RP, Barr RG, Hansel NN and SPIROMICS and COPDGene Investigators. Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts. *Respir Res* 2018; 19:20-018-0717-z
399. Morgan BW, Siddharthan T, Grigsby MR, Pollard SL, Kalyesubula R, **Wise R**, Kirenga B and Checkley W. Asthma and Allergic Disorders in Uganda: A Population-Based Study Across Urban and Rural Settings. *J Allergy Clin Immunol Pract* 2018;
400. Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, Vestbo J, Tal-Singer R, Castaldi PJ, Silverman EK, Hersh CP and COPDGene and ECLIPSE Investigators. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. *J Allergy Clin Immunol* 2018; 141:2037-2047.e10
401. Krishnan S, Dozor AJ, Bacharier L, Lang JE, Irvin CG, Kaminsky D, Farber HJ, Gerald L, Brown M, Holbrook JT, **Wise R**, Ryu J, Bose S, Yasin R, Saams J, Henderson RJ, Teague WG and American Lung Association Airway Clinical Research Centers (ALA-ACRC) Network. Clinical characterization of children with resistant airflow obstruction, a multicenter study. *J Asthma* 2018; 1-7

402. Sussan TE, Shahzad FG, Tabassum E, Cohen JE, **Wise R**, Blaha MJ, Holbrook JT and Biswal S. Correction to: electronic cigarette use behaviors and motivations among smokers and non-smokers. *BMC Public Health* 2018; 18:175-018-5048-y
403. Kesten S, Israel E, Li G, Mitchell J, **Wise R** and Stern T. Development of a novel digital breath-activated inhaler: Initial particle size characterization and clinical testing. *Pulm Pharmacol Ther* 2018; 53:27-32
404. Patel NR, Cunoosamy DM, Fageras M, Taib Z, Asimus S, Hegelund-Myrback T, Lundin S, Pardali K, Kurian N, Ersdal E, Kristensson C, Korsback K, Palmer R, Brown MN, Greenaway S, Siew L, Clarke GW, Rennard SI, Make BJ, **Wise R** and Jansson P. The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial. *Int J Chron Obstruct Pulmon Dis* 2018; 13:1009-1019
405. Tang M, Henderson RJ, Holbrook JT, Que LG, Mathews AM, **Wise R**, Dixon AE, Peters SP, Rogers L, Smith LJ, Teague WG and Lang JE. Does Obesity Increase Respiratory Tract Infections in Patients with Asthma? *J Allergy Clin Immunol Pract* 2018;
406. Siddharthan T, Pollard SL, Quaderi SA, Mirelman AJ, Cardenas MK, Kirenga B, Rykiel NA, Miranda JJ, Shrestha L, Chandyo RK, Cattamanchi A, Michie S, Barber J, Checkley W, Hurst JR and GECO Study Investigators. Effectiveness-implementation of COPD case finding and self-management action plans in low- and middle-income countries: global excellence in COPD outcomes (GECO) study protocol. *Trials* 2018; 19:571-018-2909-8
407. Morgan BW, Grigsby MR, Siddharthan T, Chowdhury M, Rubinstein A, Gutierrez L, Irazola V, Miranda JJ, Bernabe-Ortiz A, Alam D, **Wise R** and Checkley W. Epidemiology and risk factors of asthma-chronic obstructive pulmonary disease overlap in low- and middle-income countries. *J Allergy Clin Immunol* 2018;
408. Kennedy CC, Novotny PJ, LeBrasseur NK, **Wise R**, Sciruba FC, Benzo RP and NETT Research Group. Frailty and Clinical Outcomes in Chronic Obstructive Pulmonary Disease. *Ann Am Thorac Soc* 2018;
409. Wan ES, Fortis S, Regan EA, Hokanson J, Han MK, Casaburi R, Make BJ, Crapo JD, DeMeo DL, Silverman EK and COPDGene Investigators. Longitudinal Phenotypes and Mortality in Preserved Ratio Impaired Spirometry in the COPDGene Study. *Am J Respir Crit Care Med* 2018; 198:1397-1405
410. **Wise R**, Chapman KR, Scirica BM, Schoenfeld DA, Bhatt DL, Daoud SZ, Seoane B, Reisner C and Garcia Gil E. Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study. *Chronic Obstr Pulm Dis* 2018; 5:5-15
411. Yusen RD, Criner GJ, Sternberg AL, Au DH, Fuhlbrigge AL, Albert RK, Casaburi R, Stoller JK, Harrington KF, Cooper JAD, Jr, Diaz P, Gay S, Kanner R, MacIntyre N, Martinez FJ, Piantadosi S, Sciruba F, Shade D, Stibolt T, Tonascia J, **Wise R**, Bailey WC, LOTT Research Group * and LOTT Research Group. The Long-Term Oxygen Treatment Trial for Chronic Obstructive Pulmonary Disease: Rationale, Design, and Lessons Learned. *Ann Am Thorac Soc* 2018; 15:89-101
412. Putcha N, Paul GG, Azar A, **Wise R**, O'Neal WK, Dransfield MT, Woodruff PG, Curtis JL, Comellas AP, Drummond MB, Lambert AA, Paulin LM, Fawzy A, Kanner RE, Paine R, 3rd, Han MK, Martinez FJ, Bowler RP, Barr RG, Hansel NN and SPIROMICS investigators. Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS. *PLoS One* 2018; 13:e0194924
413. Putcha N and **Wise R**. Medication Regimens for Managing COPD Exacerbations. *Respir Care* 2018; 63:773-782
414. Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, **Wise R**, Pascoe SJ and IMPACT Investigators. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. *N Engl J Med* 2018; 378:1671-1680

415. Trompeter G, Grigsby MR, Miele CH, **Wise R**, Gilman RH, Miranda JJ, Bernabe-Ortiz A, Checkley W and CRONICAS Cohort Study. Patterns of Body Composition Relating to Chronic Respiratory Diseases Among Adults in Four Resource-Poor Settings in Peru. *Lung* 2018; 196:277-284
416. Wilson SR, **Wise R**, Castro M, Mulligan MJ, Ayala E, Chausow A, Huang Q and Gummidipundi S. Performance of the Asthma Impact on Quality of Life Scale (A-IQOLS) in diverse asthma research populations and demographic subgroups. *J Allergy Clin Immunol* 2018;
417. **Wise R**, Calverley PM, Carter K, Clerisme-Beaty E, Metzdorf N and Anzueto A. Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR((R)) trial. *Int J Chron Obstruct Pulmon Dis* 2018; 13:605-616
418. Bhatt SP, Kim YI, Harrington KF, Hokanson JE, Lutz SM, Cho MH, DeMeo DL, Wells JM, Make BJ, Rennard SI, Washko GR, Foreman MG, Tashkin DP, **Wise R**, Dransfield MT, Bailey WC and COPD Gene Investigators. Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years. *Thorax* 2018;
419. Baker AM, Holbrook JT, Yohannes AM, Eakin MN, Sugar EA, Henderson RJ, Casper AS, Kaminsky DA, Rea AL, Mathews AM, Que LG, Ramsdell JW, Gerald LB, **Wise R**, Hanania NA and for American Lung Association Airways Clinical Research Centers. Test Performance Characteristics of the AIR, GAD-7 and HADS-Anxiety Screening Questionnaires for Anxiety in Chronic Obstructive Pulmonary Disease. *Ann Am Thorac Soc* 2018;
420. Calverley PM, Anzueto AR, Dusser D, Mueller A, Metzdorf N and **Wise R**. Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD. *Int J Chron Obstruct Pulmon Dis* 2018; 13:1297-1308
421. Wu TD, Perzanowski M, Peng RD, **Wise R**, Balcer-Whaley S, Newman M, Cunningham A, Phipatanakul W, Matsui EC and McCormack MC. Validation of the maximum symptom day among children with asthma. *J Allergy Clin Immunol* 2018;
422. Morgan BW, Grigsby MR, Siddharthan T, Kalyesubula R, **Wise R**, Hurst JR, Kirenga B and Checkley W. Validation of the Saint George's Respiratory Questionnaire in Uganda. *BMJ Open Respir Res* 2018; 5:e000276-2018-000276. eCollection 2018
423. Soler X, Holbrook JT, Gerald LB, Berry CE, Saams J, Henderson RJ, Sugar E, **Wise R** and Ramsdell JW. Validity of the Asthma Control Test Questionnaire Among Smoking Asthmatics. *J Allergy Clin Immunol Pract* 2018; 6:151-158
424. Fawzy A, Anderson JA, Cowans NJ, Crim C, **Wise R**, Yates JC and Hansel NN. Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD. *Respir Res* 2019; 20:86-019-1059-1
425. Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Lange P, Lettis S, Lipson DA, Lomas DA, Martinez FJ, Papi A, Roche N, van der Valk RJP, **Wise R** and Singh D. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. *Lancet Respir Med* 2019; 7:745-756
426. **Wise R** and Krishnan JA. Celebration of the 50-Year Anniversary of the National Heart, Lung, and Blood Institute Division of Lung Diseases: A Half-Century of Landmark Clinical Trials. *Chronic Obstr Pulm Dis* 2019; 6:10.15326/jcopdf.6.4.2019.0157
427. Sidhaye VK, Holbrook JT, Burke A, Sudini KR, Sethi S, Criner GJ, Fahey JW, Berenson CS, Jacobs MR, Thimmulappa R, **Wise R** and Biswal S. Compartmentalization of anti-oxidant and anti-inflammatory gene expression in current and former smokers with COPD. *Respir Res* 2019; 20:190-019-1164-1

428. Balasubramanian A, MacIntyre NR, Henderson RJ, Jensen RL, Kinney G, Stringer WW, Hersh CP, Bowler RP, Casaburi R, Han MK, Porszasz J, Barr RG, Make BJ, **Wise R** and McCormack MC. Diffusing Capacity of Carbon Monoxide in Assessment of COPD. *Chest* 2019;
429. Ahmed A, Sadreameli SC, Curtin-Brosnan J, Grant T, Phipatanakul W, Perzanowski M, Balcer-Whaley S, Peng R, Newman M, Cunningham A, Divjan A, Bollinger ME, **Wise R**, Miller R, Chew G and Matsui EC. Do Baseline Asthma and Allergic Sensitization Characteristics Predict Responsiveness to Mouse Allergen Reduction? *J Allergy Clin Immunol Pract* 2019;
430. Aboumatar H, Naqibuddin M, Chung S, Chaudhry H, Kim SW, Saunders J, Bone L, Gurses AP, Knowlton A, Pronovost P, Putcha N, Rand C, Roter D, Sylvester C, Thompson C, Wolff JL, Hibbard J and **Wise R**. Effect of a Hospital-Initiated Program Combining Transitional Care and Long-term Self-management Support on Outcomes of Patients Hospitalized With Chronic Obstructive Pulmonary Disease: A Randomized Clinical Trial. *JAMA* 2019; 322:1371-1380
431. **Wise R**, Chapman KR, Scirica BM, Bhatt DL, Daoud SZ, Zetterstrand S, Reisner C and Gil EG. Effect of Acclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial. *JAMA* 2019; 321:1693-1701
432. Simkovich SM, Goodman D, Roa C, Crocker ME, Gianella GE, Kirenga BJ, **Wise R** and Checkley W. The health and social implications of household air pollution and respiratory diseases. *NPJ Prim Care Respir Med* 2019; 29:12-019-0126-x
433. Bose S, Henderson RJ, Rogers L, Casale T, Skloot G, Soler X, **Wise R** and Que LG. Identifying an at-risk population for poor asthma outcomes: Data from the American Lung Association Asthma Clinical Trials Registry. *J Allergy Clin Immunol Pract* 2019;
434. Thomashow B, Crapo JD, Drummond MB, Han MK, Kalhan R, Malanga E, Malanga V, Mannino DM, Rennard S, Scirba FC, Willard KS, **Wise R** and Yawn B. Introducing the New COPD Pocket Consultant Guide App: Can A Digital Approach Improve Care? A Statement of the COPD Foundation. *Chronic Obstr Pulm Dis* 2019; 6:10.15326/jcopdf.6.3.2018.0167
435. Wu TD, Ejike CO, **Wise R**, McCormack MC and Brigham EP. Investigation of the Obesity Paradox in Chronic Obstructive Pulmonary Disease, According to Smoking Status, in the United States. *Am J Epidemiol* 2019; 188:1977-1983
436. Hinze AM, Lin CT, Hussien AF, Perin J, Venado A, Golden JA, Boin F, Brown RH, **Wise R** and Wigley FM. Longitudinal assessment of interstitial lung disease in single lung transplant recipients with scleroderma. *Rheumatology (Oxford)* 2019;
437. Gatto NM, Koralek DO, Bracken MB, Duggan WT, Lem J, Klioze S, Koch GG, **Wise R**, Cohen RB and Jackson NC. Lung Cancer-Related Mortality With Inhaled Insulin or a Comparator: Follow-Up Study of patients previously enrolled in Exubera Controlled Clinical Trials (FUSE) Final Results. *Diabetes Care* 2019; 42:1708-1715
438. Hartley B, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lipson DA, Lomas DA, Martin N, Martinez FJ, Singh D, **Wise R** and Lettis S. Misinterpretation of time-to-first event curves can lead to inappropriate treatment. *Eur Respir J* 2019; 54:10.1183/13993003.00634-2019. Print 2019 Sep
439. Chisholm JF, Shenoy SK, Shade JK, Kim V, Putcha N, Carson KA, **Wise R**, Hansel NN, Hanes JS, Suk JS and Neptune E. Nanoparticle diffusion in spontaneously expectorated sputum as a biophysical tool to probe disease severity in COPD. *Eur Respir J* 2019;

440. Aboumatar H and **Wise R**. Notice of Retraction. Aboumatar et al. Effect of a Program Combining Transitional Care and Long-term Self-management Support on Outcomes of Hospitalized Patients With Chronic Obstructive Pulmonary Disease: A Randomized Clinical Trial. *JAMA*. 2018;320(22):2335-2343. *JAMA* 2019; 322:1417-1418
441. Koch AL, Brown RH, Woo H, Brooker AC, Paulin LM, Schneider H, Schwartz AR, Diette GB, **Wise R**, Hansel NN and Putcha N. Obstructive Sleep Apnea and Airway Dimensions in COPD. *Ann Am Thorac Soc* 2019;
442. Kaminsky DA, Chapman DG, Holbrook JT, Henderson RJ, Sugar EA, Mastrorarde J, Teague WG, Busk M, Sumino K, Dixon AE, **Wise R** and Irvin CG. Older age and obesity are associated with increased airway closure in response to methacholine in patients with asthma. *Respirology* 2019;
443. Siddharthan T, Grigsby M, Morgan B, Kalyesubula R, **Wise R**, Kirenga B and Checkley W. Prevalence of chronic respiratory disease in urban and rural Uganda. *Bull World Health Organ* 2019; 97:318-327
444. Gatto NM, Bracken MB, Kolitsopoulos F, Duggan WT, Koch GG, **Wise R** and Jackson NC. Pulmonary and cardiovascular safety of inhaled insulin in routine practice: The Exubera Large Simple Trial (VOLUME). *Contemp Clin Trials Commun* 2019; 18:100427
445. Aboumatar H and **Wise R**. Self-medication as Part of Self-management Plans for Patients With COPD-Reply. *JAMA* 2019; 321:1937
446. Wu TD, Perzanowski M, Peng RD, **Wise R**, Balcer-Whaley S, Newman M, Cunningham A, Phipatanakul W, Matsui EC and McCormack MC. Validation of the maximum symptom day among children with asthma. *J Allergy Clin Immunol* 2019; 143:803-805.e10
447. **Wise R**, Anderson JA, Amarenco P, Cowans NJ, Crim C, Denvir MA, Gomez CR, Jones MP, Morris A, Niewoehner D and Yates JC. Adjudication of cardiovascular events in patients with chronic obstructive pulmonary disease: SUMMIT trial. *Clin Trials* 2020; 17:430-436
448. Keller T, Spece LJ, Donovan LM, Udris E, Coggeshall SS, Griffith M, Bryant AD, Casaburi R, Cooper JA, Jr, Criner GJ, Diaz PT, Fuhlbrigge AL, Gay SE, Kanner RE, Martinez FJ, Panos RJ, Shade D, Sternberg A, Stibolt T, Stoller JK, Tonascia J, **Wise R**, Yusen RD, Au DH and Feemster LC. Association of Guideline-Recommended COPD Inhaler Regimens With Mortality, Respiratory Exacerbations, and Quality of Life: A Secondary Analysis of the Long-Term Oxygen Treatment Trial. *Chest* 2020; 158:529-538
449. Raju S, McCormack MC, Drummond MB, Ramamurthi HC, Merlo CA, **Wise R**, Mehta SH, Brown RH and Kirk GD. Association of Lung Function With HIV-Related Quality of Life and Health Care Utilization in a High-Risk Cohort. *J Acquir Immune Defic Syndr* 2020; 85:219-226
450. Burkes RM, Ceppe AS, Doerschuk CM, Couper D, Hoffman EA, Comellas AP, Barr RG, Krishnan JA, Cooper C, Labaki WW, Ortega VE, Wells JM, Criner GJ, Woodruff PG, Bowler RP, Pirozzi CS, Hansel NN, **Wise R**, Brown TT, Drummond MB and SPIROMICS Investigators. Associations Among 25-Hydroxyvitamin D Levels, Lung Function, and Exacerbation Outcomes in COPD: An Analysis of the SPIROMICS Cohort. *Chest* 2020; 157:856-865
451. Bose S, Bime C, Henderson RJ, Blake KV, Castro M, DiMango E, Hanania NA, Holbrook JT, Irvin CG, Kraft M, Peters SP, Reibman J, Sugar EA, Sumino K, **Wise R**, Rogers L and American Lung Association Airways Clinical Research Centers. Biomarkers of Type 2 Airway Inflammation as Predictors of Loss of Asthma Control During Step-Down Therapy for Well-Controlled Disease: The Long-Acting Beta-Agonist Step-Down Study (LASST). *J Allergy Clin Immunol Pract* 2020; 8:3474-3481
452. Kayongo A, Wosu AC, Naz T, Nassali F, Kalyesubula R, Kirenga B, **Wise R**, Siddharthan T and Checkley W. Chronic Obstructive Pulmonary Disease Prevalence and Associated Factors in a Setting of Well-Controlled HIV, A Cross-Sectional Study. *COPD* 2020; 17:297-305

453. Putcha N, Fawzy A, Matsui EC, Liu M, Bowler RP, Woodruff P, O'Neal WK, Comellas AP, Han MK, Dransfield M, Wells JM, Lugogo N, Gao L, Talbot CC, Jr, Hoffman E, Cooper CB, Paulin LM, Kanner RE, Criner G, Ortega VE, Barr RG, Krishnan JA, Martinez FJ, Drummond MB, **Wise R**, Diette GB, Hersh CP and Hansel NN. Clinical phenotypes of atopy and asthma in COPD: a meta-analysis of SPIROMICS and COPDGene. *Chest* 2020;
454. Tal-Singer R, Yawn BP, **Wise R**, Thomashow BM and Boyce DM. The COPD Foundation Coronavirus Disease 2019 International Medical Experts Survey: Results. *Chronic Obstr Pulm Dis* 2020; 7:139-146
455. Murphy KR, Chipps B, Beuther DA, **Wise R**, McCann W, Gilbert I, Eudicone JM, Gandhi HN, Harding G, Coyne KS, Zeiger RS and US PRECISION Advisory Board. Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure. *J Allergy Clin Immunol Pract* 2020; 8:2263-2274.e5
456. Ahmed A, Sadreameli SC, Curtin-Brosnan J, Grant T, Phipatanakul W, Perzanowski M, Balcer-Whaley S, Peng R, Newman M, Cunningham A, Divjan A, Bollinger ME, **Wise R**, Miller R, Chew G and Matsui EC. Do Baseline Asthma and Allergic Sensitization Characteristics Predict Responsiveness to Mouse Allergen Reduction? *J Allergy Clin Immunol Pract* 2020; 8:596-602.e3
457. Hanania NA, Mannino DM, Criner GJ, Dransfield MT, Han MK, Jones CE, Kilbride S, Lomas DA, Martin N, Martinez FJ, Singh D, **Wise R**, Halpin DMG, Lima R and Lipson DA. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of the IMPACT Trial. *Chest* 2020;
458. Halpin DMG, Dransfield MT, Han MK, Jones CE, Kilbride S, Lange P, Lipson DA, Lomas DA, Martinez FJ, Pascoe S, Singh D, **Wise R** and Criner GJ. The effect of exacerbation history on outcomes in the IMPACT trial. *Eur Respir J* 2020; 55:10.1183/13993003.01921-2019. Print 2020 May
459. Han MK, Criner GJ, Dransfield MT, Halpin DMG, Jones CE, Kilbride S, Lange P, Lettis S, Lipson DA, Lomas DA, Martin N, **Wise R**, Singh D and Martinez FJ. The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial. *Am J Respir Crit Care Med* 2020; 202:1237-1243
460. Bourdin A, Criner G, Devouassoux G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kalhan R, Lange P, Lettis S, Lipson DA, Lomas DA, Echave-Sustaeta Maria-Tome JM, Martin N, Martinez FJ, Quasny H, Sail L, Siler TM, Singh D, Thomashow B, Watz H, **Wise R** and Hanania NA. InforMing the PATHway of COPD Treatment Single-Inhaler Triple Therapy (Fluticasone Furoate/ Umeclidinium/ Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium /Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions. *Chronic Obstr Pulm Dis* 2020;
461. Hinze AM, Lin CT, Hussien AF, Perin J, Venado A, Golden JA, Boin F, Brown RH, **Wise R** and Wigley FM. Longitudinal assessment of interstitial lung disease in single lung transplant recipients with scleroderma. *Rheumatology (Oxford)* 2020; 59:790-798
462. Aboumatar H, Naqibuddin M, Neiman J, Saunders J, Kim S, Chaudhry H, Garcia-Morales E, Robinson N, McBurney M, Jager L, Ajayi T, Bone L, Chung S, Farrell B, Joo Jin H, Linnell J, Pirfo M, Rand C, Riley P, Salvaterra C, Shea K, Singh J and **Wise R**. Methodology and baseline characteristics of a randomized controlled trial testing a health care professional and peer-support program for patients with chronic obstructive pulmonary disease: The BREATHE2 study. *Contemp Clin Trials* 2020; 94:106023
463. Siddharthan T, Wosu AC, Pollard SL, Hossen S, Alupo P, Shade T, Kalyesubula R, Quaderi S, **Wise R**, Hurst JR, Kirenga B, Checkley W and LiNK Cohort Study Investigators. A Novel Case-Finding Instrument for Chronic Obstructive Pulmonary Disease in Low- and Middle-Income Country Settings. *Int J Chron Obstruct Pulmon Dis* 2020; 15:2769-2777

464. Koch AL, Brown RH, Woo H, Brooker AC, Paulin LM, Schneider H, Schwartz AR, Diette GB, **Wise R**, Hansel NN and Putcha N. Obstructive Sleep Apnea and Airway Dimensions in Chronic Obstructive Pulmonary Disease. *Ann Am Thorac Soc* 2020; 17:116-118
465. Burkes RM, Ceppe AS, Couper DJ, Comellas AP, Wells JM, Peters SP, Criner GJ, Kanner RE, Paine R, 3rd, Christenson SA, Cooper CB, Barjaktarevic IZ, Krishnan JA, Labaki WW, Han MK, Curtis JL, Hansel NN, **Wise R**, Drummond MB and SPIROMICS collaborators. Plasma Cathelicidin is Independently Associated with Reduced Lung Function in COPD: Analysis of the Subpopulations and Intermediate Outcome Measures in COPD Study Cohort. *Chronic Obstr Pulm Dis* 2020; 7:370-381
466. Moore A, Preece A, Sharma R, Heaney LG, Costello RW, **Wise R**, Ludwig-Sengpiel A, Mosnaim G, Rees J, Tomlinson R, Tal-Singer R, Stempel DA and Barnes N. A randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients. *Eur Respir J* 2021; 57:10.1183/13993003.03103-2020. Print 2021 Jun
467. Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Lettis S, Manchester P, Martin N, Midwinter D, Morris A, Pascoe SJ, Singh D, **Wise R**, Martinez FJ and IMPACT investigators. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients. *Am J Respir Crit Care Med* 2020;
468. Grant T, Phipatanakul W, Perzanowski M, Balcer-Whaley S, Peng RD, Curtin-Brosnan J, Newman M, Cunningham A, Divjan A, Bollinger ME, **Wise R** and Matsui EC. Reduction in mouse allergen exposure is associated with greater lung function growth. *J Allergy Clin Immunol* 2020; 145:646-653.e1
469. Dransfield MT, Crim C, Criner GJ, Day NC, Halpin DMG, Han MK, Jones CE, Kilbride S, LaFon D, Lipson DA, Lomas DA, Martin N, Martinez FJ, Singh D, **Wise R** and Lange P. Risk of Exacerbation and Pneumonia with Single Inhaler Triple Versus Dual Therapy in IMPACT. *Ann Am Thorac Soc* 2020;
470. Tabberer M, Jones CE, Kilbride S, Halpin DMG, Lomas DA, Pascoe S, Singh D, **Wise R**, Criner GJ, Lange P, Dransfield MT, Han MK, Martinez FJ, Kaisermann MC and Lipson DA. Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study. *Adv Ther* 2020; 37:3775-3790
471. Day NC, Kumar S, Criner G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kaisermann MC, Kilbride S, Lange P, Lomas DA, Martin N, Martinez FJ, Singh D, **Wise R** and Lipson DA. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. *Respir Res* 2020; 21:139-020-01398-w
472. Timofte I, Wijesinha M, Vesselinov R, Kim J, Reed R, Sanchez PG, Ladikos N, Pham S, Kon Z, Rajagopal K, Scharf SM, **Wise R**, Sternberg AL, Kaczorowski D, Griffith B, Terrin M and Iacono A. Survival benefit of lung transplantation compared with medical management and pulmonary rehabilitation for patients with end-stage COPD. *ERJ Open Res* 2020; 6:10.1183/23120541.00177-2019. eCollection 2020 Apr
473. Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, Darken P, Aurivillius M, Reisner C, Dorinsky P and ETHOS Investigators (incl. RA Wise). Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. *N Engl J Med* 2020; 383:35-48
474. Halpin DMG, Criner GJ, Dransfield MT, Han MK, Hartley B, Harvey C, Jones CE, Kato M, Lange P, Lettis S, Lomas DA, Martinez FJ, Martin N, Singh D, **Wise R**, Zheng J and Lipson DA. Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial. *Pulm Ther* 2020;
475. Ghosh AJ, Moll M, Hayden LP, Bon J, Regan E, Hersh CP and COPDGene Investigators (Incl. **Wise R**). Vitamin D deficiency is associated with respiratory symptoms and airway wall thickening in smokers with and without COPD: a prospective cohort study. *BMC Pulm Med* 2020; 20:123-020-1148-4

476. Zaeh SE, Lu MA, Blake KV, Ruvalcaba E, Ayensu-Asiedu C, **Wise R**, Holbrook JT and Eakin MN. "It is kind of like a responsibility thing": transitional challenges in asthma medication adherence among adolescents and young adults. *J Asthma* 2021; 1-11
477. Burkes RM, Couper DJ, Barjaktarevic IZ, Cooper CB, Labaki WW, Han MK, Woodruff PG, Lazarus SC, Parekh TM, Paine Iii R, Comellas AP, Bowler RP, Loehr LR, Putcha N, **Wise R**, Brown TT and Drummond MB. Age-Dependent Associations Between 25-Hydroxy Vitamin D Levels and COPD Symptoms: Analysis of SPIROMICS. *Chronic Obstr Pulm Dis* 2021; 8:277-291
478. Yohannes AM, N Eakin M, Holbrook JT, Sugar EA, Henderson R, Baker AM, Casper AS, Kaminsky DA, Rea AL, Mathews AM, Que LG, Ramsdell JW, Gerald LB, **Wise R** and Hanania NA. Association of mild cognitive impairment and characteristic of COPD and overall health status in a cohort study. *Expert Rev Respir Med* 2021; 15:153-159
479. Hanania NA, Mannino DM, Criner GJ, Dransfield MT, Han MK, Jones CE, Kilbride S, Lomas DA, Martin N, Martinez FJ, Singh D, **Wise R**, Halpin DMG, Lima R and Lipson DA. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial. *Chest* 2021; 159:985-995
480. Siddharthan T, Pollard SL, Jackson P, Robertson NM, Wosu AC, Rahman N, Padalkar R, Sekitoleko I, Namazzi E, Alupo P, Hurst JR, Kalyesubula R, Dowdy D, **Wise R**, Barnes PJ, Checkley W and Kirenga B. Effectiveness of low-dose theophylline for the management of biomass-associated COPD (LODOT-BCOPD): study protocol for a randomized controlled trial. *Trials* 2021; 22:213-021-05163-2
481. **Wise R**, Chapman KR, Scirica BM, Daoud SZ, Lythgoe D and Garcia-Gil E. The Impact of Exacerbation History on the Safety and Efficacy of Acclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial. *Int J Chron Obstruct Pulmon Dis* 2021; 16:689-699
482. Turnier L, Eakin M, Woo H, Dransfield M, Parekh T, Krishnan JA, Kanner R, Cooper CB, Woodruff PG, **Wise R**, Han MK, Romero K, Paulin LM, Peters S, Drummond B, Bleecker ER, Bowler R, Comellas AP, Couper D, Paine R, Martinez F, Barr G, Putcha N and Hansel NN. The influence of social support on COPD outcomes mediated by depression. *PLoS One* 2021; 16:e0245478
483. Bourdin A, Criner G, Devouassoux G, Dransfield M, Halpin DMG, Han MK, Jones CE, Kalhan R, Lange P, Lettis S, Lipson DA, Lomas DA, Echave-Sustaeta Maria-Tome JM, Martin N, Martinez FJ, Quasny H, Sail L, Siler TM, Singh D, Thomashow B, Watz H, **Wise R** and Hanania NA. InforMing the PATHway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions. *Chronic Obstr Pulm Dis* 2021; 8:10.15326/jcopdf.2020.0158
484. Wu TD, Fawzy A, Kinney GL, Bon J, Neupane M, Tejwani V, Hansel NN, **Wise R**, Putcha N and McCormack MC. Metformin use and respiratory outcomes in asthma-COPD overlap. *Respir Res* 2021; 22:70-021-01658-3
485. Han MK, Criner GJ, Dransfield MT, Halpin DMG, Jones CE, Kilbride S, Lange P, Lettis S, Lipson DA, Lomas DA, Martin N, Martinez FJ, **Wise R**, Naya IP and Singh D. Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis. *ERJ Open Res* 2021; 7:10.1183/23120541.00663-2020. eCollection 2021 Jan
486. Lipson DA, Han MK, **Wise R** and Martinez FJ. Reply to Lopez-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect. *Am J Respir Crit Care Med* 2021; 203:928-929
487. Mason SE, Moreta-Martinez R, Labaki WW, Strand M, Baraghoshi D, Regan EA, Bon J, San Jose Estepar R, Casaburi R, McDonald MN, Rossiter H, Make BJ, Dransfield MT, Han MK, Young KA, Kinney G, Hokanson JE,

- San Jose Estepar R, Washko GR, COPDGene Investigators (incl. **Wise R.**) and COPDGene(R) Investigators. Respiratory exacerbations are associated with muscle loss in current and former smokers. *Thorax* 2021;
488. D'Urzo AD, Singh D, Donohue JF, Chapman KR and **Wise RA**. Acclidinium bromide/formoterol fumarate as a treatment for COPD: an update. *Expert Rev Respir Med* 2021; 15:1093-1106
489. Sanders EC, Burkes RM, Mock JR, Brown TT, **Wise RA**, Hansel NN, Liu MC and Drummond MB. Bronchoalveolar Lavage and Plasma Cathelicidin Response to 25-Hydroxy Vitamin D Supplementation: A Pilot Study. *Chronic Obstr Pulm Dis* 2021; 8:371-381
490. Brigham EP, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Diserens JE, Martinez FJ, McCormack MC, Newby DE, Yates J, Vestbo J, Wu TD and **Wise RA**. Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial. *ERJ Open Res* 2021; 7:10.1183/23120541.00902-2020. eCollection 2021 Jul
491. **Wise RA**, Scirica BM, Bhatt DL, Daoud SZ, Chuecos F, Garcia Gil E and Chapman KR. Efficacy of Acclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial. *Adv Ther* 2021; 38:5381-5397
492. Balasubramanian A, Henderson RJ, Putcha N, Fawzy A, Raju S, Hansel NN, MacIntyre NR, Jensen RL, Kinney GL, Stringer WW, Hersh CP, Bowler RP, Casaburi R, Han MK, Porszasz J, Make BJ, McCormack MC and **Wise RA**. Haemoglobin as a biomarker for clinical outcomes in chronic obstructive pulmonary disease. *ERJ Open Res* 2021; 7:10.1183/23120541.00068-2021. eCollection 2021 Jul
493. Sadreameli SC, Ahmed A, Curtin-Brosnan J, Perzanowski MS, Phipatanakul W, Balcer-Whaley S, Divjan A, Peng RD, Newman M, Cunningham A, Bollinger ME, **Wise RA**, Miller RL and Matsui EC. Indoor Environmental Factors May Modify the Response to Mouse Allergen Reduction Among Mouse-Sensitized and Exposed Children with Persistent Asthma. *J Allergy Clin Immunol Pract* 2021; ; 9:4402-4409.e2
494. Singh D, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Lange P, Lettis S, Lipson DA, Mannino D, Martin N, Martinez FJ, Miller BE, **Wise R**, Zhu CQ and Lomas D. InforMing the PATHway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations. *Respir Res* 2021; 22:130-021-01706-y
495. **Wise RA**, Holbrook JT, Brown RH, Criner GJ, Dransfield MT, Han MK, Krishnan JA, Looney E, Neptune E, Palombizio V and Rea A. Losartan Effects on Emphysema Progression Randomized Clinical Trial: Rationale, Design, Recruitment, and Retention. *Chronic Obstr Pulm Dis* 2021; 8:414-426
496. Putcha N, Anzueto AR, Calverley PMA, Celli BR, Tashkin DP, Metzdorf N, Mueller A and **Wise RA**. Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR((R)) and UPLIFT((R)). *Ann Am Thorac Soc* 2022; 19:204-213
497. Fawzy A, Woo H, Balasubramanian A, Barjaktarevic I, Barr RG, Bowler RP, Comellas AP, Cooper CB, Couper D, Criner GJ, Dransfield MT, Han MK, Hoffman EA, Kanner RE, Krishnan JA, Martinez FJ, McCormack M, Paine Iii R, Peters S, **Wise R**, Woodruff PG, Hansel NN and Putcha N. Polycythemia is Associated with Lower Incidence of Severe COPD Exacerbations in the SPIROMICS Study. *Chronic Obstr Pulm Dis* 2021; 8:326-335
498. McCormack MC, Balasubramanian A, Matsui EC, Peng R, **Wise RA** and Keet CA. Race, Lung Function and Long-term Mortality in the National Health and Examination Survey III. *Am J Respir Crit Care Med* 2021;
499. Hansel NN, Putcha N, Woo H, Peng R, Diette GB, Fawzy A, **Wise RA**, Romero K, Davis MF, Rule AM, Eakin MN, Breyse PN, McCormack MC and Koehler K. Randomized Clinical Trial of Air Cleaners to Improve Indoor Air Quality and COPD Health: Results of the CLEAN AIR STUDY. *Am J Respir Crit Care Med* 2022; 205:421-430

500. M, Barnes N, Bourke SC, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Jones CE, Lange P, Lettis S, Lipson DA, Lomas DA, Martin N, Martinez FJ, **Wise R** and Singh D. A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial. *Eur Respir J* 2021; 58:10.1183/13993003.04522-2020. Print 2021 Sep
501. Adcock IM, Bhatt SP, Balkissoon R and Wise RA. The Use of Inhaled Corticosteroids for Patients with COPD Who Continue to Smoke Cigarettes: An Evaluation of Current Practice. *Am J Med* 2022; 135:302-312
502. Goel K, Maleki-Fischbach M, George MP, Kim D, Richards J, Wise RA and Serban KA. A 56-Year-Old Man With Emphysema, Rash, and Arthralgia. *Chest* 2021; 160:e513-e518
503. Dixon AE, Blake KV, DiMango EA, Dransfield MT, Feemster LC, Johnson O, Roy G, Hazucha H, Harvey J, McCormack MC, Wise RA and Holbrook JT. The challenge of addressing obesity in people with poorly controlled asthma. *Obes Sci Pract* 2021; 7:682-689
504. Wise RA, Bafadhel M, Crim C, Criner GJ, Day NC, Halpin DMG, Han MK, Lange P, Lipson DA, Martinez FJ, Maselli DJ, Midwinter D, Singh D, Zysman M, Dransfield MT and Russell REK. Discordant diagnostic criteria for pneumonia in COPD trials: a review. *Eur Respir Rev* 2021; 30:210124. doi: 10.1183/16000617.0124-2021. Print 2021 Dec 31
505. Chapman KR, Wise RA, Scirica BM, Bhatt DL, Daoud SZ, Lythgoe D and Gil EG. Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers. *Respir Res* 2021; 22:272-2
506. Kamenar K, Hossen S, Gupte AN, Siddharthan T, Pollard S, Chowdhury M, Rubinstein AL, Irazola VE, Gutierrez L, Miranda JJ, Bernabe-Ortiz A, Alam D, Kirenga B, Jones RC, van Gemert F, Wise RA and Checkley W. Previous tuberculosis disease as a risk factor for chronic obstructive pulmonary disease: a cross-sectional analysis of multicountry, population-based studies. *Thorax* 2021;
507. Ghosh AJ, Hobbs BD, Moll M, Saferali A, Boueiz A, Yun JH, Scirba F, Barwick L, Limper AH, Flaherty K, Criner G, Brown KK, Wise R, Martinez FJ, Lomas D, Castaldi PJ, Carey VJ, DeMeo DL, Cho MH, Silverman EK, Hersh CP and COPDGene Investigators. Alpha-1 Antitrypsin MZ Heterozygosity Is an Endotype of Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2022; 205:313-323
508. Chipps BE, Murphy KR, Wise RA, McCann WA, Beuther DA, Reibman J, George M, Gilbert I, Eudicone JM, Gandhi HN, Harding G, Ross M and Zeiger RS. Assessing Construct Validity of the Asthma Impairment and Risk Questionnaire Using a 3-month Exacerbation Recall. *Ann Allergy Asthma Immunol* 2022;
509. Aboumatar H, Garcia Morales EE, Jager LR, Naqibuddin M, Kim S, Saunders J, Bone L, Linnell J, McBurney M, Neiman J, Riley M, Robinson N, Rand C and Wise R. Comparing Self-management Programs with and without Peer Support Among Patients with Chronic Obstructive Pulmonary Disease. *Ann Am Thorac Soc* 2022;
510. Tabberer M, Jones CE, Kilbride S, Halpin DMG, Lomas DA, Pascoe S, Singh D, Wise RA, Criner GJ, Lange P, Dransfield MT, Han MK, Martinez FJ, Kaisermann MC and Lipson DA. Correction to: Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study. *Adv Ther* 2022; 39:1446-8
511. Thomashow B, Stiegler M, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Lange P, Martinez FJ, Midwinter D, Singh D, Tabberer M, Wise RA, Lipson DA and Jones P. Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT Trial. *Chronic Obstr Pulm Dis* 2022; 9:68-79
512. Putcha N, Woo H, McCormack MC, Fawzy A, Romero K, Davis MF, Wise RA, Diette GB, Koehler K, Matsui EC and Hansel NN. Home Dust Allergen Exposure Is Associated with Outcomes among Sensitized Individuals with Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2022; 205:412-420

513. Calverley PMA, Martinez FJ, Vestbo J, Jenkins CR, Wise R, Lipson DA, Cowans NJ, Yates J, Crim C and Celli BR. International Differences in the Frequency of COPD Exacerbations Reported in Three Clinical Trials. *Am J Respir Crit Care Med* 2022;
514. Ghosh AJ, Hobbs BD, Yun JH, Saferali A, Moll M, Xu Z, Chase RP, Morrow J, Ziniti J, Sciruba F, Barwick L, Limper AH, Flaherty K, Criner G, Brown KK, Wise R, Martinez FJ, McGoldrick D, Cho MH, DeMeo DL, Silverman EK, Castaldi PJ, NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium and Hersh CP. Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. *Respir Res* 2022; 23:97-w
515. Johnson O, Gerald LB, Harvey J, Roy G, Hazucha H, Large C, Burke A, McCormack M, Wise RA, Holbrook JT and Dixon AE. An Online Weight Loss Intervention for People With Obesity and Poorly Controlled Asthma. *J Allergy Clin Immunol Pract* 2022;
516. McCormack MC, Balasubramanian A, Matsui EC, Peng RD, Wise RA and Keet CA. Race, Lung Function, and Long-Term Mortality in the National Health and Nutrition Examination Survey III. *Am J Respir Crit Care Med* 2022; 205:723-724
517. Martinez FJ, Agusti A, Celli BR, Han MK, Allinson JP, Bhatt SP, Calverley P, Chotirmall SH, Chowdhury B, Darken P, Da Silva CA, Donaldson G, Dorinsky P, Dransfield M, Faner R, Halpin DM, Jones P, Krishnan JA, Locantore N, Martinez FD, Mullerova H, Price D, Rabe KF, Reisner C, Singh D, Vestbo J, Vogelmeier CF, Wise RA, Tal-Singer R and Wedzicha JA. Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. *Am J Respir Crit Care Med* 2022; 205:275-287

Chapters and Reviews

1. Britt EJ, **R Wise**, J Sylvester. "Localized Pulmonary Infiltrates". In: The Principles and Practice of Medicine, 20th ed, AM Harvey (ed) New York, Appleton-Century-Crofts, 1980.
2. **Wise RA**, WR Summer. Pulmonary Mechanics and Artificial Support of the Arrested Circulation. In: Clinics in Chest Medicine 4(2):189-198 May 1983, W.B. Saunders Co. Philadelphia, Pa.
3. Britt JE, **RA Wise**, and JT Sylvester. Localized Pulmonary Infiltration. In: The Principles and Practice of Medicine, Harvey, Johns, McKusick, Owens, and Ross (eds) 21st Ed. Appleton- Century Crofts, pp. 357-367, 1984.
4. Summer WR, JR Michael, and **RA Wise**. Acute Respiratory Failure (ARF). In: The Principles and Practice of Medicine, Harvey, Johns, McKusick, Owens, and Ross (eds) 21st Ed. Appleton-Century Crofts, pp. 403-413, 1984.
5. **Wise RA** and WR Summer. Pulmonary Mechanics and Artificial Support of the Arrested Circulation. In: Cardiology Clinics C Venkata and S Ram (eds) W.B. Saunders Co., Philadelphia, PA., May 1984.
6. **Wise RA** and S Permutt. Evaluation of Lung Function: Determination of Pulmonary Impairment. DH Simmons (ed) In: Current Pulmonology Vol. 6, pp. 307-327, 1985, John Wiley & Sons, Inc. NY,

7. Permutt S, **R Wise**, and JT Sylvester. Interaction between the ventilatory and circulatory pumps. In: The Thorax Charis Roussos (ed) Marcel Dekker, Inc. Pub. pp. 701-735. 1985.
8. Permutt S and **Wise RA**. Mechanical Interaction of Respiration and Circulation. A Fishman, (ed) In: Handbook of Physiology: Section 3: The Respiratory System. American Physiological Society. Vol. III, Mechanics of Breathing, Part 2, pp. 647-656, 1986.
9. Permutt S and **Wise RA**. The control of cardiac output through coupling of heart and blood vessels. Frank CP Yin (ed) In: Ventricular Vascular Coupling pp. 159-179, Springer-Verlag, New York, 1986.
10. **Wise RA** and WR Summer. Cardiopulmonary Resuscitation. In: Cardiopulmonary Critical Care 2nd ed. D Dantzker (ed) Grune and Stratton. Orlando. 1986.
11. **Wise RA**. Pulmonary Function Tests and Mortality. In: Medical Section Proceedings 1986: American Council of Life Insurance Washington, D.C. pp. 81-88. The Eleventh Annual Meeting of the Medical Section of the American Council of Life Insurance.
12. **Wise RA**. Basic studies in respiratory structure and function. In: Year Book of Pulmonary Disease GM Green (ed) Year Book Medical Publishers, Inc. Chicago, pp.15-57, 1986.
13. **Wise RA**. Respiratory structure and function. In: Year Book of Pulmonary Disease GM Green (ed) Year Book Medical Publishers, Inc. Chicago, pp. 13-49, 1987.
14. **Wise RA**. Respiratory structure and function. In: Year Book of Pulmonary Disease GM Green, (ed) Year Book Medical Publishers, Inc. Chicago, pp. 1-35, 1988.
15. **Wise RA**. Respiratory structure and function. In: Year Book of Pulmonary Disease GM Green, (ed) Year Book Medical Publishers, Inc. Chicago, pp. 1-51, 1989.
16. Permutt S, **Wise RA**, and RG Brower. How changes in pleural and alveolar pressure cause changes in afterload and preload. In: Lung Biology in Health and Disease. Vol 42. "Heart-Lung Interactions in Health and Disease," SM Scharf, and SS Cassidy, eds. Marcel Dekker, Inc. New York, pp. 243-250, 1989.
17. **Wise RA**. Respiratory structure and function. In: Year Book of Pulmonary Disease GM Green, (ed) Year Book Medical Publishers, Inc. Chicago, pp. 277-305. 1990.
18. Smith PL, AR Schwartz, E Gauda, **R Wise**, R Brower, and S Permutt. The modulation of upper airway critical pressures during sleep. In: Sleep and Respiration 1990, Wiley-Liss, Inc., pp. 253-260.
19. **Wise RA** and MJ Hausknecht. Interaction of Respiration and Circulation; Cardiopulmonary Resuscitation In: Heart-Lung Interactions in Health and Disease. SM Scharf, and SS Cassidy, (eds) Marcel Dekker, Inc. New York. pp. 565-577, 1990.
20. **Wise RA**. Chronic obstructive pulmonary disease and the peripheral circulation. In: Chronic Obstructive Pulmonary Disease. Neil S Cherniack (ed) W.B. Saunders Co. Phila. PA. 1991.
21. Fessler H, and **R Wise**. Retour Veineux. In: Hemodynamique: concepts et pratique en reanimation JF Dhainaut, and D Payen (eds) Collection D'Anesthesiologie et de reanimation. publice sous la direction de F. Lemaire et J.M. Desmots. Masson, Paris, pp. 27-38, 1991.
22. **Wise RA**. Pulmonary complications in collagen vascular disease. In: Immunologically Mediated Pulmonary Diseases. Lynch JP III, and RA DeRemee (eds) J.B. Lippincott Co. pp. 40-88, 1991.
23. **Wise RA**. Respiratory structure and function. In: Year Book of Pulmonary Disease. G M Green (ed) Year Book Medical Publishers, Inc. Chicago 1991.

24. **Wise RA** and WR Summer. Cardiopulmonary Resuscitation. In: Cardiopulmonary Critical Care, 2nd Edition, D Dantzker (ed) Saunders, Philadelphia. Florida 1991.
25. **Wise RA**. Pulmonary Pathophysiology and Evaluation of Lung Function. In: The Principles of Nuclear Medicine 2nd Ed. HN Wagner, Jr. (ed) W.B. Saunders Co., Philadelphia, PA 1994.
26. Tashkin DF, MD Altose, JE Connett, RE Kanner, WW Lee, **R Wise** and The Lung Health Study Group. Airway Responsiveness in Irreversible Chronic Obstructive Pulmonary Disease. In: Provocative Challenge Testing in Clinical Practice. S L Spector (ed) Marcel Dekker, Inc. New York. Ch. 21. 1995.
27. Wigley FM, **Wise RA**. Systemic Sclerosis: Management of Pulmonary Involvement and "Evaluation of pulmonary involvement" In: Connective Tissue Disorders, Cower Medical Publishing, London 1994.
28. **Wise RA**. Historical Perspectives on the Mechanical Interactions of Respiration and Circulation. In: Interactions Cardio-Pulmonaires Proceedings of Les interactions cardio-pulmonaires meeting in Lausanne, Switzerland, June 1995. C Perret (ed). Arnette, Paris, Publ.
29. Rand CS, **RA Wise**. Adherence with asthma therapy in the management of asthma. In: Lung Biology in Health and Disease, Vol. 86 Severe Asthma: Pathogenesis and Clinical Management, SJ Szeffler and DYM Leung (eds) Marcel Dekker, Inc. pp 435-463, 1995.
30. Magder S and **Wise RA**. Cardiopulmonary resuscitation. In: Lung Biology in Health and Disease., Vol 85 The Thorax. C Roussos (ed) Marcel Dekker, Inc. pp 1641-1685. 1995.
31. Janicki JS, DD Sheriff, JL Robotham, and **RA Wise**. Cardiac output during exercise: contributions of the cardiac, circulatory and respiratory systems. In: Handbook of Physiology, Section 12. Exercise: Regulation and Integration of Multiple Systems LB Rowell, JT Shepherd, (eds). Oxford University Press, New York, NY pp 649-704, 1996.
32. **Wise RA**, MC Liu. Obstructive Airway Diseases: Asthma and Chronic Obstructive Pulmonary Disease. In: Principles of Ambulatory Medicine, 4th Edition. Barker LR, JR Burton, and PD Zieve (eds) Williams and Wilkins, Baltimore, MD pp 650-677, 1996.
33. **Wise RA**, GG Weinmann. Chronic Obstructive Pulmonary Disease. In: The Principles and Practice of Medicine, 23rd Edition. Stobo JD, DB Hellmann, PW Ladenson, BG Petty, and TA Traill (eds) Appleton & Lange, Norwalk, CT pp 133-139, 1996.
34. **Wise RA**. Pulmonary function during pregnancy. In: Asthma and Allergy in Pregnancy and Early Infancy. Schatz M, RS Zeiger, HN Claman (eds) Marcel Dekker, Inc. 1997.
35. Rand CS, RB Mellins, F Malveaux, and **RA Wise**. The role of patient adherence in fatal asthma. Ch 28. In: Fatal Asthma. A Sheffer (ed). Marcel Dekker, Inc. pp 429-456, 1998.
36. **Wise RA**. Chronic Obstructive Pulmonary Disease. In: The Consultation Guide. Ladenson PW (ed) Baltimore: Lippincott Williams and Wilkins, 1999: 484-485.
37. **Wise RA** and M Liu. Obstructive Airway Diseases: Asthma and Chronic Obstructive Pulmonary Disease. In: Principles of Ambulatory Medicine, 5th Edition. Barker LR, JR Burton, and PD Zieve (eds) Williams and Wilkins, Baltimore, MD pp 677-705, 1999.
38. **Wise RA** and Polito AJ. Respiratory Physiologic Changes in Pregnancy. In: Immunology and Allergy Clinics of North America. Asthma and Allergy During Pregnancy. Schatz M (ed) W.B. Saunders Co., No. 20:4 Nov. 663-672, 2000.

39. **Wise RA.** The Epidemiology of Chronic Obstructive Pulmonary Disease. In: Lung Volume Reduction Surgery for Emphysema, Fessler HE, JJ Reilly, Jr., and DJ Sugarbaker (eds) Lung Biology in Health and Disease Monographs. Marcel Dekker, Vol 184, pp 1-22, 2004.
40. **Wise RA** and MC Liu. Obstructive Airway Diseases: Asthma and Chronic Obstructive Pulmonary Disease. In: Principles of Ambulatory Medicine, 6th Edition. Barker LR, JR Burton, and PD Zieve (eds) Williams and Wilkins, Baltimore, MD, 2003.
41. Brown C and **Wise RA.** Pathophysiological Basis for Treatment of COPD. Lung development and regeneration, DJ Massaro, GD Massaro, P Chambon (eds) In: Lung biology in health and disease (v. 190) Marcel Dekker, 2004.
42. **Wise RA.** Understanding, Preventing, and Managing COPD. In: Advanced Studies in Medicine. Thomas PA (ed), Johns Hopkins University, Vol 4 (10A), p. S736, November 2004.
43. Holbrook JT, Shade DM, **Wise RA.** Data Collection and Quality Control. In: Translational and Experimental Clinical Research Schuster DP, Powers WJ (eds) Lippincott Williams & Wilkins, Philadelphia, 2005.
44. **Wise RA**, Holbrook JT, Meinert CL. Monitoring Experimental Interventions. In: Translational and Experimental Clinical Research Schuster DP, Powers WJ (eds) Lippincott Williams & Wilkins, Philadelphia, 2005.
45. **Wise RA**, Herpel LB. Obstructive Lung Disease. In: The Johns Hopkins Internal Medicine Board Review, 2008-2009 2nd Ed, Certification and Recertification. pp. 151-161 Miller RG, Ashar BH, Sisson SD (eds) Mosby Elsevier, Philadelphia, 2007.
46. **Wise RA**, McCormack MC. Pulmonary Function Testing. In: The Johns Hopkins Internal Medicine Board Review, 2008-2009 2nd Ed, Certification and Recertification. pp. 161-165 Miller RG, Ashar BH, Sisson SD (eds) Elsevier, Philadelphia, 2007.
47. **Wise RA**, MC Liu. Obstructive Airway Diseases: Asthma and Chronic Obstructive Pulmonary Disease. In: Principles of Ambulatory Medicine, 7th Edition. Barker LR, JR Burton, and PD Zieve (eds) Williams and Wilkins, Baltimore, MD, 2007.
48. **Wise RA.** Treatment of Chronic Obstructive Pulmonary Disease. In: Fishman's Pulmonary Diseases and Disorders. AP Fishman, J. Elias (eds) McGraw-Hill, New York. May 2008.
49. **Wise RA.** Giving new hope to patients with COPD: Introduction - Evaluating optimal management strategies. In: Advanced Studies in Medicine. Johns Hopkins University. Pp. 443-444, 8(13):2008.
50. **Wise RA.** Proceedings: Current therapies and new approaches to the treatment of COPD. Evaluating optimal management strategies. In: Advanced Studies in Medicine. Johns Hopkins University. pp. 445-450, 8(13):2008.
51. McCormack MC, **Wise RA.** Respiratory Physiology in Pregnancy. In: Pulmonary Problems in Pregnancy. G Bourjeily and K Rosene-Montella (eds) Humana Press. Pp 19-26, 2009
52. **Wise RA.** The Situation in North America: view from the United States. In: Multidisciplinary Respiratory Medicine. Official Scientific Journal of AIMAR. De Benedetto F, Donner CF, Sanguinetti CM (eds) 5(2): 2010.
53. **Wise R.** Pulmonary medicine. In: Oxford American Handbook of Geriatric Medicine. Durso SC (ed). Oxford University Press. Ch 11, pp 325-362, 2010.
54. McCormack M, **R Wise.** Chronic Obstructive Pulmonary Disease. In: the Netter Collection of Medical Illustrations: Respiratory System. 2nd Ed D. Kaminsky (ed). Elsevier, 2011.

55. **Wise RA**, Drummond MB. Obstructive Lung Disease. In: The Johns Hopkins Internal Medicine Board Review, 4th Ed, pp. 133-140 Ashar BH, Miller RG, Sisson SD (eds) Elsevier, Baltimore, 2012.
56. **Wise RA**, McCormack MC. Pulmonary Function Testing. In: The Johns Hopkins Internal Medicine Board Review, 4th Ed, pp. 141-144 Miller Ashar BH, Miller RG, Sisson SD (eds) Elsevier, Baltimore, 2012.
57. Sumino, K., Holbrook JT, **Wise RA**, Rogers L. Asthma clinical trials of American Lung Association/Asthma Clinical Research Centers (ALA-ACRC): what have we learned in 12 years? *Curr Respir Care Rep* 2012 epub.
58. **Wise RA**, Brigham EP. Other Pulmonary Abnormalities – Coexisting and Differential Diagnosis. In: Asthma Comorbidities, Coexisting Conditions, and Differential Diagnosis. pp. 139-147 Lockey RF, Ledford DK (eds) Oxford University Press 2014.
59. **Wise RA**, Drummond MB. Treatment of Chronic Obstructive Pulmonary Disease. In: Fishman's Pulmonary Diseases and Disorders. M. Grippi, J. Elias (eds) McGraw-Hill, New York. May 2008.
60. **Wise RA**, Drummond MB. Obstructive Lung Disease. In: The Johns Hopkins Internal Medicine Board Review, 4th Ed, pp. 142-150 Ashar BH, Miller RG, Sisson SD (eds) Elsevier, Baltimore, 2015.
61. **Wise RA**, McCormack MC. Pulmonary Function Testing. In: The Johns Hopkins Internal Medicine Board Review, 4th Ed, pp. 151-154 Miller Ashar BH, Miller RG, Sisson SD (eds) Elsevier, Baltimore, 2015.
59. Drummond MB, **Wise RA**. Chapter 42: Course and Treatment of Chronic Obstructive Pulmonary Disease. In: Fishman's Pulmonary Diseases and Disorders. M. Grippi, J. Elias, J. Fishman, R. Kotloff, A Pack, R Senior, M Siegel (eds) McGraw-Hill, New York. 2015.

- **Audiovisual Presentation**

Respiratory Muscle Failure, The Johns Hopkins Medical Grand Rounds, Vol XI, Program 3, 1985.

Asthma in the Elderly, The Johns Hopkins Medical Grand Rounds, Vol XIX, Program 4, April 1993.

Dyspnea of Obscure Cause Recalcitrant Asthma, The Johns Hopkins Distinguished Author Series for Internal Medicine. CD Disc 7, Oakstone Medical Publishing, Birmingham, AL, December 2005.

Pulmonary Physiology Case Presentations, The Johns Hopkins Living Textbook (ed. H. Goldberg) 2006.

Chronic Obstructive Pulmonary Disease, The Diane Rehm Show, NPR. 2007.

<http://thedianerehmshow.org/shows/2007-03-01/chronic-obstructive-pulmonary-disease>

COPD with sleep disturbance, including sleep apnea. Virtual case reviews. www.circulatecme.org 2009

Co-morbidities in COPD, Peer-to-peer podcast. www.circulatecme.org 2010

Comprehensive Management of COPD, VHAtv, <https://www.youtube.com/watch?v=5U8-5rTh80g> 2014

COPD Management: At the Confluence of Pharmacotherapies and Delivery Systems : 2017

<https://www.medscape.org/viewarticle/880337>

- **Abstracts**

1. Wang KP, **R Wise**, W Summer, P Terry. Successful cannulation of the left mainstem bronchus with a controllable suction catheter. *Crit Care Med* 6:100, 1978.
2. **Wise RA**, H Newball, S Permutt. Use of the rocking bed in chronic ventilatory failure due to neuropathic and myopathic disorders. *Am Rev Respir Dis* 117:195, 1978.
3. Wang KP, **R Wise**, J Kaplan, B Marsh. Comparison of large and small forceps for transbronchial biopsy in diffuse lung disease. *Am Rev Respir Dis* 117:190, 1978.
4. **Wise RA**, J Robotham, B Bromberger-Barnea, S Permutt. The effect of positive end-expiratory pressure on the aortic pressure-flow relationship. *Fed Proc* 38:1237, 1979.
5. **Wise RA**, J Robotham, B Bromberger-Barnea, S Permutt. Mechanism of elevation of left atrial pressure due to PEEP. *Am Rev Respir Dis*. 119:392, 1979.
6. **Wise RA**, J Robotham, B Bromberger-Barnea, WR Taylor, S Permutt. Left ventricular diastolic pressure by PEEP in the isolated *in-situ* heart. *Physiologist* 22: 134, 1979.
7. **Wise RA**, WR Taylor, B Bromberger-Barnea, S Permutt. Effect of positive end-expiratory pressure (PEEP) on determinants of venous return. *Fed Proc* 39:270, 1980.
8. Taylor WR, B Bromberger-Barnea, **RA Wise**. Left main coronary artery pressure-flow relationships throughout the cardiac cycle. *Physiologist*, 23:158, 1980.
9. Bromberger-Barnea B, **RA Wise**, WR Taylor. Instantaneous systolic and diastolic coronary pressure-flow relationships. Proceedings, XXVIII International Congress of Physiological Sciences Budapest, July, 1980.
10. Fisher J, **R Wise**, M Pinsky, M Weisfeldt, S Permutt, W Ehrlich. Respiratory pattern changes accompanying acute fall in cardiac output. *Physiologist* 23:181, 1980.
11. Bourguignon MH, KH Douglass, JM Links, **RA Wise**, W Ehrlich, HN Wagner. "Fully Automated Measurement of Global Ventricular Function: *Am J of Cardiol* 1981.
12. Bourguignon MH, **RA Wise**, W Ehrlich, K Douglass, E Camargo, K Harrison HN Wagner. Precision of gaited equilibrium radionuclide ventriculography (GERV) in measuring left ventricular stroke volume. *Fed Proc* 1981.
13. Bourguignon MH, KH Douglass, JM Links, **RA Wise**, WE Ehrlich, HN Wagner. "Fully Automated Processing in Gaited Blood Pool Scintigraphy" *J Nucl Med* 22(6):P59, 1981.
14. Schneider PD, MC Hochberg, **RA Wise**, FM Wigley. "Serial Pulmonary Function in Patients with Systemic Sclerosis" *Arthritis & Rheumatism*, 24:S104, 1981.
15. Pinsky MR., WS Summers, **RA Wise**, B Bromberger-Barnea. Augmentation by phasic increases in pleural pressure in dogs. *Am Rev Respir Dis* 123(4):100, 1981.
16. **Wise RA**, WR Taylor, MR Pinsky, S Permutt, B Bromberger-Barnea. Effect of duty cycle and frequency on blood flow in a model of cardiopulmonary resuscitation (CPR). *Fed Proc* 41(5):1608, 1982.
17. **Wise RA**, WR Taylor, MR Pinsky, B Bromberger-Barnea, S Permutt. Aortic flow limitation during cardiopulmonary resuscitation (CPR). *Am Rev Respir Dis* 125:283, 1982.
18. Peters-Golden M, **RA Wise**, PD Schneider, MC Hochberg, and FM Wigley. A prospective evaluation of pulmonary function in systemic sclerosis. *Clin Res* 30(2):436A, 1982

19. Robotham J, **RA Wise**, B Bromberger-Barnea. Effects of abdominal pressure on regional blood flow and left ventricular performance. *Am Rev Respir Dis* 125:237, 1982.
20. Haponik EF, A Munster, PL Smith, **RA Wise**, ER Bleecker. Upper airway injury in burn patients: Evaluation with flow volume curves and fiberoptic nasopharyngoscopy. *Chest* 82:250, 1982.
21. Ettinger WH, **RA Wise**, FM Wigley. Absence of positional change in diffusing capacity in systemic sclerosis. *Arthritis & Rheumatism* 25(S):45, 1982.
22. Peters-Golden M, **RA Wise**, PD Schneider, MC Hochberg, FM Wigley. A prospective evaluation of pulmonary function in systemic sclerosis: Correlations of demographic and clinical features. *Arthritis & Rheumatism* 25(S):126, 1982.
23. Taylor WR, H Silverman, **RA Wise**, S Permutt, PL Smith, ER Bleecker. Circulatory mechanics during anaphylactic shock. *Clinical Research* 30(3):679A, 1982.
24. Taylor WR, HJ Silverman, **RA Wise**, S Permutt, PL Smith, ER Bleecker. Cardiovascular mechanisms of anaphylactic shock. *The Physiologist* 25(4):307, 1982.
25. Rodenhoffer R, J Rommer, FM Wigley, **RA Wise**. A randomized double blind trial of nifedipine in the treatment of digital Raynaud's phenomenon. *Am Heart Assoc* 1982.
26. Ettinger WH, EF Haponik, FM Wigley, **RA Wise**. Physiologic correlations of laryngeal involvement in rheumatoid arthritis. *Arth Rheum* 26:S26, 1983.
27. Wigley FM, M Peters-Golden, **RA Wise**, P Schneider, MC Hochberg. Abnormalities in pulmonary function and mortality in systemic sclerosis. *Arth Rheum* 26:S27, 1983.
28. Wagner EM, PL Smith, **RA Wise**, ER Bleecker. Peripheral hemodynamics in anaphylactic shock. *Fed Proc* 42(5):1251, 1983.
29. Karam M, **R Wise**, TK Natarajan, S Permutt, HN Wagner. Effect of inspiratory threshold loading on left ventricular performance. *Fed Proc* 42(3):309, 1983.
30. Brower R, **R Wise**, C Hassapoyannes, S Permutt. The effect of lung inflation on pulmonary venous return. *Fed Proc* 42(3):594, 1983.
31. **Wise R**, B Bromberger-Barnea, S Permutt. Effect of lung inflation on pulsus paradoxus. *Fed Proc* 42(3):595, 1983.
32. Peters-Golden M, **R Wise**, P Schneider, M Hochberg, F Wigley. Diffusing capacity as a predictor of five-year mortality in systemic sclerosis. *Am Rev Respir Dis*. 127(4):102, 1983.
33. **Wise R**, B Bromberger-Barnea, H Scott, S Permutt. Effect of steady-state changes in pleural pressure on left ventricular (LV) performance. *Am Rev Respir Dis*. 127(4):312, 1983.
34. Hassapoyannes C, **R Wise**, R Brower, B Bromberger-Barnea, S Permutt. Effect of intrathoracic counter-pulsation on left ventricular performance. *Am Rev Respir Dis*. 127(4):311, 1983.
35. Stokes DC, **RA Wise**, RE Pyeritz, EA Murphy. Pulmonary function and the chest wall in short-limbed dwarfism. *Am Rev Respir Dis* 127(4):217, 1983.
36. Hausknecht MJ, R Brower, **RA Wise**, C Hassapoyannes, ML Weisfeldt, S Permutt. Lung inflation produces opposite effects in CPR depending on flow limitation. *Circulation*. 6g(4): 943, 1983.

37. **Wise RA**, C Hassapoyannes, R Brower, B Bromberger-Barnea and S Permutt. Ventricular Interdependence Does Not Cause Pulsus Paradoxus. *Am Rev Respir Dis.* 129(4):A335, 1984.
38. Ettinger WH, **RA Wise**, DA Schaffhauser, FM Wigley. Controlled double blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon. *Clin Res* 32:718A, 1984.
39. Brower R, J Gottlieb, **R Wise**, S Permutt, JT. Sylvester. Hypoxia Causes Constriction of Venous Extra-alveolar Vessels in Isolated Ferret Lungs. *Am Rev Respir Dis* 129(4):A341, 1984.
40. Brower R, **R Wise**, C Hassapoyannes, M Hausknecht, S Permutt. The Longitudinal Distribution of Pulmonary Vascular Compliance. *Fed Proc* 43(4): 922, 1984.
41. **Wise RA**, M. Peters-Golden, RM Watson, FM Wigley. Prognostic value of ribonucleoprotein (RNP) in systemic sclerosis (PSS). *Clin Res* 318A, 1984.
42. Peters-Golden M, F Wigley, M Hochberg, **R Wise**. Incidence of Lung Cancer in Systemic Sclerosis. *Am Rev Respir Dis* 129(4):A326, 1984.
43. Synkowski DR, **RA Wise**, M Peters-Golden, RM Watson, F Wigley. Prognostic value of ribonucleoprotein (RNP) Antibody in Systemic Sclerosis (PSS). *Clinical Research* 32(2):618A, 1984.
44. Gottlieb J, R Brower, **R Wise**, S Permutt, and J Sylvester. Hypoxic pulmonary vasoconstriction (HPC) in isolated ferret lungs: Evidence for an extraalveolar locus. *Fed Proc* 43(4):922, 1984.
45. Smith PL, **RA Wise**, S Permutt. Upper airway pressure flow relationships in patients with obstructive sleep apnea. *Am Rev Respir Dis* 129(4):A245, 1984.
46. Natarajan TK, M Karam, **R Wise**, HN Wagner, Jr. Effect of positive pleural pressure on left ventricular performance. *J Nucl Med* 25:P5, May, 1984.
47. Malamet R, W Ettinger, **RA Wise**, and FM Wigley. Adaptability to cold provocation in Raynaud's phenomenon. *Clin Res* 32:701A, 1984.
48. Malamet R, WH Ettinger, **RA Wise**, FM Wigley. Nifedipine inhibition of platelet activation in Raynaud's. *Clin Res* 32:720A, 1984.
49. Hochberg MC, **RA Wise**, M Peters-Golden, FM Wigley. Incidence of lung cancer in systemic sclerosis. *Am Rev Respir Dis* 129:A326, 1984.
50. Scott TE, **RA Wise**, MC Hochberg, and FM Wigley. HLA-DR4, Smoking, and pulmonary function in rheumatoid arthritis (RA). *Arth Rheum* 29:S33, 1985.
51. Fuenning CR, **RA Wise**, RG Brower, and S Permutt. The mechanism of pulsus paradoxus in cardiac tamponade. *Federation Proceedings*, 44(5): 1379, 1985.
52. Brower R, JT Sylvester, C Fuenning, **R Wise**, and S Permutt. Flow-volume characteristics of the pulmonary circulation in normoxia and hypoxia. *Am. Rev Respir Dis.* 131(4): A410, 1985.
53. Fuenning CR, **RA Wise**, RG Brower, and S Permutt. The effect of end-expiratory pleural pressure on pulsus paradoxus in cardiac tamponade. *Am Rev Respir Dis* 131(4): A147, 1985.
54. Malamet R, **RA Wise**, FM Wigley. A longitudinal study of *in vivo* platelet activation in Raynaud's phenomenon. *Clinical Research* 33(3): 790A, 1985.

55. Scott TE, **RA Wise**, MC Hochberg, and FM Wigley. HLA-DR4, smoking, and pulmonary function in rheumatoid arthritis. *Am Rev Respir Dis* 133(4):A64, 1986.
56. Schwartz AR, PL Smith, AR Gold, **RA Wise**, S Permutt. Induction of obstructive sleep apnea in normal individuals. *Am Rev Respir Dis* 133(4): A307, 1986.
57. Gleadhill IC, **RA Wise**, SA Schonfeld, PP Scott, T Guarnieri, LSC Griffith, EP Veltri. Lung function in patients taking amiodarone. *Circulation* 74(4): 900, 1986.
58. **Wise R**, R Malamet, F Wigley. Acute effects of nifedipine on digital hemodynamics in Raynaud's Phenomenon: A double-blind placebo controlled trial. *Am Rheum Assoc* 1986.
59. Scott T, **RA Wise**, R Malamet, FM Wigley. Nicardipine inhibits platelet activation in Raynaud's phenomenon. *Arth Rheum* 29:S51, 1986.
60. Schwartz AR, PL Smith, **RA Wise**, and S Permutt. The effect of pressure loads on upper airway collapsibility in obstructive sleep apnea. *Am Rev Respir Dis* 135(4): A183, 1987.
61. Fessler H, R Brower, **R Wise**, H Scott, S Permutt. Effects of early systolic vs. late systolic positive pleural pressure on left ventricular (LV) function. *Am Rev Respir Dis* 135(4): A114, 1987
62. **Wise RA**, JL Robotham. Determinants of inferior vena cava (IVC) blood flow with changes in abdominal pressure. *Am Rev Respir Dis* 135(4): A115, 1987.
63. Gleadhill IC, AR Schwartz, PL Smith, **RA Wise**, and S Permutt. Measurement of upper airway critical pressure in patients with obstructive hypopnea. *Am Rev Respir Dis* 135(4): A185, 1987.
64. Fessler H, R Brower, **R Wise**, H Scott, S Permutt. The effect of systolic vs. diastolic positive pleural pressure on left ventricular (LV) afterload. *Federation Proceedings* 46(3): 497, 1987.
65. Brower R, A Dunn, **R Wise**, JT Sylvester, S Permutt. Effects of hypoxia on determinants of edema formation in isolated ferret lungs. *Am Rev Respir Dis* 137(4):A108, 1988.
66. Fessler H, R Brower, **R Wise**, H Scott, S Permutt. Effects of positive pleural pressure on myocardial perfusion. *Am Rev Respir Dis* 137(4):A293, 1988.
67. Fessler H, R Brower, **R Wise**, H Scott, S Permutt. Effects of systolic and diastolic positive pleural pressure on cardiac output with altered cardiac contractility. *Am Rev Respir Dis* 137(4):A293, 1988.
68. Rand CS, Tashkin D, **Wise RA**, Nides M, Simmon M, Bleecker ER. How accurate are canister weighing and self-report as measures of metered-dose inhaler compliance in a clinical trial? *Am Rev Respir Dis* 139(4):A16, 1989.
69. Schwartz AR, Gold AR, **Wise RA**, Permutt S, Smith PL. Effect of weight loss on upper airway collapsibility in obstructive sleep apnea. *Am Rev Respir Dis* 137(4):A126, 1988.
70. Schwartz A, Brower R, Smith P, **Wise R**, Permutt S. Mechanism of inspiratory flow limitation in the isolated canine upper airway during neuromuscular blockade. *Am Rev Respir Dis* 139(4):A79, 1989.
71. Seibold JR, Wigley FM, **Wise RA**, Schaffhauser D, Fico-Soja A, McCloskey D, and Dole WP. Intravenous carbaprostacyclin treatment of Raynaud's phenomenon (RP) secondary to systemic sclerosis (SS). *Am Rheum. Assoc.* 1989.
72. Fessler H, R Brower, **R Wise**, A Dunn, S Permutt. Effects of abdominal pressure (Pabd) and elastance (Eabd) on venous return (VR) during positive end-expiratory pressure (PEEP). *Fed Proc* 3(4):A1182, 1989.

73. Mikdashi JA, **RA Wise**, RJ Spence, FM Wigley. Absence of digital reactive hyperemia in patients with systemic sclerosis (SS). *Arth Rheum* 32:S94, 1989.
74. Fessler HE, RG Brower, **RA Wise**, D Roach, S Permutt. Effects of positive end-expiratory pressure (PEEP) on the Determinants of venous return (VR) from the superior and inferior vena cavae (SVC and IVC). *Am Rev Respir Dis* 141(4):A66, 1990.
75. Blosser SL, **RA Wise**, FM Wigley. Translaryngeal resistance during phonation is increased in patients with rheumatoid arthritis. *Am Rev Respir Dis* 141(4): A926, 1990.
76. Schwartz AR, D Thut, E Gauda, **RA Wise**, S Permutt, PL Smith. Effect of phasic neuromuscular activity (NMA) on airflow mechanics in the isolated canine upper airway. *Am Rev Respir Dis*. 141(4): A742, 1990.
77. Wigley FM, R Miller, and **R Wise**. Ischemic loss of multiple digits associates with sclerodactyly ALO in patients with systemic sclerosis. *Am Col Rheum*. Dec. 1990.
78. Seibold JR, McCloskey DA, Peek R, Underwood J, Wigley FM, **Wise RA**, Mayes IVD, Dole WP. Iloprost treatment of digital ulcerations secondary to systemic sclerosis (SSc). *Am Col Rheum* Jan. 1991.
79. Fessler H, RG Brower, **RA Wise**, D Roach, S Permutt. Effects of PEEP and body position on the pressure gradients in the thoracic great veins. *Am Rev Respir Dis* 143(4):A243, 1991
80. Kanner RE, MD Altose, JE Connett, WW Lee, DP Tashkin, **RA Wise**. The lung health study (LHS): Analysis of male-female prevalence differences in airway hyperreactivity in smokers with mild COPD. *Am Rev Respir Dis* 143(4):A442, 1991.
81. Becker PM, JT Sullivan, KL Preston, DR Jasinski, F Wigley, **RA Wise**. Effects of Intravenous cocaine on pulmonary and peripheral blood flow. *Am Rev Respir Dis* 145 (4):A594, 1992.
82. Alms WJ, FM Wigley, **R Wise**, ER Bleecker, BS Needleman. Immunologic analyses of broncho-alveolar lavage (BAL) cells from scleroderma patients and controls. *Arth Rheum* 35:S38, 1992.
83. Jabs EW, CM Tucker-Muller, GJ Anhalt, W Earnshaw, **RA Wise**. Cytogenetic survey in systemic sclerosis: correlation of aneuploidy with the presence of anticentromere antibodies. *Am College of Rheumatology* 1992.
84. Flynn JA, S Schulman, **R Wise**, F Wigley. Electrocardiographic silent myocardial ischemia is common in patients with systemic sclerosis. *Am College of Rheumatology* 1992.
85. Yurovsky VV, FM Wigley, **RA Wise**, and B White. Evidence for oligoclonality of V δ 1+T cell antigen receptor transcripts in scleroderma patients. *J Immunol* 150(8):73A, 1993.
86. Enright PL, MK Cowles, **RA Wise**, RE Kanner, DP Tashkin, JE Connett. The two-point slope analysis method is better than PD-20 to express the bronchial reactivity of 5734 cigarette smokers. *European Respiratory Society* 1993.
87. Owen M, **R Wise**. Myasthenia gravis and upper airway obstruction. *Am J Resp and Crit Care Med* 151(4):A752, 1995.
88. Weeks K, C Rand, **R Wise**, B Bender, H Milgrom. Home use of a computerized peak flow meter in asthmatic patients. *Am J Resp and Crit Care Med* 151(4): 1995.
89. Atames S, W Alms, V Yurovsky, **R Wise**, E Bleecker, F Wigley, B White. Production of Tc2 cytokines in the lungs of systemic sclerosis (Ssc) patients with alveolitis. *Arthritis Rheum* 39:S232, 1996.

90. Moore W, **R Wise**, F Wigley, C White, B White. Stabilization or improvement of pulmonary function in systemic sclerosis patients (Ssc) with alveolitis treated with cyclophosphamide (CYP), compared to untreated patients. *Arthritis Rheum* 39:S319, 1996.
91. Punjabi N, **R Wise**. Single breath helium dilution in the assessment of static lung volumes. *Am J Resp and Crit Care Med* 155:A907, 1997.
92. **Wise RA**. Sjögren's syndrome -- dry lung. *Pediatric Pulmonology*. Suppl 13:179, 1996
93. Weeks K, C Rand, **R Wise**. Reliability of the thermistor-actuated metered dose inhaler (MDI) chronolog. *Am J Resp and Crit Care Med* 155(4):A259, 1997.
94. Weeks K, C Rand, **R Wise**. Guidelines for interpreting metered dose inhaler (MDI) adherence with a thermistor-actuated MDI chronolog. *Am J Resp and Crit Care Med* 155(4):A310, 1997.
95. Moore W, **R Wise**, F Wigley, C White, B White. Stabilization or improvement of pulmonary function in systemic sclerosis patients (Ssc) with alveolitis treated with cyclophosphamide (CTX), compared to untreated patients. *Am J Resp and Crit Care Med* 155(4):A741, 1997.
96. Punjabi N, **R Wise**. Single breath helium dilution in the assessment of static lung volumes. *Am J Resp and Crit Care Med* 155(4):A906, 1997.
97. Punjabi NM, DJ O'Hearn, AR Schwartz, PL Smith, **RA Wise**, DE Ford, KJ Badeen-Roche. Determinants of multiple sleep latency test (MSLT) in patients with obstructive sleep apnea (OSA). *Am J Resp and Crit Care Med* 157(3):A51, 1998.
98. Rand C, K Weeks, V Santopietro, **R Wise**. Patient adherence with bronchodilator therapy is superior with salmeterol. *Am J Resp and Crit Care Med* 157(3):A274, 1998.
99. Weeks K, V Santopietro, **R Wise**, C Rand. PRN bronchodilator use in a clinical trial of adherence to salmeterol and albuterol therapy. *Am J Resp and Crit Care Med* 157(3):A275, 1998.
100. Taylor ML, PW Noble, B White, MC Liu, **R Wise**, BS Bochner. Alveolar macrophages (AM) in interstitial lung disease (ILD) display an activated surface phenotype. *Am J Resp and Crit Care Med* 157(3):A72, 1998.
101. Greidinger EL, **RA Wise**, FM Wigley, A Rosen. Topoisomerase I antibodies and race: independent associations with pulmonary function in patients with diffuse scleroderma. *Arthritis and Rheumatism Abstract Supplement* 40(9): S101: September 1997.
102. White P, G Diette, S Otterbein, **RA Wise**. Cytopathology on-site evaluation improves diagnostic success in fiberoptic bronchoscopy evaluation of suspected lung cancer. *Am J Resp and Crit Care Med* 157(3):A223, 1998.
103. Diette G, P White, S Otterbein, **RA Wise**. Predictors of pneumocystis carinii (PC) recovery by fiberoptic bronchoscopy in immune compromised (IC) patients. *Am J Resp and Crit Care Med* 157(3):A237, 1998.
104. Diette G, P White, M Jenckes, S Otterbein, **RA Wise**, H Rubin. Patient reported symptoms from fiberoptic bronchoscopy. *Am J Resp and Crit Care Med* 157(3):A222, 1998.
105. Punjabi NM, KJ Badeen-Roche, DJ O'Hearn, RP Allen, AR Schwartz, PL Smith, **RA Wise**, DE Ford. Prediction of obstructive sleep apnea (OSA) using symptom scores from the Hopkins Sleep Survey. *Am J Resp and Crit Care Med* 157(3):A649, 1998.
106. Luzina IG, SP Atamas, **R Wise**, FM Wigley, B White. Global analysis of gene expression in unseparated and CD8+ Cells from bronchoalveolar lavage of patients with scleroderma lung disease. *ACR 64th Annual Scientific Meeting*, 2000.

107. Schiller K, V Santopietro, **R Wise**, C Rand, M Simmons. Concomitant inhaled corticosteroid and PRN bronchodilator use. ATS 2001 Annual Scientific Meeting
108. Schiller K, V Santopietro, **R Wise**, C Rand, C Demuro-Mercon. Validation of a metered-dose inhaler adherence scale. ATS 2001 Annual Scientific Meeting.

(After 2001, Abstracts are located on-line)

Inventions, Patents, Copyrights (pending, awarded)

Ambulatory surface skin temperature monitor patents/US6847913US Pat. 6847913 - Filed Oct 4, 2002 - Issued Jan 25, 2005
- The Johns Hopkins University

Pulmonary Function Laboratory Data Management System, Copyright 1999-2012

Extramural Funding (current, pending, previous)**CURRENT****S-ALP1920-CF41** Wise (PI)

09/06/2016 – 07/31/21

GWU/NIH - Subaward

Pulmonary Complications in a Birth Cohort after a Randomized Trial of Exposure to Antenatal Corticosteroids: the ALPS Follow-Up Study

The goal of this study is to determine whether corticosteroids given to mothers of late pre-term infants lead to a reduction in childhood respiratory illness and improved lung function.

Role: PI

CDR-1507-31247 Aboumatar (PI)

07/01/16 -06/30/20

Patient Centered Outcomes Research Institute(PCORI)

Comparing Effectiveness of Self-management and Peer Support Communication Programs amongst Chronic Obstructive Pulmonary Disease Patients and their Family Caregivers

The goal of this project is to compare the effectiveness of a physician-centered compared to a peer-centered self-management program to improve health status and reduce healthcare utilization in patients with COPD.

Role: Co-PI

1U01HL146408-01 Sugar (PI)

06/15/19 – 04/30/2025

Northwestern University/NHLBI

The American Lung Association (ALA) Lung Health Cohort

The goal of this project is to establish a cohort of 4000 young adults at the age of peak lung health (25-35) to determine risk factors for impaired lung health and the development of airways disease.

Role: Co-Investigator

90085473 Wise (PI)

09/18/19-09/18/21

Clinical Trial (4DX)

Proof of concept Functional Lung Imaging and Ventilation (4DX) analysis COPD

The goal of this study is to examine the feasibility of Novel Functional Lung Imaging and Ventilation (4DxV) Analysis software to measure lung ventilation abnormalities and to compare the 4DxV data obtained at first visit to spirometry and a recent-CT (not performed for this study).

Role: PI

761126-0-RSUB Wise (PI)

05/01/2018 – 03/31/2023

NIH/Nemours Children Clinic (MATCH)

Improving Medication Adherence with Telehealthcare Medication Therapy

The long-term goal is to develop a tailored, effective, and sustainable MTM video telehealthcare intervention to increase medication adherence and improve health outcomes.

Role: PI

Clinical Trial PT010005 Wise (PI)

06/29/15 -- 07/12/20

Pearl Therapeutics

A Randomized, Double-Blind, Multi-Center, Parallel Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations over a 52-Week Treatment Period in Subjects

This is a randomized, double-blind, multi-center, parallel group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations over a 52-week treatment period in subjects with frequent exacerbations.

Role: PI

- R01HL126549** Kirk (PI) 09/15/14 – 05/31/20
NIH
Predictors, consequences and mechanisms of accelerated lung aging in HIV
The goal of this program is to establish risk factors, associated co-morbidities, and immunologic and inflammatory biomarkers associated with accelerated decline in lung function in the SHIELD cohort of HIV-positive inner-city intravenous drug users.
Role: Co-Investigator
- R34HL132369** Wise (PI) 09/01/16 – 06/30/20
NIH-NHLBI
Pilot Study of Zinc Acetate for Chronic Cough
This is a pilot study to determine the feasibility and to inform the design of a clinical trial of Zinc supplementation for treatment of chronic refractory cough.
Role: PI
- T32 HL007534** Wise (PI) 07/01/13 - 06/30/23
NIH-NHLBI
Multidisciplinary training program in lung diseases
The goal of this program is to produce independent biomedical scientists to investigate the mechanisms, manifestations, preventions and cures of lung diseases.
Role: PI
- IH-1304-711:** Aboumatar (PI) 11/01/13-10/31/20
Patient Centered Outcomes Research Institute
An Integrative Multilevel Study for Improving Patient-Centered Care Delivery
The goal of the study is to conduct a comparative effectiveness study to compare patient caregiver and family centered strategies to usual care in order to prevent hospital readmissions for COPD.
(Role: Co-PI)
- Award ID: 24020306 Wise (PI) 01/01/13-07/31/20
National Jewish Health (Sub)
Genetic Epidemiology of COPD Program: Clinical Study Center
The aim of this research is to enroll and characterize patients with COPD and first-degree relatives, so that genetic determinants of susceptibility to this disease can be established through association and linkage methods using genome-wide genotyping.
Role: PI
- 902443** Wise (PI) 10/01/02 – 6/30/2020
American Lung Association (funded by GlaxoSmithKline)
Title: ALA - ACRC Leukotriene Modifier of Corticosteroid Trial (LOCCS)
The LOCCS trial is a clinical trial to determine the relative efficacy of step-down treatments in patients with well-controlled asthma on inhaled twice-daily corticosteroids. The step-down treatment arms included once-daily salmeterol-fluticasone combination and once-daily montelukast. Participants in the trial also donated bio-specimens that are being stored for on-going research.
- 90083894: American Lung Association Wise (PI) 07/01/17-06/30/21
ACRC- Airway Clinical Research Centers Coordinating Center
This is a data coordinating center for the ALA-ACRC which is a network of 17 centers at 23 sites that conduct clinical research in airway diseases including asthma, COPD, and chronic cough.
Role: PI
- PCS-1504-30430: PCORI/Clinical Trial Pucha (PI) 11/1/17-12/15/23
Roflumilast or Azithromycin to prevent (RELIANCE) Study
Johns Hopkins is a clinical site to enroll participants with COPD into the Reliance Trial
Role: Co-Investigator (study site)

PREVIOUS (5-years)

- 1237.19** (Wise) 03/01/14 – 12/31/17 0.12 cal months
Boehringer Ingelheim \$145,948
A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared with tiotropium on Chronic Obstructive Pulmonary Disease (COPD) exacerbation in patients with severe to very severe COPD. [DYNAGITO]
The goal of this study is to determine the effect of one-year of treatment with tiotropium-olodaterol combination compared to tiotropium alone on COPD exacerbations in patients with COPD
- (Aboumatar) 07/01/16 -06/30/20 0.60 cal months
Patient Centered Outcomes Research Institute \$1,499,493
Comparing Effectiveness of Self-management and Peer Support Communication Programs amongst Chronic Obstructive Pulmonary Disease Patients and their Family Caregivers
The goal of this project is to compare the effectiveness of a physician-centered compared to a peer-centered self-management program to improve health status and reduce healthcare utilization in patients with COPD.
- IH-1304-7118** (Aboumatar) 11/01/13-04/30/18 1.20 cal months
Patient Centered Outcomes Research Institute \$520,162
An Integrative Multilevel Study for Improving Patient-Centered Care Delivery
The goal of the study is to conduct a comparative effectiveness study to compare patient caregiver and family centered strategies to usual care in order to prevent hospital readmissions for COPD.
- P30AG021334** (Walston) 07/15/13 – 06/30/18 0.60 cal months
NIH \$691,083
Older Americans Independence Center
This is a multiproject grant to assess the biological genesis of frailty in elderly patients. The Translational Core (PI Wise) will provide consultative and logistic support for clinical research conducted in the project.
- Clinical Trial PT010005** (Wise) 06/29/15-07/12/18 0.12 cal months
Pearl Therapeutics \$283,842
A Randomized, Double-Blind, Multi-Center, Parallel Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations over a 52-Week Treatment Period in Subjects
This is a randomized, double-blind, multi-center, parallel group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations over a 52-week treatment period in subjects with frequent exacerbations.
- R01HL126549** (Kirk) 09/15/14 – 05/31/18 0.36 cal months
NIH \$499,997
Predictors, consequences and mechanisms of accelerated lung aging in HIV
The goal of this program is to establish risk factors, associated co-morbidities, and immunologic and inflammatory biomarkers associated with accelerated decline in lung function in the SHIELD cohort of HIV-positive inner-city intravenous drug users.
- R34HL132369** (Wise) 09/01/16 – 06/30/2019 0.60 cal months
NIH \$175,000
Pilot Study of Zinc Acetate for Chronic Cough
This is a pilot study to determine the feasibility and to inform the design of a clinical trial of Zinc supplementation for treatment of chronic refractory cough.

T32 HL007534 (Wise) 07/01/13 - 06/30/18 0.60 cal months
 NHLBI \$1,135,574

Multidisciplinary training program in lung diseases

The goal of this program is to produce independent biomedical scientists to investigate the mechanisms, manifestations, preventions and cures of lung diseases.

U01HL121814 (Kirk) 09/26/13-07/31/18 0.36 cal months
 NIH \$533,005

Immune Mechanisms of HIV-associated COPD

This proposal directly addresses critical gaps in our understanding of the clinical spectrum and consequences of HIV-associated COPD and will identify key biologic mechanisms contributing to the disease. Findings will inform the clinical management and development of interventions targeting HIV-associated COPD, and may also inform broader strategies for COPD in non-HIV infected populations.

U01HL128951 (Wise) 08/01/15 – 07/31/19 1.20 cal months
 NHLBI \$225,000

Effect of Losartan on Progression of Emphysema

This is a multicenter trial to determine whether the angiotensin receptor antagonist losartan is effective in reducing the progression of emphysema in patients with COPD.

R01HL119476-01A1 (Armanios) 07/15/14-04/30/19 1.20 cal months NHLBI
 \$339,896

Mechanisms of Telomere-Induced Emphysema This award examines the mechanisms by which telomere dysfunction promotes emphysema in mice and in humans.

R01HL125432-01A1 (Drummond) 04/01/15 – 02/29/20 0.60 cal months
 NIH/UNC pending relinquish and JHU \$332,140

Cathelicidin and Vitamin D: Impact on Populations At-Risk and with COPD

This proposal will use two unique cohorts to define the role of the antimicrobial peptide cathelicidin in lung function impairment and pulmonary outcomes in individuals at-risk and with established COPD, as well conduct a proof-of-concept intervention to augment cathelicidin within the lung compartment with vitamin D replacement. This application will improve the understanding of factors which can lead to chronic lung disease. If effective, this application would also provide the justification to study vitamin D as a therapy to improve lung health.

HHSN26800736197C (Tonascia) 10/31/06-05/31/15 1.20 cal months (10%)
 NHLBI \$3,307,740

Long-Term Oxygen Treatment Trial (LOTT) – Data Coordinating Center

Coordinating Center for a multi-center clinical trial establishing whether long-term oxygen treatment improves survival in patients with COPD and moderate hypoxemia.

(90027415 / 906398 - 90048060 / 111441)

SCO104960 (Wise) 03/15/06-12/31/15 0.12 cal months (1%)
 GSK \$527,058

Longitudinal Study

A multicentre 3-year longitudinal prospective study to identify novel endpoints and compare these with forced expiratory volume in 1 second FEV1 for their ability to measure and predict COPD severity and its progression over time

SCO104960 ECLIPSE. (90023739 / 905290)

DC002N (Wise)	10/01/02-06/30/15	0.12 cal months (1%)
ALA	\$816,828	
<u>ACRC Asthma Clinical Trials Network (CORE)</u>		
To establish a network of clinical research centers that will conduct clinical trials to establish improved care for people with asthma. (90003237/902444)		
Study Protocol #115922 (Wise)	08/30/2011 – 08/31/2014	0.12 cal months (1%)
ALA	\$1.6 million (total costs for DCC)	
<u>Long-acting beta-agonist step-down study (LASST)</u>		
Proposing a 56 week multicenter, prospective, randomized, three-arm parallel group comparative effectiveness study comparing three approaches to care of patients with asthma well-controlled for three months on combination ICS/LABA: reduction of ICS and continuation of stable dose ICS/LABA. The primary goal is to perform a pragmatic study that resembles clinical practice and determine the optimal treatment strategy that results in the lowest rate of treatment failure over 48 weeks of follow-up. (90048911/111895)		
UCLA (Wise)	10/01/08-06/31/15	0.24 cal months (2%)
Subaward – NIH prime R01HL089901	\$67,917	
<u>Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease</u>		
The aim of this research is to provide a clinical site for a multicenter trial comparing two treatments for patients with scleroderma lung disease. (90038403 / 106077)		
R01HL105546 (Schneider)	07/01/11 - 05/31/16	0.48 cal months (4%)
NIH	\$250,000	
<u>Pathogenesis and Outcomes of Sleep Disordered Breathing in COPD</u>		
This project will pilot novel methods for exploring sleep disordered breathing pathogenesis and treatment in COPD. (90046549 / 110511)		
NJMRC (Wise)	09/27/07-07/31/17	0.12 cal months (1%)
Subaward – NIH prime U01HL089897	\$164,991	
<u>COPD Genetic Epidemiology Program: Clinical Study Center</u>		
The aim of this research is to enroll and characterize patients with COPD and first-degree relatives, so that genetic determinants of susceptibility to this disease can be established through association and linkage methods using genome-wide genotyping. (90033395 / 102999)		
U01 AI083238-01A1 (Matsui)	05/15/10 – 04/30/15	0.48 cal months (4%)
NIH	\$1,175,472	
<u>Mouse Allergen and Asthma Intervention Trial</u>		
The goal of this study is to conduct a multi-site study of a multi-disciplinary approach to abatement of mouse antigen in inner-city dwellings to determine if severity of asthma can be modified. (90042373 and 90042374 / 107952)		
Clinical Innovator Award (Biswal)	07/01/12 – 06/30/15	0.30 cal months (2.5%)
Flight Attendant Medical Research Institute	\$100,000	
<u>Develop a Proof of Concept Trial of a Novel Therapy for COPD</u>		
The goal of this translational proposal is to conduct a proof of concept clinical trial in COPD patients with sulforaphane to determine whether enhancing Nrf2 regulated antioxidant defenses restore the corticosteroid responses.		
Clinical Trial (Wise)	07/01/13 – 12/31/15	0.36 cal months (3%)
Pearl Therapeutics	\$154,939	

A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects with Moderate to Very Severe COPD, Compared with Placebo.

Clinical Trial (Wise) 01/28/14 – 01/31/15 0.24 cal months (2%)
 Pearl Therapeutics \$65,933

A 28-Week, Multi-Center, Randomized, Double-Blind, Parallel-Group, Active- Controlled Safety Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® as an Active Control

HHSN266200900017C (Hansel) 02/01/09-12/31/14 0.09 cal months (0.78%)
 Columbia University/NIH 123,504 Sub Only

Subpopulations & Intermediate Outcome Measure in COPD Study SPIROMICS: Clinical

The aim of this research is to identify subpopulations of COPD subjects that are likely to be similar with respect to the molecular mechanism of disease and identify and validate indices of disease severity and progression that are likely to be useful as intermediate outcome measures in clinical trials.

IH-1304-7118 (Aboumatar) 11/01/13-10/31/16 1.05 cal months (8.73%)
 Patient Centered Outcomes Research Institute 499,992

An Integrative Multilevel Study for Improving Patient-Centered Care Delivery

The goal of the study is to conduct a comparative effectiveness study to compare patient caregiver and family centered strategies to usual care in order to prevent hospital readmissions for COPD.

U01HL088367-01A2 (Wise) 09/30/09-06/30/14 0.90 cal months (7.5%)
 NIH \$223,482

Study of Soy Isoflavones in Asthma (SOYA)

The SOYA study will investigate if a dietary supplementation with soy isoflavones is an effective treatment in patients with poorly controlled asthma.

(90039009 / 106412)

U01HL089510-01A2 (Wise) 09/30/09-06/30/14 0.90 cal months (7.5%)
 NIH \$250,000

Study of Asthma and Nasal Steroid (STAN)

The objective of the proposed clinical trial is to determine if treatment of chronic rhinitis and sinusitis improves control of asthma. Proposed is a six-month randomized, double-blinded, placebo-controlled trial enrolling 420 participants with poorly controlled asthma and chronic rhinitis/sinusitis.

(90039010 / 106417)

U01 HL105569 (Wise/Biswal) 09/17/10 - 06/30/13 0.90 cal months (7.5%)
 NIH \$798,988

Enhancing Nrf2 by Sulforaphane Treatment in COPD

The goal of this study is to conduct a phase II multi-site clinical trial to provide proof of concept whether the *in vitro* antioxidant stimulator sulforaphane is also effective *in vivo* in humans with COPD. Ancillary studies are proposed to explore whether this agent also improves corticosteroid sensitivity and increases bacterial phagocytosis by alveolar macrophages.

(90044411/109252)

BI Trial #205.452 (Wise) 06/01/2010 – 05/31/2013 0.12 cal months (1%)
Boehringer Ingelheim Pharmaceuticals, Inc. \$605,303

Clinical Trial of Tiotropium-bromide

A randomized, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 mcg and 5 mcg Tiotropium Inhalation Solution delivered by the Respimat Inhaler with Tiotropium inhalation capsules 18mcg delivered by the Handihaler, Protocol No. 205.452
(90043248 / 108799)

P50HL084945 (Wise) 09/14/07 – 08/31/12 2.04 cal months (17%)
NIH \$2,007,146

SCCOR: Mechanisms and Treatment of COPD Progression

The overall goal of this SCCOR program is to understand the complex interplay of mechanisms that promote the progression of COPD and to translate that understanding into treatments that can benefit persons who suffer from COPD.

Project 2: Leader, 1.80 calendar months (IO: 90031572 / 101667)

CORE A: Leader, 0.60 calendar months (IO: 90031575 / 101667)

P50HL107169 (Wise/Biswal) 04/01/11 – 03/31/13 1.44 cal months (12%)
NIH \$303,126

Developing Nrf2 as a target for treatment of corticosteroid resistance in COPD

The goal of this study is to determine the efficacy and mechanisms of Nrf2 activation in animal models and human subjects with COPD to overcome resistance to corticosteroids.

(90046054 / 110253)

P50 HL107190 (Neptune) 04/01/11 – 03/31/13 0.72 cal months (6%)
NIH \$300,000

TGF β Modulation: Therapeutic Targeting for COPD-Emphysema

The goal of this proposal is to use a combination of animal models and patient material to 1) dissect out the compartmental effects of TGF β signaling in COPD and mouse models, 2) explore the efficacy of novel targeted anti TGF β treatments for CS-induced emphysema and 3) determine whether serum or lung TGF β 1 levels can be used as therapeutic biomarkers for COPD.

(90046424 / 110518)

U01HL108730 (Holbrook) 07/01/2011-06/30/2014 0.90 cal months (7.5%)
NIH \$798,518

Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients with Asthma

The goal of this study is to conduct a phase II clinical trial to determine whether application of CPAP reduces airways reactivity in individuals with asthma.

(90047251/110919)

R34HL117349 (Kirk) 09/26/12-06/30/14 0.60 cal months (5%)
NIH \$376,291

Using mHealth to Respond Early to Acute Exacerbations of COPD in HIV mREACH

This is a project to evaluate system-based protocols to identify and treat exacerbations of COPD in patients with HIV infection and injection drug use.

EDUCATIONAL ACTIVITIES

Educational Publications

Teaching

Classroom Instruction

1981- 2009	Pulmonary Pathophysiology, Lecturer, Discussion Group Leader
1987- 1993	Pulmonary Pathophysiology - Course Director
1987- Present	Topics in Internal Medicine - Coordinator, Pulmonary Section
1987-1993	Exercise Physiology and Disability Evaluations Johns Hopkins School of Hygiene and Public Health - Occupational Lung Disease
1987-1991	Johns Hopkins School of Hygiene and Public Health Physiology Course
1987- Present	Lecturer, Discussion Group Leader - Pulmonary Physiology
1993-1994	Coordinator - Pulmonary Section - 2nd year Curriculum
1993-2003	Methods in Clinical Research, GTPCI
1994-2004	Occupational Medicine Course
2010-	Physiology, Lung Mechanics
2010-	Genes to Society, Pulmonary Section Discussion groups, lecturer

Clinical Instruction

1990-Present	Longcope Firm Attending Physician
1981-1998	Clinical Physiology Rotation (Coordinator)
1993-2005	Director, Pulmonary Fellowship Training Program
2005-present	Director, Pulmonary T32 Research Training Grant

Mentoring (post-doctoral):

Trainee	Year	Research Topic	Initial / Current Position
Paul Schneider	1981	Scleroderma Lung Disease	
Roy Brower, M.D.	1982-1984	Cardio-pulmonary interactions	Professor of Medicine, Johns Hopkins
Mark Peters-Golden, M.D.	1982-1983	Scleroderma Lung Disease	Professor of Medicine, University of Michigan
Mark J. Hausknecht, M.D.	1983-1984	Cardio-pulmonary interactions	Interventional Cardiology Practice, Baylor University, Methodist Hospital, Houston, TX
Maroun Karam, M.D.	1983-84	Cardiopulmonary resuscitation	Associate Professor, Radiology, Albany Medical College
Thomas E. Scott, M.D.	1985-1986	Raynaud's phenomenon	Rheumatology Private Practice, Kansas City, MO.
David Prince, M.D.	1983-1984	Lung function in BM Transplant	Practice, Bryn Mawr, PA
MaryAnn Putman, M.D.	1984	Myasthenia Gravis and Pulmonary Function	Private Practice, Lowell, MA
Walter Ettinger, M.D.	1984-1985	The lung in connective tissue diseases	Associate Professor of Geriatrics, Wake Forest University
Ian Gleadhill, M.D.	1986	Amiodarone-induced lung disease.	Consultant, Belfast City Hospital, Queen's University
Henry Fessler, M.D.	1985-1987	Cardio-pulmonary interactions	Professor of Medicine, Johns Hopkins, Assistant Dean for Medical Education
Cynthia Rand, Ph.D.	1985-1986	Chronic Obstructive Lung Disease Early Intervention	Professor of Medicine, Johns Hopkins, Associate Dean of Faculty Development
Raymond Malamet, M.D.	1985-86	Raynaud's phenomenon	Practice of Rheumatology, Hagerstown, MD
Sandralee Blosser, M.D., Ph.D.	1988-1990	Rheumatoid Lung Disease	Professor of Medicine, Penn State
Gregory Diette, M.D., M.H.S.	1994-1998	Outcomes and quality improvement in bronchoscopy / K23 mentor	Professor of Medicine, Johns Hopkins
Charles Fuenning M.D.	1984-1987	Cardiopulmonary interactions	Practice, Akron, Ohio
Eric Greidinger, M.D.	1997-1998	Scleroderma Lung Disease	Professor of Medicine, Univ of Miami
Branko Kesler, M.D.	1997-2001	Rheumatoid Lung Disease	Private Practice, Lowell, MA
Naresh Punjabi, M.D., Ph.D.	1995-1999	Pulmonary function Testing	Professor of Medicine, Johns Hopkins
Betty Chang, M.D., Ph.D.	1998-2001	Scleroderma Lung Disease, Thesis Advisor	Professor of Medicine, University of New Mexico / Associate Deane Graduate Med Education
Laura Herpel, M.D.	2003-2007	COPD and Sleep Disorders	Asst professor, MUSC / Private Practice

Cynthia Brown, M.D.	2004-2007	COPD	Professor, Univ Indiana
Meredith McCormack, M.D., MPH	2005-2008	Asthma, COPD	Assoc Prof, Johns Hopkins
Michael B. Drummond, M.D.	2004-present	COPD, K23 Mentor	Assoc Prof, U North Carolina
Emmanuelle Clerisme-Beatty, MD	2005-2011	Asthma, K23 Mentor	Research Director, BIPI
Cristine Berry, MD MHS	2007-2011	COPD	Assistant Prof, Univ of Arizona / Banner Health
Christian Bime MD, MPH	2009-2012	Asthma	Assistant Prof., Univ of Arizona
Jessica Nguyen MD	2010-2012	Asthma, Allergy	Medical Staff, FDA / Private Practice
Niru Putcha, MD, MHS	2010-2014	COPD, K23 Mentor	Assistant Prof, Johns Hopkins University
Allison Lambert, MD, MHS	2011-2015	COPD, KL2 Mentor	Instructor, Johns Hopkins University / U. Wash

Educational Program Building/Leadership

1988-1997	Associate Director	Division of Pulmonary and Critical Care Medicine, Johns Hopkins Medical Inst.
1997-1998	Interim Director	Division of Pulmonary and Critical Care Medicine, The Johns Hopkins Medical Institutions
2014-2018	Associate Director	Division of Pulmonary and Critical Care Medicine, Johns Hopkins Medical Inst.
1993-2005	Director	Pulmonary Fellowship Training Program
2005- 2022	Director	Pulmonary T32 Research Training Grant

Educational Extramural Funding (current, pending, previous)

CLINICAL ACTIVITIES

Certification

Medical licensure: Maryland 1977 – present (License # - D20775)

Boards, other specialty certification

American Board of Internal Medicine, 1976
Subspecialty, Pulmonary Medicine, 1980

Clinical Service Responsibilities

Pulmonary Function Laboratory	Johns Hopkins Hospital Johns Hopkins Bayview Medical Center
Pulmonary Consultation Service	Johns Hopkins Bayview Medical Center Johns Hopkins Hospital
Oncology Critical Care Service	Johns Hopkins Hospital
Pulmonary Progressive Care Unit	Johns Hopkins Bayview Medical Center
Medical Intensive Care Unit:	Johns Hopkins Hospital Johns Hopkins Bayview Medical Center

SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES

2000-	Director, American Lung Association Airways Clinic Research Centers, Data Coordinating Center
2010-	Physician Champion, COPD Clinical Council, Johns Hopkins Bayview Medical Center
2019-	Co-Director COPD Precision Medicine Center of Excellence
2021-	Co-Director Obstructive Lung Disease Clinic, Johns Hopkins Asthma & Allergy Center

ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments

1981-2005	Director, Pulmonary Function Laboratory, Johns Hopkins Hospital, Baltimore, MD
1981 -	Director, Pulmonary Function Laboratory, Johns Hopkins Bayview Medical Center (formerly Francis Scott Key Medical Center), Baltimore, MD
1993 - 2005	Director Pulmonary and Critical Care Fellowship Training Program
2005 -	Director, Institutional Training Program in Pulmonary Diseases (Institutional National Research Service Award T32)

Editorial Activities

Associate Editor	1985-1991	Yearbook of Respiratory Disease
Editorial Board	1994-1998	Respiratory Medicine
Editorial Board	2013-	COPD, Journal of the COPD Foundation
Author / Editor	2012-	Merck Manual, COPD chapter

Guest Reviewer

American Review of Respiratory Disease
 American Journal of Physiology
 Archives of Internal Medicine
 Chest
 Circulation Research
 Journal of Applied Physiology
 Journal of Clinical Investigation
 New England Journal of Medicine
 Journal of Allergy and Clinical Immunology
 American Journal of Respiratory and Critical Care Medicine
 Respiratory Medicine
 Clinical Trials
 American Journal of Epidemiology
 Journal of Allergy and Clinical Immunology

Advisory committees

1989-1993	American Lung Association of Maryland - Grants and Awards Committee
1991-1993	American Heart Association - Executive Committee, Cardiopulmonary Council
1986, 1992	National Standards Conference on CPR, ATS Representative
1992	American Medical Association, Guidelines for Disability and Impairment (Respiratory System)
1993-1995	American Thoracic Society - Proficiency Standards Committee for Pulmonary Function Laboratories
2000-2001	Executive Committee, Maryland Thoracic Society
2000-2002	American Thoracic Society Pulmonary Function Proficiency Standards Committee Advisory Group
2001-2004	Steering Committee, ACCP, Pulmonary Physiology, Function and Rehabilitation Network
2002-2004	Medical Advisory Board, Scleroderma Foundation
2005-	Medical Advisory Board, Scleroderma Foundation of Washington D.C.
2004-	Medical Advisory Board, National Emphysema and COPD Association (NECA)
2004-2007	Johns Hopkins University School of Medicine Committee on Conflict of Interest
2004-	Johns Hopkins University Advisory Committee on Continuing Medical Education
2004-2006	American Thoracic Society Spirometry Task Force
2007-2008	Alpha-1 Foundation Epidemiology and Research Registry Lung Group
2007-2011	Alpha-1 Foundation Research Registry Advisory Committee
2007-2009	ATS Proficiency Standards Committee for Pulmonary Function Laboratories

2010-	ATS Document Development and Implementation Committee
2010-	Medical Co-chair, Maryland COPD Coalition
2010-2012	ATS Documents Development and Implementation Committee
2010-	American Lung Association Scientific Advisory Committee
2012-	Medical Scientific Advisory Steering Committee, COPD Foundation
2012-	ATS Clinical Problems Assembly Nominating Committee
2013-	Co-Chair, Medical and Scientific Advisory Committee, COPD Foundation
2014-15	ATS, Drug and Device Development and Discovery Committee
2015-22	Chair, COPD Foundation Medical and Scientific Advisory Committee
2015 -	Board of Directors, Executive Committee, COPD Foundation

Federal advisory committees

1985	NIH-NHLBI	- Steering Committee "Early Intervention in COPD"
1987	NCHS	- NHANES Study Pulmonary Function Evaluation Advisory Panel
1988	NIH-NHLBI	- Lung Health Study, Publications & Presentations Committee
1988	NIH	- Pulmonary Preventive Academic Award Study Section
1988	HHS-SSA	- Respiratory Disability Evaluation Advisory Panel, Co-Chairman
1989-1991	NIH-NHLBI	- Pulmonary Complication of HIV Infection Site Review Committee
1990	NIH	- Respiratory and Applied Physiology Study Section (Ad Hoc)
1990	NIH	- Cardiovascular and Renal Study Section (Ad Hoc), Chairman
1991-	NIH-NHLBI	- Steering Committee, Childhood Asthma Management Program
1991-	NIH-NHLBI	- Asthma and Pregnancy Expert Panel
1991-	NIH-NHLBI	- Raynaud's Clinical Trial Steering Committee
1992-	NIH-NHLBI	- Respiratory and Applied Physiology Study Section (AHR-S2)
1993-97	NIH-NHLBI	- Clinical Trials Review Group (Standing Member)
1994-	NIH-NHLBI/NICHD	- Asthma & Pregnancy Clinical Studies Subcommittee
1995-97	NIH-NHLBI	- Clinical Trials Review Group - Chair
1997	NIH-NHLBI	- Chair: Special Emphasis Panel - Asthma Clinical Research Network
1998	NIH-NHLBI	- Study Section - Patient-oriented Research Career Development Award
1998	NIH-NHLBI	- ACRN Protocol Review Committee
1998	NIA-NHLBI	- Chair: Workshop on feasibility. Clinical Trials of Retinoic Acid in the Treatment of Emphysema
1999	NIH-NHLBI	- Chair: Special Emphasis Panel - Patient-oriented Research Career Development Award
1999-	NIH-NHLBI	- Chair: FORTE Trial (Feasibility of Retinoic Acid in Treatment of Emphysema)
2000	NIH-NHLBI	- Chair: Special Emphasis Panel - Patient-Oriented Research Career Development Award
2000	NIH	- Co-chair PULSE Workshop - Cardiopulmonary Resuscitation
2000-03	NIH-NHLBI	- ACRN Protocol Review Committee
2001-02	NIH-NHLBI	- Chair, Ancillary Studies in Clinical Trials Review Group
2001	NIH-NHLBI	- Workshop on Improving Efficiency and Design of Clinical Trials
2001	NIH-NHLBI	- Workshop on Research Directions in COPD
2002	FDA	- Advisory Panel Consultant, Pulmonary and Allergy Drug Section
2002	NHLBI	- Workshop on characterization of COPD
2003	NIH-NHLBI	- Workshop on Clinical Research Priorities in COPD
2004-	NIH-NHLBI	- Chair: Lung Tissue Research Consortium
2004	NIH-NHLBI	- Workshop on Long Term Oxygen Therapy
2004	NIH-NHLBI	- Review Committee, Mentored Clinical Investigator Awards
2005	NIH-NHLBI	- Review Committee, Clinical Research Loan Repayment Program
2006	NIH-NHLBI	- Review Committee, Clinical Research Loan Repayment Program
2006	NIH-NHLBI	- Review Committee, Mentored Clinical Investigator Awards
2006	NIH-NHLBI	- Strategic Planning Committee – Clinical Research

2006	NIH	-	Review Committee – CTSA Planning Grant Awards
2006-2010	NIH-NHLBI	-	Program Project Parent Review Committee (HLBP)
2008	NIH-NIA	-	Planning Committee, Workshop on Asthma in the Elderly
2009	NIH-NHLBI	-	Co-chair, Physiology Section, Asthma Clinical Outcomes Workshop
2009	NIH-NHLBI	-	COPD Research Priorities Workshop
2010	NIH-NHLBI	-	T32 Multidisciplinary Training Program Review Committee
2011	NIH-NHLBI	-	Chair, Translational Program Project Grant Review Committee
2011	NIH-NHLBI	-	Severe Asthma Research Program Coordinating Center Review
2012	NIH-NHLBI	-	Ad Hoc Co-Chair, Program Project Grant Special Emphasis Panel
2012	NIH-NHLBI	-	Review Committee – Translational Program Project Grant
2012	Dept of Defense	-	PRMP Discovery Award Review Committee
2012	NIH-NHLBI	-	Program Project Scientific Review Committee, Ad Hoc, Chair
2013	NIH-NHLBI	-	Program Project Scientific Review Committee, Ad Hoc, Chair
2013-	NIH-NHLBI	-	T32 Institutional Training Program Review Committee
2013	NIH-NHLBI	-	Primary Prevention in Lung Disease Workshop, COPD group
2014	NIH-NHLBI	-	Loan Repayment Program Review Committee
2014	NIH-NHLBI	-	Program Project Scientific Review Committee, Special Emphasis Panel
2015	NIH-NHLBI	-	Loan Repayment Program Review Committee
2015	NIH-NHLBI	-	Program Project Scientific Review Committee, Special Emphasis Panel
2016	NIH-NHLBI	-	Co-Chair, Workshop, Asthma-COPD Overlap Syndrome
2016	NIH-NHLBI	-	Chair, Loan Repayment Program Review Committee
2017	NIH-NHLBI	-	Chair, Loan Repayment Program Review Committee
2018	NIH-NHLBI	-	Chair, Loan Repayment Program Review Committee
2020	NIH-NHLBI	-	Chair, Sepecial Emphasis Panel, Pulmonary Fibrosis Models
2021	NIH-NHLBI	-	Special Emphasis Panel, R03 Review Committee

Professional Societies

1976-	American Thoracic Society
1978-	American Medical Association
1980-2013	Cardiopulmonary Council, American Heart Association
1984-1987	American Federation for Clinical Research
1985-	American Physiological Society
1985-	Fellow, American College of Chest Physicians
2011-	European Respiratory Society

RECOGNITION**Awards, Honors**

1963	Choate Scholar, Dartmouth College
1966	Phi Beta Kappa, Dartmouth College
1969	Mosby Scholarship Award, Dartmouth Medical School
1976	Diplomate, American Board of Internal Medicine
1978-80	Fellow, American Lung Association of Maryland
1979	Parker B. Francis Fellow
1980	E.L. Trudeau Fellow, American Lung Association
1981	Clinical Investigator Award, NIH - NHLBI
2001	George Wills Comstock, M.D. Award - American Lung Association of Maryland.
2007	Tisdale Lecture, University of Vermont
2009	Herbert S. Sweet Lecture, St. Louis University
2009	Sills Family Lectureship, Los Angeles, CA
2010	Distinguished Achievement Award, American Thoracic Society
2012	David M. Levine Mentoring Award, Johns Hopkins University Department of Medicine
2014	Keynote Lecture ICONIC International Conference on COPD, Pune India
2016	Jean Wall Bennett Visiting Professor for COPD Education, Cleveland Clinic
2017	American Lung Association Chairman's Award
2017	ATS Clinical Problems Assembly Sreedhar Nair Lifetime Achievement Award in COPD
2018	Johns Hopkins Women's Task Force Women's Sponsorship Award
2012-present	Castle & Connolly Top Doctors, Pulmonary Diseases